US5338665A - Peptide library and screening method - Google Patents

Peptide library and screening method Download PDF

Info

Publication number
US5338665A
US5338665A US07/963,321 US96332192A US5338665A US 5338665 A US5338665 A US 5338665A US 96332192 A US96332192 A US 96332192A US 5338665 A US5338665 A US 5338665A
Authority
US
United States
Prior art keywords
peptide
seq
dna
vector
library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/963,321
Inventor
Peter J. Schatz
Willem P. C. Stemmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymax Technologies NV
Original Assignee
Affymax Technologies NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US07/963,321 priority Critical patent/US5338665A/en
Application filed by Affymax Technologies NV filed Critical Affymax Technologies NV
Assigned to AFFYMAX TECHNOLOGIES N.V. reassignment AFFYMAX TECHNOLOGIES N.V. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: STEMMER, WILLEM PETER CHRISTIANN, CULL, MILLARD G., MILLER, JEFF E., SCHATZ, PETER J.
Assigned to AFFYMAX TECHNOLOGIES N.V. reassignment AFFYMAX TECHNOLOGIES N.V. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: MILLER, JEFF F., STEMMER, WILLEM PETER CHRISTIANN, CULL, MILLARD G., SCHATZ, PETER J.
Assigned to AFFYMAX TECHNOLOGIES N.V. reassignment AFFYMAX TECHNOLOGIES N.V. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: MILLER, JEFF F., STEMMER, WILLEM PETER CHRISTIANN, CULL, MILLARD G., SCHATZ, PETER J.
Priority to US08/290,641 priority patent/US5498530A/en
Publication of US5338665A publication Critical patent/US5338665A/en
Application granted granted Critical
Priority to US08/548,540 priority patent/US5733731A/en
Priority to US09/010,216 priority patent/US6156511A/en
Assigned to AFFYMAX, INC. reassignment AFFYMAX, INC. EXHIBIT A/ W AFFIDAVIT Assignors: AFFYMAX TECHNOLOGIES, N.V.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1075Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass

Definitions

  • the present invention relates generally to methods for selecting peptide ligands to receptor molecules of interest and, more particularly, to methods for generating and screening large peptide libraries for peptides with desired binding characteristics.
  • RNA molecules with the ability to bind a particular protein see Tuerk and Gold, 1990, Science 249:505-510 or a dye (see Ellington and Szostak, 1990, Nature 346:818-822) have been selected by alternate rounds of affinity selection and PCR amplification.
  • a similar technique was used to determine the DNA sequences that bound a human transcription factor (see Thiesen and Bach, 1990, Nucl. Acids Res. 18:3203-3209).
  • the present invention provides random peptide libraries and methods for generating and screening those libraries with significant advantages over the prior art methods.
  • the present invention provides random peptide libraries and methods for generating and screening those libraries to identify peptides that bind to receptor molecules of interest.
  • the peptides can be used for therapeutic, diagnostic, and related purposes, e.g., to bind the receptor or an analogue of the receptor and so inhibit or promote the activity of the receptor.
  • the peptide library of the invention is constructed so that the peptide is expressed as a fusion product; the peptide is fused to a DNA binding protein.
  • the peptide library is constructed so that the DNA binding protein can bind to the recombinant DNA expression vector that encodes the fusion product that contains the peptide of interest.
  • the method of generating the peptide library of the invention comprises the steps of (a) constructing a recombinant DNA vector that encodes a DNA binding protein and contains a binding site for the DNA binding protein; (b) inserting into the coding sequence of the DNA binding protein in the vector of step (a) a coding sequence for a peptide such that the resulting vector encodes a fusion protein composed of the DNA binding protein and the peptide; (c) transforming a host cell with the vector of step (b); and (d) culturing the host cell transformed in step (c) under conditions suitable for expression of the fusion protein.
  • the screening method of the invention comprises the steps of (a) lysing the cells transformed with the peptide library under conditions such that the fusion protein remains bound to the vector that encodes the fusion protein; (b) contacting the fusion proteins of the peptide library with a receptor under conditions conducive to specific peptide-receptor binding; and (c) isolating the vector that encodes a peptide that binds to said receptor.
  • the present invention also relates to recombinant DNA vectors useful for constructing the random peptide library, the random peptide library, host cells transformed with the recombinant vectors of the library, and fusion proteins expressed by those host cells.
  • FIG. 1 shows a recombinant vector of a random peptide library of the invention.
  • the DNA binding protein is the lacI gene product
  • the fusion protein forms a tetramer
  • the tetramer interacts with the vector and immobilized receptor, as shown in the Figure.
  • the library plasmid carries the lacI gene with random coding sequence fused to the 3' end of the coding sequence of the gene, as well as two lacO sequences.
  • the lac repressor-peptide fusions produced by the hybrid genes bind to the lacO sites on the same plasmid that encodes them.
  • those plasmid-repressor-peptide complexes that specifically bind a chosen receptor are enriched by avidity panning against the immobilized receptor. Transformation of E. coli with recovered plasmids allows additional rounds of panning or sequencing of isolated clones.
  • FIG. 2 shows a partial restriction site, DNA sequence, and function map of plasmid pMC5.
  • Hybridization of oligonucleotide ON-332 to oligonucleotides ON-369 and ON-370 produces a fragment with cohesive ends compatible with SfiI, HindIII digested plasmid pMC5.
  • the ligation product adds sequence coding for twelve random amino acids to the end of lacI through a six codon linker.
  • the library plasmid also contains: the rrnB transcriptional terminator, the bla gene to permit selection on ampicillin, the M13 phage intragenic region to permit rescue of single-stranded DNA, a plasmid replication origin (ori), two lacO S sequences, and the araC gene to permit positive and negative regulation of the araB promoter that drives expression of the lacI fusion gene.
  • FIGS. 3A and 3B shows sequences isolated by panning with the D32.39 antibody. Each sequence is listed with a clone number, the panning round in which the clone was isolated, and the result of the ELISA with D32.39 antibody. The sequences are aligned to show the D32.39 epitope that they share (box).
  • FIG. 4 shows the linker sequences from vectors pJS141 and pJS142.
  • DNA Binding Protein refers to a protein that specifically interacts with deoxyribonucleotide strands. Those of skill in the art will recognize that, for purposes of the present invention, the DNA binding protein must bind specifically to a recombinant DNA vector and, in a preferred embodiment, bind to a specific sequence of DNA contained in the vector. In embodiments of the invention in which RNA vectors are used, DNA binding protein can also refer to an RNA binding protein.
  • Epitope refers to that portion of an antigen that interacts with an antibody.
  • Host Cell refers to a eukaryotic or procaryotic cell or group of cells that can be or has been transformed by a recombinant DNA vector.
  • a host cell is typically a bacterium, such as an E. coli K12 cell or an E. coli B cell.
  • Ligand refers to a molecule, such as a random peptide, that is recognized by a particular receptor.
  • Ligand Fragment refers to a portion of a gene encoding a ligand and to the portion of the ligand encoded by that gene fragment.
  • Ligand Fragment Library refers not only to a set of recombinant DNA vectors that encodes a set of ligand fragments, but also to the set of ligand fragments encoded by those vectors, as well as the fusion proteins containing those ligand fragments.
  • Linker refers to a molecule or group of molecules that connects two molecules, such as a DNA binding protein and a random peptide, and serves to place the two molecules in a preferred configuration, e.g., so that the random peptide can bind to a receptor with minimal steric hindrance from the DNA binding protein.
  • Peptide or “polypeptide” refers to a polymer in which the monomers are alpha amino acids joined together through amide bonds. Peptides are two or often more amino acid monomers long. Standard abbreviations for amino acids are used herein (see Stryer, 1988, Biochemistry, Third Ed., incorporated herein by reference.)
  • Random Peptide refers to an oligomer composed of two or more amino acid monomers and constructed by a stochastic or random process.
  • a random peptide can include framework or scaffolding motifs, as described below.
  • Random Peptide Library refers not only to a set of recombinant DNA vectors that encodes a set of random peptides, but also to the set of random peptides encoded by those vectors, as well as the fusion proteins containing those random peptides.
  • Receptor refers to a molecule that has an affinity for a given ligand. Receptors can be naturally occurring or synthetic molecules. Receptors can be employed in an unaltered state or as aggregates with other species. Receptors can be attached, covalently or noncovalently, to a binding member, either directly or via a specific binding substance. Examples of receptors include, but are not limited to, antibodies, including monoclonal antibodies and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials), cell membrane receptors, enzymes, and hormone receptors.
  • Recombinant DNA Vector refers to a DNA or RNA molecule that encodes a useful function and can be used to transform a host cell.
  • a recombinant DNA vector typically is a phage or plasmid and can be extrachromosomally maintained in a host cell or controllably integrated into and excised from a host cell chromosome.
  • the present invention provides random peptide libraries and methods for generating and screening those libraries to identify either peptides that bind to receptor molecules of interest or gene products that modify peptides or RNA in a desired fashion.
  • the peptides are produced from libraries of random peptide expression vectors that encode peptides attached to a DNA binding protein.
  • a method of affinity enrichment allows a very large library of peptides to be screened and the vector carrying the desired peptide(s) to be selected.
  • the nucleic acid can then be isolated from the vector and sequenced to deduce the amino acid sequence of the desired peptide. Using these methods, one can identify a peptide as having a desired binding affinity for a molecule.
  • the peptide can then be synthesized in bulk by conventional means.
  • peptide de novo By identifying the peptide de novo, one need not know the sequence or structure of the receptor molecule or the sequence or structure of the natural binding partner of the receptor. Indeed, for many "receptor" molecules a binding partner has not yet been identified.
  • a significant advantage of the present invention is that no prior information regarding an expected ligand structure is required to isolate peptide ligands of interest.
  • the peptide identified will have biological activity, which is meant to include at least specific binding affinity for a selected receptor molecule and, in some instances, will further include the ability to block the binding of other compounds, to stimulate or inhibit metabolic pathways, to act as a signal or messenger, to stimulate or inhibit cellular activity, and the like.
  • the receptor molecule may be an antibody (or a binding portion thereof).
  • the antigen to which the antibody binds may be known and perhaps even sequenced, in which case the invention may be used to map epitopes of the antigen. If the antigen is unknown, such as with certain autoimmune diseases, for example, sera, fluids, tissue, or cell from patients with the disease can be used in the present screening method to identify peptides, and consequently the antigen, that elicits the autoimmune response.
  • the present invention can be used to identify peptide ligands for a wide variety of receptors in addition to antibodies.
  • ligands include, by way of example and not limitation, growth factors, hormones, enzyme substrates, interferons, interleukins, intracellular and intercellular messengers, lectins, cellular adhesion molecules, and the like.
  • Peptide ligands can also be identified by the present invention for molecules that are not peptides or proteins, e.g., carbohydrates, non-protein organic compounds, metals, etc.
  • antibodies are widely available and conveniently manipulated, antibodies are merely representative of receptor molecules for which peptide ligands can be identified by means of the present invention.
  • the peptide library is constructed so that the DNA binding protein-random peptide fusion product can bind to the recombinant DNA expression vector that encodes the fusion product that contains the peptide of interest.
  • the method of generating the peptide library comprises the steps of (a) constructing a recombinant DNA vector that encodes a DNA binding protein and contains binding sites for the DNA binding protein; (b) inserting into the coding sequence of the DNA binding protein in a multiplicity of vectors of step (a) coding sequences for random peptides such that the resulting vectors encode different fusion proteins, each of which is composed of the DNA binding protein and a random peptide; (c) transforming host cells with the vectors of step (b); and (d) culturing the host cells transformed in step (c) under conditions suitable for expression of the fusion proteins.
  • a random peptide library will contain at least 10 6 to 10 8 different members, although library sizes of 10 8 to 10 13 can be achieved.
  • the peptide library produced by this method is especially useful in screening for ligands that bind to a receptor of interest.
  • This screening method comprises the steps of (a) lysing the cells transformed with the peptide library under conditions such that the fusion protein remains bound to the vector that encodes the fusion protein; (b) contacting the fusion proteins of the peptide library with a receptor under conditions conducive to specific peptide-receptor binding; and (c) isolating the vector that encodes a peptide that binds to said receptor.
  • the vectors that encode the peptides of interest may be enriched.
  • peptides of increasingly higher affinity can be identified.
  • fusion protein-plasmid complexes by gel filtration, affinity, or other purification methods can be used to prevent such interference. For instance, purification of the cell lysate on a column (such as the Sephacryl S-400 HR column) that removes small proteins and other molecules may be useful.
  • the recombinant vectors of the random peptide library are constructed so that the random peptide is expressed as a fusion product; the peptide is fused to a DNA binding protein.
  • a DNA binding protein of the invention must exhibit high avidity binding to DNA and have a region that can accept insertions of amino acids without interfering with the DNA binding activity.
  • the half-life of a DNA binding protein-DNA complex produced by practice of the present method must be long enough to allow screening to occur. Typically, the half-life will be one to four hours or longer.
  • Suitable DNA binding proteins for purposes of the present invention include proteins selected from a large group of known DNA binding proteins including transcriptional regulators and proteins that serve structural functions on DNA. Examples include: proteins that recognize DNA by virtue of a helix-turn-helix motif, such as the phage 434 repressor, the lambda phage cI and cro repressors, and the E.
  • coli CAP protein from bacteria and proteins from eukaryotic cells that contain a homeobox helix-turn-helix motif; proteins containing the helix-loop-helix structure, such as myc and related proteins; proteins with leucine zippers and DNA binding basic domains such as fos and jun; proteins with ⁇ POU ⁇ domains such as the Drosophila paired protein; proteins with domains whose structures depend on metal ion chelation such as Cys 2 His 2 zinc fingers found in TFIIIA, Zn 2 (Cys) 6 clusters such as those found in yeast Ga14, the Cys 3 His box found in retrovital nucleocapsid proteins, and the Zn 2 (Cys) 8 clusters found in nuclear hormone receptor-type proteins; the phage P22 Arc and Mnt repressors (see Knight et al., 1989, J.
  • Proteins that bind DNA in a non-sequence-specific manner could also be used, for example, histones, protamines, and HMG type proteins.
  • proteins could be used that bind to DNA indirectly, by virtue of binding another protein bound to DNA. Examples of these include yeast Ga180 and adenovirus E1A protein.
  • the lac repressor is preferred for several reasons.
  • the lac repressor a 37 kDa protein, is the product of the E. coli lacI gene and negatively controls transcription of the lacZYA operon by binding to a specific DNA sequence called lacO. Structure-function relationships in the lac repressor have been studied extensively through the construction of thousands of amino acid substitution variants of the protein (see Gordon et al., 1988, J. Mol. Biol. 200:239-251, and Kleina and Miller, 1990, J. Mol. Biol. 212:295-318).
  • the repressor exists as a tetramer in its native form with two high affinity DNA binding domains formed by the amino termini of the subunits (see Beyreuther, 1980, The Operon (Miller and Reznikoff, eds., Cold Spring Harbor Laboratory), pp. 123-154).
  • the two DNA binding sites exhibit strong cooperativity of binding to DNA molecules with two lacO sequences.
  • a single tetramer can bind to suitably spaced sites on a plasmid, forming a loop of DNA between the two sites, and the resulting complex is stable for days (see Besse et al., 1986, EMBO J. 1377-1381; Flashner and Gralla, 1988, Proc. Natl. Acad. Sci.
  • the carboxy terminal domains of the lac repressor form the dimer and tetramer contacts, but significantly, fusions of proteins as large as ⁇ -galactosidase can be made to the carboxy terminus without eliminating the DNA binding activity of the repressor (see Muller-Hill and Kania, 1974, Nature 249:561-563; and Brake et al., 1978, Proc. Natl. Acad. Sci. USA 75:4824-4827).
  • the lac repressor fusion proteins of the present invention include not only carboxy terminus fusions but also amino terminus fusions and peptide insertions in the lac repressor.
  • the binding of the lac repressor to a single wild-type lacO is both tight and rapid, with a dissociation constant of 10 -13 M, an association rate constant of 7 ⁇ 10 9 M -1 s -1 , and a half-life for the lac repressor-lacO complex of about 30 min. (see Barkley and Bourgeois, 1980, The Operon (Miller and Reznikoff, eds., Cold Spring Harbor Laboratory), pp 177-220)
  • the high stability of the lac repressor-DNA complex has permitted its use in methods for identifying DNA binding proteins (see Levens and Howley, 1985, Mol. Cell. Biol.
  • a variety of techniques can be used to increase the stability of the DNA binding protein-DNA complex. These techniques include altering the amino acid sequence of the DNA binding protein, altering the DNA sequence of the DNA binding site, increasing the number of DNA binding sites on the vector, adding compounds that increase the stability of the complex (such as lactose or ONPF for the lac system), and various combinations of each of these techniques.
  • Plasmid pMC5 has two lacO sequences to take advantage of the strong cooperative interaction between a lac repressor tetramer and two lac repressor binding sites, and each of these sequences is the symmetric variant of the lacO sequence, called lacO S or lacO id , which has about ten fold higher affinity for repressor than the wild-type sequence (see Sadler et al., 1983, Proc. Natl. Acad. Sci. USA 80:6785-6789, and Simons et al., 1984, Proc. Natl. Acad. Sci.
  • Plasmid pMC5 is shown in FIGS. 1 and 2, and details of the construction of the plasmid are in Example 1, below.
  • This library plasmid contains two major functional elements in a vector that permits replication and selection in E. coli.
  • the lacI gene is expressed under the control of the araB promoter and has a series of restriction enzyme sites at the 3' end of the gene. Synthetic oligonucleotides cloned into these sites fuse the lac repressor protein coding sequence to additional random peptide coding sequence.
  • the random peptide library of the invention is constructed by cloning an oligonucleotide that contains the random peptide coding sequence (and any spacers, framework determinants, etc., as discussed below) into a selected cloning site of a vector that encodes a DNA binding protein and binding sites for that protein.
  • the central portion of the oligonucleotide will generally contain one or more random peptide coding sequences (variable region domain) and spacer or framework residues.
  • the sequences are ultimately expressed as peptides (with or without spacer or framework residues) fused to or in the DNA binding protein.
  • variable region domain of the oligonucleotide encodes a key feature of the library: the random peptide.
  • the size of the library will vary according to the number of variable codons, and hence the size of the peptides, that are desired. Generally, the library will be at least 10 6 to 10 8 or more members, although smaller libraries may be quite useful in some circumstances.
  • a codon motif is used, such as (NNK) x , where N may be A, C, G, or T (nominally equimolar), K is G or T (nominally equimolar), and x is typically up to about 5, 6, 7, or 8 or more, thereby producing libraries of penta-, hexa-, hepta-, and octa-peptides or more.
  • the third position may also be G or C, designated "S".
  • NNK or NNS code for all the amino acids, (ii) code for only one stop codon, and (iii) reduce the range of codon bias from 6:1 to 3:1.
  • the size of the library that is generated can become a constraint in the cloning process, but the larger libraries can be sampled, as described below.
  • the expression of peptides from randomly generated mixtures of oligonucleotides in recombinant vectors is discussed in Oliphant et al., 1986, Gene 44:177-183, incorporated herein by reference.
  • NNK x An exemplified codon motif (NNK) x produces 32 codons, one for each of 12 amino acids, two for each of five amino acids, three for each of three amino acids and one (amber) stop codon. Although this motif produces a codon distribution as equitable as available with standard methods of oligonucleotide synthesis, it results in a bias against peptides containing one-codon residues. For example, a complete collection of hexacodons contains one sequence encoding each peptide made up of only one-codon amino acids, but contains 729 (3 6 ) sequences encoding each peptide with three-codon amino acids.
  • An alternate approach that minimizes the bias against one-codon residues involves the synthesis of 20 activated trinucleotides, each representing the codon for one of the 20 genetically encoded amino acids.
  • These trinucleotides are synthesized by conventional means, removed from the support with the base and 5-OH-protecting groups intact, and activated by the addition of 3'-O-phosphoramidite (and phosphate protection with beta-cyanoethyl groups) by the method used for the activation of mononucleosides, as generally described in McBride and Caruthers, 1983, Tetr. Letters 22:245, which is incorporated herein by reference.
  • oligocodons are prepared using these trimers as building blocks.
  • the trimers are mixed at the desired molar ratios and installed in the synthesizer. The ratios will usually be approximately equimolar, but may be a controlled unequal ratio to obtain the over- to under-representation of certain amino acids coded for by the degenerate oligonucleotide collection.
  • the condensation of the trimers to form the oligocodons is done essentially as described for conventional synthesis employing activated mononucleosides as building blocks. See generally, Atkinson and Smith, 1984, Oligonucleotide Synthesis (M. J. Gait, ed.), pp. 35-82.
  • This procedure generates a population of oligonucleotides for cloning that is capable of encoding an equal distribution (or a controlled unequal distribution) of the possible peptide sequences.
  • This approach may be especially useful in generating longer peptide sequences, because the range of bias produced by the (NNK) x motif increases by three-fold with each additional amino acid residue.
  • the codon motif is (NNK) x , as defined above, and when x equals 8, there are 2.6 ⁇ 10 10 possible octapeptides.
  • a library containing most of the octapeptides may be produced, but a sampling of the octapeptides may be more conveniently constructed by making only a subset library using about 0.1%, and up to as much as 1%, 5%, or 10%, of the possible sequences, which subset of recombinant vectors is then screened. As the library size increases, smaller percentages are acceptable.
  • the recovered vector subset may be subjected to mutagenesis and then subjected to subsequent rounds of screening. This mutagenesis step may be accomplished in two general ways: the variable region of the recovered phage may be mutagenized or additional variable amino acids may be added to the regions adjoining the initial variable sequences.
  • a library can be constructed in pMC5 using the half-site cloning strategy of Cwirla et al., supra.
  • a random dodecamer peptide sequence connected to the C-terminus of the lac repressor through a linker peptide GADGGA (GADGA [SEQ. ID NO.:65]) would also be an acceptable linker), can be specified by a degenerate oligonucleotide population containing twelve codons of the form NNK, where N is any base, and K is G or T. Transformation of E. coli strain MC1061 using 4 ⁇ g of pMC5 ligated to a four fold molar excess of annealed oligonucleotides yielded a test library of 5.5 ⁇ 10 8 independent clones.
  • host cells are transformed with the library vectors.
  • the successful transformants are typically selected by growth in a selective medium or under selective conditions, e.g., an appropriate antibiotic, which, in the case of plasmid pMC5 derivatives, is preferably ampicillin.
  • an appropriate antibiotic which, in the case of plasmid pMC5 derivatives, is preferably ampicillin.
  • This selection may be done on solid or in liquid growth medium.
  • the cells are grown at a high density ( - 10 8 to 10 9 transformants per m 2 ) on a large surface of, for example, L-agar containing the selective antibiotic to form essentially a confluent lawn.
  • cells may be grown in L-broth (with antibiotic selection) through about 10 or more doublings. Growth in liquid culture may be more convenient because of the size of the libraries, while growth on solid media likely provides less chance of bias during the amplification process.
  • fusion proteins For best results with the present method, one should control the ratio of fusion proteins to vectors so that vectors are saturated with fusion proteins, without a vast excess of fusion protein. Too little fusion protein could result in vectors with free binding sites that might be filled by fusion protein from other cells in the population during cell lysis, thus breaking the connection between the genetic information and the peptide ligand. Too much fusion protein could lead to titration of available receptor sites during panning by fusion protein molecules not bound to plasmid.
  • a regulated promoter is also useful to limit the amount of time that the peptide ligands are exposed to cellular proteases. By inducing the promoter a short time before lysing the cells containing a library, one can minimize the time during which proteases act.
  • the araB promoter normally drives expression of the enzymes of the E. coli araBAD operon, which are involved in the catabolism of L-arabinose.
  • the araB promoter is regulated both positively and negatively, depending on the presence of L-arabinose in the growth medium, by the AraC protein. This promoter can be catabolite repressed by adding glucose to the growth medium and induced by adding L-arabinose to the medium.
  • Plasmid pMC5 encodes and can drive expression of the AraC protein (see Lee, 1980, The Operon (Miller and Reznikoff, eds., Cold Spring Harbor Laboratory), pp. 389-409).
  • the araB promoter is also regulated by the CAP protein, an activator involved in the E. coli system of catabolite repression.
  • Plasmid pMC3 is such a vector and can be constructed by attaching an oligonucleotide that encodes a short peptide linker (GADGA [SEQ. ID NO.:65]) followed by dynorphin B (YGGFLRRQFKVVT [SEQ. ID NO.:66]) to the lacI gene in plasmid pMC5.
  • Monoclonal antibody D32.39 binds to dynorphin B, a 13 amino acid opioid peptide (see Barrett and Goldstein, 1985, Neuropeptides 2:113-120, incorporated herein by reference).
  • plasmids pMC3 and pMC5 and receptor D32.39 provide a test receptor and positive and negative controls for use in panning experiments, described below.
  • Growth of E. coli transformants harboring plasmid pMC3 in LB broth (10 g of tryptone, 5 g of NaCl, and 5 g of yeast extract per liter) allowed detection in a Western blot of a faint band of the expected molecular weight, while addition of 0.2% glucose rendered this band undetectable.
  • Growth in LB plus 0.2% L-arabinose led to the production of a very heavy band on a stained gel, representing greater than 25% of the total cell protein.
  • a plasmid pMC5 derivative or any other vector of the present invention that has an inducible promoter
  • non-inducing conditions to minimize exposure of the fusion protein to cellular proteases and to minimize exposure of the cell to the possibly deleterious effects of the fusion protein
  • partial induction can be achieved with as little as 3.3 ⁇ 10 -5 % of L-arabinose (as demonstrated by increased repression in the assay described below).
  • a preferred way to achieve partial induction consists of growing the cells in 0.1% glucose until about 30 min. before the cells are harvested; then, 0.2 to 0.5% L-arabinose is added to the culture to induce expression of the fusion protein.
  • Other methods to express the protein controllably are available.
  • lacI expression level necessary to fill the available binding sites in a typical plasmid pMC5 derivative by observing the behavior of strain ARI 20 (lacI - lacZYA + ) transformed with pMC3 or pMC5 (encoding only the linker peptide GADGA [SEQ. ID NO.:65]). Because the lacO sites in plasmids pMC3 and pMC5 have higher affinity than those in the lacZYA operon, the available repressor should fill the plasmid sites first. Substantial repression of lacZYA should be observed only if there is an excess of repressor beyond the amount needed to fill the plasmid sites.
  • the amount of repressor produced by pMC5 is sufficient to fill the lacO sites and repress greater than 200 fold lacZYA in ARI 20 host cells during growth in normal LB medium (2.4 units compared to 500 units from ARI 20 transformed with vector pBAD18, which has no lacI).
  • the repressor encoded by pMC3 was partially inactivated by the addition of the dynorphin B tail, allowing about 10 fold higher expression of lacZYA (37 units). Because of the apparent excess production of repressor under these conditions, LB is a preferred medium for expressing similar fusion proteins of the invention.
  • the fusion protein will be expressed. Because the random peptide vector also contains DNA binding sites for the DNA binding protein, fusion proteins will bind to the vectors that encode them. After these complexes form, the cells containing a library are lysed, and the complexes are partially purified away from cell debris. Following cell lysis, one should avoid cross reaction between unbound fusion proteins of one cell with heterologous DNA molecules of another cell. The presence of high concentrations of the DNA binding site for the DNA binding protein will minimize this type of cross reaction. Thus, for the lac system, one can synthesize a DNA duplex encoding the lacO or a mutated lacO sequence for addition to the cell lysis solution. The compound ONPF, as well as lactose, is known to strengthen the binding of the lac repressor to lacO, so one can also, or alternatively, add ONPF or lactose to the cell lysis solution to minimize this type of cross reaction.
  • plasmid-peptide complexes that bind specifically to immobilized receptors are separated from nonbinding complexes, which are washed away.
  • Bulk DNA can be included during the lysis and panning steps to compete for non-specific binding sites and to lower the background of non-receptor-specific binding to the immobilized receptor.
  • washing procedures can be used to enrich for retention of molecules with desired affinity ranges.
  • a library equivalent is one of each recombinant; 10 4 equivalents of a library of 10 9 members is 10 13 vectors), but typically 10 3 to 10 4 library equivalents, are incubated with a receptor (or portion thereof) for which a peptide ligand is desired.
  • the receptor is in one of several forms appropriate for affinity enrichment schemes. In one example the receptor is immobilized on a surface or particle, and the library is then panned on the immobilized receptor generally according to the procedure described below.
  • a second example of receptor presentation is receptor attached to a recognizable ligand (which may be attached via a spacer).
  • a recognizable ligand which may be attached via a spacer.
  • a specific example of such a ligand is biotin.
  • the receptor, so modified, is incubated with the library, and binding occurs with both reactants in solution.
  • the resulting complexes are then bound to streptavidin (or avidin) through the biotin moiety. See PCT patent publication No. 91/07087.
  • the streptavidin may be immobilized on a surface such as a plastic plate or on particles, in which case the complexes (vector/DNA binding protein/peptide/receptor/biotin/streptavidin) are physically retained; or the streptavidin may be labelled, with a fluorophore, for example, to tag the active fusion protein for detection and/or isolation by sorting procedures, e.g., on a fluorescence-activated cell sorter.
  • Vectors that express peptides without the desired specificity are removed by washing.
  • the degree and stringency of washing required will be determined for each receptor/peptide of interest. A certain degree of control can be exerted over the binding characteristics of the peptides recovered by adjusting the conditions of the binding incubation and the subsequent washing.
  • the temperature, pH, ionic strength, divalent cation concentration, and the volume and duration of the washing will select for peptides within particular ranges of affinity for the receptor. Selection based on slow dissociation rate, which is usually predictive of high affinity, is the most practical route. This may be done either by continued incubation in the presence of a saturating amount of free ligand, or by increasing the volume, number, and length of the washes.
  • each complex may bind to more than one antibody binding site, either by a single complex binding through the multiple peptides displayed to both sites of a single IgG molecule or by forming a network of complex-IgG. Multivalent interaction produces a high avidity and tenacious adherence of the vector during washing. Multivalent interactions can be mimicked by using a high density of immobilized monovalent receptor.
  • a substantially monovalent interaction between vector and the receptor may be appropriate.
  • the screening (selection) with substantially monovalent interaction can be repeated as part of additional rounds of amplification and selection of vectors.
  • Monovalent interactions may be achieved by employing low concentrations of receptor, such as the Fab binding fragment of an antibody molecule.
  • a strategy employing a combination of conditions favoring multivalent or monovalent interactions can be used to advantage in producing new peptide ligands for receptor molecules.
  • By conducting the first rounds of screening under conditions to promote multivalent interactions one can then use high stringency washing to reduce greatly the background of non-specifically bound vectors.
  • This high avidity step may select a large pool of peptides with a wide range of affinities, including those with relatively low affinity.
  • Subsequent screening under conditions favoring increasingly monovalent interactions and isolation of phage based on a slow dissociation rate may then allow the identification of the highest affinity peptides.
  • the present invention also provides univalent display vectors.
  • the lac operator is an inverted DNA repeat, and two separate lac repressor proteins bind to the operator. However, only a portion of the lac repressor protein binds to the operator. This portion, called the "headpiece,” can be made as a recombinant protein (see Kaptein et al., 1990, Bioch. Pharmacol. 40:89-96).
  • the present invention provides a recombinant DNA vector that encodes two or more fused lac headpieces and contains a site into which random peptide coding sequences can be introduced.
  • This vector provides a monovalent display system, although a more preferred version of the system would comprise only one lacO sequence per vector (the vector in Example 5 has two lacO sequences).
  • the vector DNA is then released from bound complexes by, for example, treatment with high salt or extraction with phenol, or both.
  • IPTG a compound known to decrease the stability of the lac repressor-lacO complex
  • the elution buffer includes 1 mM IPTG, 10 ⁇ g/mL of a double-stranded oligonucleotide that encodes lacO S , and 0.05 to 0.2M KCl.
  • the preferred method of transformation is electroporation. Using this new population of transformants, one can repeat additional cycles of panning to increase the proportion of peptides in the population that are specific for the receptor. The structure of the binding peptides can then be determined by sequencing the 3' region of the lacI fusion gene.
  • antibody D32.39 and the pMC3 complex serves as a receptor-ligand positive control in panning experiments to determine ability to recover plasmids based on the sequence of the fusion peptide.
  • Useful negative controls are pMC5, which encodes only the linker fusion peptide (GADGA [SEQ. ID NO.:65]), and pMC1, which encodes the dynorphin B peptide, but lacks the lacO sequences carreid by pMC3 and pMC5. Lysates of E. coli strains carrying each plasmid were panned on D32.39 immobilized on polystyrene petri dishes. After washing, plasmids were recovered from complexes bound to the plates by phenol extraction, followed by transformation of E. coli.
  • results with pure lysates demonstrated about 100 fold more transformants recovered from pMC3 lysates as compared to the negative controls.
  • the results with mixed lysates revealed enrichment of pMC3 versus controls among the population of recovered plasmids.
  • the results with cells that were mixed before lysis yielded similar results. These results show that the plasmid-lacI-peptide complexes were sufficiently stable to allow enrichment of plasmids on the basis of the peptide the plasmids encode.
  • the random dodecapeptide library in pMC5 described above was used in the screening method of the invention to identify vectors that encode a fusion protein that comprised a peptide that would bind to D32.39 antibody coupled to sheep antimouse antibody coated magnetic beads.
  • the number of complexes added to the beads at each round of panning yielded the equivalent of 10 10 to 10 11 transformants (see Example 3).
  • the recovered plasmids yielded transformants ranging in number from about 10 8 in early rounds to almost 10 11 in the fourth and final round. Compared to the number of transformants from antibody panned complexes, panning against unmodified polystyrene beads produced orders of magnitude fewer transformants.
  • lac repressor can act as a link between random peptides and the genetic material encoding them and so serve as the base on which to construct large peptide ligand libraries that can be efficiently screened.
  • plasmid-repressor-peptide complexes are isolated by panning on immobilized receptor, the plasmids are amplified after transformation of E. coli, and the procedure is repeated to enrich for plasmids encoding peptides specific for the receptor.
  • the repressor binds to the library plasmid with sufficient avidity to allow panning of the library on immobilized receptor without problematic levels of dissociation.
  • This system can be used to identify a series of related peptides that bind to a monoclonal antibody whose epitope has not been characterized and to identify peptide ligands for other receptors.
  • a variety of techniques can be used to diversify a peptide library to construct ligands with improved properties.
  • the positive vectors (those identified in an early round of panning) are sequenced to determine the identity of the active peptides.
  • Oligonucleotides are then synthesized based on these peptide sequences, employing all bases at each step at concentrations designed to produce slight variations of the primary oligonucleotide sequences.
  • This mixture of (slightly) degenerate oligonucleotides is then cloned into the random peptide library expression vector as described herein.
  • This method produces systematic, controlled variations of the starting peptide sequences but requires, however, that individual positive vectors be sequenced before mutagenesis. This method is useful for expanding the diversity of small numbers of recovered vectors.
  • Another technique for diversifying a selected peptide involves the subtle misincorporation of nucleotide changes in the coding sequence for the peptide through the use of the polymerase chain reaction (PCR) under low fidelity conditions
  • PCR polymerase chain reaction
  • a protocol described in Leung et al., 1989, Technique 1:11-15, utilizes altered ratios of nucleotides and the addition of manganese ions to produce a 2% mutation frequency.
  • Yet another approach for diversifying a selected random peptide vector involves the mutagenesis of a pool, or subset, of recovered vectors.
  • Recombinant host cells transformed with vectors recovered from panning are pooled and isolated.
  • the vector DNA is mutagenized by treating the cells with, e.g., nitrous acid, formic acid, hydrazine, or by use of a mutator strain as described below. These treatments produce a variety of mutations in the vector DNA.
  • the segment containing the sequence encoding the variable peptide can optionally be isolated by cutting with restriction nuclease(s) specific for sites flanking the variable region and then recloned into undamaged vector DNA.
  • the mutagenized vectors can be used without recloning of the mutagenized random peptide coding sequence.
  • the sequences of peptides selected in early panning are determined individually and new oligonucleotides, incorporating all or part of the determined sequence and an adjoining degenerate sequence, are synthesized. These are then cloned to produce a secondary library.
  • a restriction site is installed next to the primary variable region.
  • the enzyme should cut outside of its recognition sequence, such as BspMI, which cuts leaving a four base 5' overhang, four bases to the 3' side of the recognition site.
  • the recognition site may be placed four bases from the primary degenerate region.
  • a degenerately synthesized oligonucleotide is then ligated into this site to produce a second variable region juxtaposed to the primary variable region.
  • This secondary library is then amplified and screened as before.
  • variable regions may be separated by spacers that allow the diversity domains of the peptides to be presented to the receptor in different ways.
  • the distance between variable regions may be as little as one residue or as many as five to ten to up to about 100 residues.
  • variable regions separated by a spacer containing 20 to 30 amino acids For probing a large binding site, one may construct variable regions separated by a spacer containing 20 to 30 amino acids.
  • the number of spacer residues, when present, will preferably be at least two to three or more but usually will be less than eight to ten.
  • An oligonucleotide library having variable domains separated by spacers can be represented by the formula: (NNK) y --(abc) n --(NNK) z , where N and K are as defined previously (note that S as defined previously may be substituted for K); y+z is equal to about 5, 6, 7, 8, or more; a, b and c represent the same or different nucleotides comprising a codon encoding spacer amino acids; and n is up to about 20 to 30 codons or more.
  • the spacer residues may be somewhat flexible, comprising polyglycine, for example, to provide the diversity domains of the library with the ability to interact with sites in a large binding site relatively unconstrained by attachment to the DNA binding protein.
  • Rigid spacers such as, e.g., polyproline, may also be inserted separately or in combination with other spacers, including glycine residues.
  • the variable domains can be close to one another with a spacer serving to orient the one variable domain with respect to the other, such as by employing a turn between the two sequences, as might be provided by a spacer of the sequence Gly-Pro-Gly, for example.
  • Cys residues at either or both ends of each variable region.
  • the Cys residues would then form disulfide bridges to hold the variable regions together in a loop, and in this fashion may also serve to mimic a cyclic peptide.
  • various other types of covalent linkages for cyclization may also be accomplished.
  • spacer residues described above can also be encoded on either or both ends of the variable nucleotide region.
  • a cyclic peptide coding sequence can be made without an intervening spacer by having a Cys codon on both ends of the random peptide coding sequence.
  • flexible spacers e.g., polyglycine
  • rigid spacers may allow the peptide to be presented as if on the end of a rigid arm, where the number of residues, e.g., Pro, determines not only the length of the arm but also the direction for the arm in which the peptide is oriented.
  • Hydrophilic spacers made up of charged and/or uncharged hydrophilic amino acids, (e.g., Thr, His, Asn, Gln, Arg, Glu, Asp, Met, Lys, etc.), or hydrophobic spacers made up of hydrophobic amino acids (e.g., Phe, Leu, Ile, Gly, Val, Ala, etc.) may be used to present the peptides to binding sites with a variety of local environments.
  • hydrophilic amino acids e.g., Thr, His, Asn, Gln, Arg, Glu, Asp, Met, Lys, etc.
  • hydrophobic spacers made up of hydrophobic amino acids
  • the present invention can be used to construct improved spacer molecules.
  • a random peptide library that encodes a DNA binding protein, such as the lac repressor or a cysteine depleted lac repressor (described below), a random peptide of formula NNK 5 (sequences up to and including NNK 10 or NNK 15 could also be used), and a peptide ligand of known specificity.
  • a DNA binding protein such as the lac repressor or a cysteine depleted lac repressor (described below)
  • a random peptide of formula NNK 5 sequences up to and including NNK 10 or NNK 15 could also be used
  • a peptide ligand of known specificity One would then screen the library for improved binding of the peptide ligand to the receptor specific for the ligand using the method of the present invention; fusion proteins that exhibit improved specificity would be isolated together with the vector that encodes them, and the vector would be sequenced to determine the structure of the spacer responsible for
  • recombinant peptide libraries consist of sequences of the 20 normal L-amino acids. While the available structural diversity for such a library is large, additional diversity can be introduced by a variety of means, such as chemical modifications of the amino acids. For example, as one source of added diversity a peptide library of the invention can be subjected to carboxy terminal amidation. Carboxy terminal amidation is necessary to the activity of many naturally occurring bioactive peptides.
  • This modification occurs in vivo through cleavage of the N-C bond of a carboxy terminal Gly residue in a two-step reaction catalyzed by the enzymes peptidylglycine alpha-amidation monooxygenase (PAM) and hydroxyglycine aminotransferase (HGAT).
  • PAM peptidylglycine alpha-amidation monooxygenase
  • HGAT hydroxyglycine aminotransferase
  • Amidation can be performed by treatment with enzymes, such as PAM and HGAT, in vivo or in vitro, and under conditions conducive to maintaining the structural integrity of the fusion protein/vector complex.
  • enzymes such as PAM and HGAT
  • amidation will occur on a library subset, i.e., those peptides having a carboxy terminal Gly.
  • a library of peptides designed for amidation can be constructed by introducing a Gly codon at the end of the variable region domain of the library. After amidation, an enriched library serves as a particularly efficient source of ligands for receptors that preferentially bind amidated peptides.
  • Conditions for C-terminal amidation of the libraries of the invention were developed using a model system that employed an antibody specific for the amidated C-terminus of the peptide cholecystokinin (CCK).
  • the reaction conditions to make the peptide alpha-amidating monooxygenase (PAM) enzyme active when used to amidate the libraries were developed using an 125 I labeled small peptide substrate and an ELISA with a positive control glycine extended CCK octamer peptide fused to the lac repressor.
  • the E. coli strain used in the experiment carried plasmid pJS129, which encodes the cysteine free lac repressor (described below) fused to the CCK substrate peptide (DYMGWMDFG) (SEQ. ID NO. 79).
  • a panning lysate was made from this strain using the standard panning protocol (see Example 6). After concentration of the column fractions in a Centriprep 100, four samples were prepared, each containing 0.25 ml of lysate and 0.25 ml of 2x PAM buffer (prepared by mixing 0.2 ml of 1M HEPES, pH 7.4 (with KOH), 0.9 ml of 20% lactose, 3.65 ml of H 2 O, and 0.1 ml of a solution composed of 20 mg/ml catalase, 100 ⁇ l of 20 mM CuSO 4 , 16.6 ⁇ l of 6M NaI, and 150 ⁇ l of 0.1M ascorbic acid).
  • 2x PAM buffer prepared by mixing 0.2 ml of 1M HEPES, pH 7.4 (with KOH), 0.9 ml of 20% lactose, 3.65 ml of H 2 O, and 0.1 ml of a solution composed of 20 mg/ml catalase, 100 ⁇ l of 20
  • PAM enzyme was added to the tubes in different amounts and incubated at 37° C. for 30 minutes. Then, 120 ⁇ l of 5% BSA in HEKL buffer and 6 ⁇ l of 10 mg/ml herring DNA were added to each tube; the contents of each tube were then added to 6 microtiter wells that had been coated with 2 ⁇ g/well anti-CCK antibody and blocked with BSA. The microtiter plate was agitated at 4° C. for 150 minutes, washed 5 ⁇ with cold HEKL, washed for 10 minutes with a solution composed of HEKL, 1% BSA, and 0.1 mg/ml herring DNA, and washed again 5 ⁇ with cold HEKL. The plasmids were eluted using the standard protocol and used to transform E. coli host cells. The results showed a dramatic increase in the recovery of plasmid transformants with increasing amounts of PAM enzyme, demonstrating that the amidation reaction worked.
  • variable region library can be provided with codons that code for amino acid residues involved in phosphorylation, glycosylation, sulfation, isoprenylation (or the addition of other lipids), etc.
  • Modifications not catalyzed by naturally occurring enzymes can be introduced by chemical means (under relatively mild conditions) or through the action of, e.g., catalytic antibodies and the like.
  • an efficient strategy for library construction involves specifying the enzyme (or chemical) substrate recognition site within or adjacent to the variable nucleotide region of the library so that most members of the library are modified.
  • the substrate recognition site added can be simply a single residue (e.g., serine for phosphorylation) or a complex consensus sequence, as desired.
  • Conformational constraints, or scaffolding can also be introduced into the structure of the peptide libraries.
  • a number of motifs from known protein and peptide structures can be adapted for this purpose.
  • the method involves introducing nucleotide sequences that code for conserved structural residues into or adjacent to the variable nucleotide region so as to contribute to the desired peptide structure. Positions nonessential to the structure are allowed to vary.
  • a degenerate peptide library as described herein can incorporate the conserved frameworks to produce and/or identify members of families of bioactive peptides or their binding receptor elements.
  • families of bioactive peptides are related by a secondary structure that results in a conserved "framework," which in some cases is a pair of cysteines that flank a string of variable residues. This results in the display of the variable residues in a loop closed by a disulfide bond, as discussed above.
  • a more complex framework that contributes to the bioactivity of the peptides is shared among members of a peptide family.
  • An example of this class is the conotoxins: peptide toxins of 10 to 30 amino acids produced by venomous molluscs known as predatory cone snails.
  • the conotoxin peptides generally possess a high density of disulfide crosslinking. Of those that are highly crosslinked, most belong to two groups, mu and omega, that have conserved primary frameworks as follows (C is Cys): ##STR1## The number of residues flanked by each pair of Cys residues varies from 2 to 6 in the peptides reported to date.
  • the mu and omega classes (with 6 Cys residues) have 15 possible combinations of disulfide bonds. Usually only one of these conformations is the active ("correct") form.
  • the correct folding of the peptides may be directed by a conserved 40 residue peptide that is cleaved from the N-terminus of the conopeptide to produce the small, mature bioactive peptides that appear in the venom.
  • a sequence for the structural framework for use in the present invention comprises Cys-Cys-Y-Cys-Y-Cys-Cys, or Cys-Y-Cys-Y-Cys-Cys-Y-Cys, where Y is (NNK) x or (NNS) x ; N is A, C, G or T; K is G or T; S is G or C; and x is from 2 to 6.
  • Plasmid pJS123 is derived from plasmid pMC5 by site specific mutagenesis and encodes a lac repressor identical to the lac repressor encoded on plasmid pMC5, except the cysteine codon at position 107 has been changed to an serine codon; the cysteine codon at position 140 has been changed to an alanine codon (alanine works better than serine at this position); and the cysteine codon at position 281 has been changed to a serine codon.
  • Plasmid pJS123 (available in strain ARI 161 from the American Type Culture Collection under the accession number ATCC No. 68819) is therefore preferred for constructing random peptide libraries involving cysteine-linked framework structures.
  • the lac repressor coding sequence in plasmid pJS123 can be subjected to mutagenesis to improve the binding of the mutant protein with lacO type sequences.
  • a preferred method for performing this mutagenesis involves the construction of a coding sequence in plasmid pJS123 that encodes a fusion protein comprised of the cysteine depleted lac repressor, a spacer peptide, and a peptide ligand of known specificity.
  • the resulting vector is subjected to mutagenesis by any of a variety of methods; a preferred method involves transformation of an E. coli mutator strain such as mutD5 (see Schaaper, 1988, Proc. Natl. Acad. Sci.
  • the fusion proteins are screened by the present method to find vectors that have been mutated to increase the binding affinity of the cysteine depleted lac repressor to the lacO sequence.
  • plasmid pJS123 was modified to include a D32.39 antibody epitope to create plasmid pJS128, which was then introduced into a mutD mutator strain. Oligonucleotides were then cloned into the mutagenized vector to encode a D32.39 epitope joined to repressor via a random region of 5, 10, or 15 amino acids. This library was panned on D32.39 antibody for 5 rounds under increasingly stringent conditions. Individual clones were selected from the population of plasmids surviving after the fifth round and tested by a variety of assays.
  • tests for ability to repress the chromosomal lac operon included: (1) tests for ability to repress the chromosomal lac operon (a test of DNA binding affinity); (2) tests for plasmid copy number; (3) ELISA with D32.39 antibody to test for display of the peptide epitope; and (4) tests of plasmid recovery during panning.
  • Several of these plasmids were sequenced in the random tail region to determine the structure of the linker peptide.
  • a series of subcloning experiments were also conducted to determine regions of the plasmids that determined the observable properties of the plasmids.
  • plasmids carrying a higher copy number replication origin and encoding one of the linker regions were constructed and sequenced to ascertain that no base changes in the cysteine free repressor gene, as compared to the starting plasmid, were introduced.
  • the linker tail of this plasmid and the cloning strategy for random libraries is shown in FIG. 4.
  • Two versions of the vector were constructed, one with the cysteine-free lac repressor gene (ARI246/pJS141; ATCC No. 69088) and one with the wild-type lac repressor gene (ARI280/pJS142; ATCC No.69087).
  • ARI246 has the genotype E. coli B lon-11 sulA1 hsdR17 ⁇ (ompT-fepC) ⁇ clpA319::kan lacI42::Tn10 lacZU118.
  • the lon-11, ⁇ (ompT-fepC), and ⁇ clpA319::kan mutations destroy three genes involved in proteolysis, so this strain should allow greater diversity of peptides to be expressed on the library particles.
  • the sulA1 mutation suppresses the filamentation phenotype caused by the lon-11 allele.
  • the hsdR17 mutation destroys the restriction system to allow more efficient transformation of unmodified DNA.
  • the lacI42::Tn10 mutation eliminates expression of the chromosomal lac repressor gene to prevent competition of wild-type repressor for binding sites on the library plasmids.
  • the lacZU118 allele stops expression of ⁇ -galactosidase, which would otherwise be constitutive in the lacI42::Tn10 background, leading to unnecessary use of cell resources and reducing growth rates.
  • E. coli B cells grow more quickly than K12 cells and yield excellent electrocompetent cells for transformation. Transformation frequencies of around 5 ⁇ 10 10 tf/ ⁇ g of Bluescript plasmid DNA can be frequently observed with ARI246 cells.
  • ARI280 has the same genotype as ARI246, except that the lacI mutation has been converted to a deletion by selecting for loss of the Tn10 insertion, and a recA::cat mutation has been introduced.
  • the recA::cat mutation is useful to prevent homologous recombination between plasmids. As a consequence, the library plasmids exist more frequently as monomers, rather than multimeric forms that can be observed in ARI246.
  • the monomers are better for two reasons: monomers reduce the valency of peptides per library particle, allowing more stringent selection for higher affinity peptide ligands; and growth as monomers increases the number of plasmids per amount of DNA, increasing the number of library equivalents that can be panned against receptors.
  • the recA::cat mutation makes the strain less healthy, so growth rates are slower, and the transformation frequency is reduced to about 2 ⁇ 10 10 tf/ ⁇ g.
  • residues that contribute to the peptide structure, around which the variable amino acids are encoded by the library members can provide for alpha helices, a helix-turn-helix structure, four helix bundles, a beta-sheet, or other secondary or tertiary structural (framework or scaffolding) motifs. See U.S. patent application Ser. No. 07/718,577, filed Jun. 20, 1991, incorporated herein by reference.
  • DNA binding peptides such as those that correspond to the transcriptional transactivators referred to as leucine zippers, can also be used as a framework, provided the DNA binding peptide is distinct from the DNA binding protein component of the fusion protein and the library vector does not contain the binding site for the DNA binding peptide.
  • leucine residues are repeated every seven residues in the motifs, and the region is adjacent to an alpha helical region rich in lysines and arginines and characterized by a conserved helical face and a variable helical face.
  • fragments of a gene encoding a known ligand prepared by, e.g., limited DNAse digestion into pieces of 20 to 100 base pairs, are subcloned into a variable nucleotide region system as described herein either singly or in random combinations of several fragments.
  • the fragment library is then screened in accordance with the procedures herein for binding to the receptor to identify small peptides capable of binding to the receptor and having characteristics which differ as desired from the parental peptide ligand.
  • the peptide library can contain as few as 10 to 100 different members, although libraries of 1000 or more members will generally be used.
  • the present invention can be used to construct peptide ligands of great diversity.
  • novel features of the preferred embodiment of the invention called "peptides on plasmids", in which the lac repressor is the DNA binding protein and a plasmid vector encodes the fusion protein, are distinct from those of the previously described phage libraries.
  • the random peptides of the present libraries can be displayed with a free carboxy terminus instead of being displayed at the amino terminus or internal to the carrier protein and so add diversity to the peptide structures available for receptor binding.
  • the presentation of peptide ligands at the carboxy terminus also facilitates amidation, as discussed above.
  • This mode of display also ensures that stop codons in the degenerate region, which occur more often in longer degenerate oligonucleotides, shorten rather than destroy individual clones.
  • the presence of stop codons in the random peptide coding sequence actually serves to create additional diversity, by creating peptides of differing lengths.
  • the lac repressor fusions of the invention also allow the display of potential ligands with a wide range of sizes.
  • lac repressor fusions are cytoplasmic proteins, unlike the phage fusions, which are exported to the periplasm.
  • the use of both fusion methods increases total available peptide diversity, because the two types of libraries are exposed to different cellular compartments and so are exposed to different sets of E. coli proteases and to different reduction/oxidation environments.
  • the peptides need simply be compatible with the formation of at least a repressor dimer, which is the smallest form of the protein that can bind DNA (see Daly and Matthews, 1986, Biochem. 25:5474-5478, and Kania and Brown, 1976, Proc. Natl. Acad, Sci. USA 73:3529-3533).
  • the lac repressor fusion library displays multiple copies of the peptide on each library particle.
  • Each repressor tetramer in principle, displays four peptides that are available for binding to receptors.
  • each plasmid monomer can bind up to two tetramers (if no loop is formed), and multimers of the plasmid can display higher multiples of two tetramers.
  • This multivalent display allows the isolation of ligands with moderate affinity (micromolar K d , see Cwirla et al., supra). For receptors with known, high affinity peptide ligands, these moderate affinity ligands can obscure the high affinity ones simply because of their greater numbers.
  • This problem can be overcome by immobilizing monovalent receptors at low density, which allows high affinity (nanomolar K d ) ligands to be identified, as discussed above.
  • high affinity (nanomolar K d ) ligands For receptors whose normal ligands are not small peptides, however, this multivalency of display will be an advantage for identifying initial families of moderate affinity ligands, which can then be optimized by additional rounds of screening under monovalent conditions.
  • the multivalency of ligand display therefore allows the isolation of peptides with a wide range of affinities, depending on the density of the receptor during the panning procedure.
  • Libraries of peptides produced and screened according to the present invention are particularly useful for mapping antibody epitopes.
  • the ability to sample a large number of potential epitopes as described herein has clear advantages over the methods based on chemical synthesis now in use and described in, among others, Geysen et al., 1987, J. Immunol. Meth. 102:259-274.
  • these libraries are useful in providing new ligands for important binding molecules, such as hormone receptors, adhesion molecules, enzymes, and the like.
  • the present libraries can be generalized to allow the screening of a wide variety of peptide and protein ligands.
  • the vectors are constructed so that screening of other ligands encoded by the plasmid is possible.
  • the system can be simply modified to allow screening of RNA ligands.
  • a known RNA binding protein e.g., a ribosomal protein
  • a promoter elsewhere on the vector drives expression of an RNA molecule composed of the known binding site for the RNA binding protein followed by random sequence.
  • the DNA-RNA binding fusion protein would link the genetic information of the vector with each member of a library of RNA ligands. These RNA ligands could then be screened by panning techniques.
  • Another large class of possible extensions to this technique is to use a modified version of the vector to isolate genes whose products modify peptides, proteins, or RNA in a desired fashion. This requires the availability of a receptor that binds specifically to the modified product.
  • a connection is made between the plasmid and the substrate peptide, protein, or RNA, as described above.
  • the plasmid is then used as a cloning vector to make libraries of DNA or cDNA from a source with the potential to contain the desired modification gene (specific organisms, PCR amplified antibody genes, etc.) under the control of a promoter that functions in E. coli. Plasmids carrying the gene in question could then be isolated by panning lysates of the library with the receptor specific for the modified product.
  • a gene encoding an enzyme that cleaves a particular amino acid sequence could be isolated from libraries of DNA from organisms that might have such a protease or from amplified antibody cDNA.
  • An antibody for use as the receptor would first be made to the peptide that would remain after the desired cleavage reaction had taken place. Many such antibodies will not bind to that peptide unless it is exposed at the N- or C-termius of the protein.
  • the coding sequence for the uncleaved substrate sequence would be attached to the DNA binding protein coding sequence in a vector. This vector would be used to make an expression library from an appropriate source.
  • the bacterial strains used were E. coli K12 strains MC1061 (araD139 ⁇ (araABC-leu)7696 thr ⁇ lacX74 galU galK hsdR mcrB rpsL(strA) thi), ARI 20 (F' lac + pro + lacIqL8 lacIam74 // ⁇ (lac-pro) thi rpsL(strA) recA::cat), and XL1-Blue (F' proAB lacIq lacZ ⁇ M15 Tn10 // recA1 endA1 gyrA96 thi hsdR17 supE44 relA1 lac), and E.
  • coli B strain ARI 161 (lon-11, sulA1, hsdR17, ⁇ (ompT-fepC), ⁇ clpA319::kan).
  • ARI 161 is a protease deficient strain and serves to minimize proteolysis of the peptides in the library, which would reduce the available diversity for panning. Mutations known to reduce proteolysis include degP, lon, htpR, ompT, and clpA,P.
  • Plasmid pBAD18 contains the araB promoter followed by a polylinker and a terminator under the control of the positive/negative regulator AraC, also specified by the plasmid. Plasmid pBAD18 also contains a modified plasmid pBR322 origin and the bla gene to permit replication and selection in E. coli, as well as the phage M13 intragenic region to permit rescue of single-stranded DNA for sequencing.
  • the lacI gene was modified for cloning into plasmid pBAD18 using the GeneAmp® PCR amplification kit (Perkin-Elmer Cetus Instruments) with oligonucleotides ON-286 and ON-287, shown below:
  • ON-286 contains a nonhomologous 5' region that adds an NheI site, a consensus ribosome binding site (see Gold and Stormo, 1990, Methods in Enzymology (Goeddel, ed., Boston: Academic Press), pp. 89-103, incorporated herein by reference), and changes the initiation codon of lacI from GTG to ATG.
  • ON-287 changes codons 356 and 357 of lacI to an XhoI site through two silent mutations, and adds a SacI site after the lacI stop codon.
  • ON-295 adds an NdeI site and a lacO S sequence at one end of the amplified fragment
  • ON-296 adds a ClaI site and lacO S at the other end. Cloning of the NdeI to ClaI fragment into pJS100 produced plasmid pJS102.
  • the library plasmid pMC5 was constructed by cloning complementary oligonucleotides ON-335 and ON-336 to replace the SfiI to HindIII dynorphin B segment of pMC3, as shown in FIG. 2. Oligonucleotides ON-335 and ON-336 are shown below: ##STR4## Plasmid pMC3 is available in strain ARI161 from the American Type Culture Collection under the accession number ATCC No. 68818.
  • Oligonucleotide ON-332 was synthesized with the sequence: ##STR5## where N is A, C, G, or T (equimolar) and K is G or T (see Cwirla et al., supra).
  • the oligonucleotide was purified by HPLC and phosphorylated with T4 kinase (New England Biolabs).
  • the two half-site oligonucleotides ON-369 and ON-370 were phosphorylated during synthesis and are shown below: ##STR6##
  • ON-369 and ON-370 annealed to ON-332 produce SfiI and HindIII-compatible ends, respectively, but the ligated product does not have either recognition sequence (see FIG. 2).
  • oligonucleotide Four hundred pmoles of each oligonucleotide were annealed in a 25 ⁇ l reaction buffer (10 mM Tris, pH 7.4, 1 mM EDTA, 100 mM NaCl), by heating to 65° C. for 10 min. and cooling for 30 min. to room temperature.
  • Vector pMC5 was digested to completion with SfiI and HindIII, the vector backbone was isolated by 4 rounds of washing with TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA) in a Centricon 100 microconcentrator (Amicon) by the manufacturer's instructions, followed by phenol extraction and ethanol precipitation.
  • the annealed oligonucleotides were added to 64 micrograms of digested pMC5 at a 4:1 molar ratio in a 3.2 ml ligation reaction containing 5% PEG, 3200 units of HindIII, 194 Weiss units of T4 ligase (New England Biolabs), 1 mM ATP, 20 mM Tris, pH 7.5, 10 mM MgCl2, 0.1 mM EDTA, 50 ⁇ g/ml BSA, and 2 mM DTT. The reaction was split equally into 8 tubes and incubated overnight at 15° C.
  • the cells containing the library were concentrated by centrifugation at 5500 x g for 6 min., washed once in ice-cold 50 mM Tris (pH 7.6), 10 mM EDTA, 100 mM KCl, followed by a wash in ice-cold 10 mM Tris, 0.1 mM EDTA, 100 mM KCl.
  • the final pellet was resuspended in 16 ml of HEG buffer (35 mM HEPES/KOH pH 7.5, 0.1 mM EDTA, 100 mM Na Glutamate), distributed into 19 tubes of 1.0 ml each, frozen on dry ice, and stored at -70° C.
  • lysis buffer 35 mM HEPES ⁇ pH 7.5 with KOH ⁇ , 0.1 mM EDTA, 100 mM Na glutamate, 5% glycerol, 0.3 mg/ml BSA, 1 mM DTT, and 0.1 mM PMSF. Lysozyme was added (0.3 ml at 10 mg/ml in HEG), and the mixture was incubated on ice for 1 hr.
  • the cellular debris was removed by centrifugation of the lysate at 20,000 x g for 15 min., and the supernatant was concentrated by centrifugation in a Centriprep® 100 concentrator (Amicon) at 500 x g for 40 min.
  • the concentrated supernatant (about 0.5 ml) was washed with 10 ml of HEG buffer and centrifuged as before. A sample (5%) of the total lysate was removed to determine the pre-panned input of plasmid complexes.
  • An alternate method for partially purifying and concentrating the lysate is as follows. About 2.0 ml of the frozen cells in HEG are thawed on ice, and then 8 ml of lysis buffer without Na glutamate (high ionic strength inhibits lysozyme; DTT is optional) are added to the cells, and the mixture is incubated on ice for 1 hr. The cellular debris is removed from the lysate by centrifugation at 20,000 x g for 15 min., and the supernatant is loaded onto a Sephacryl® S-400 High Resolution (Pharmacia) gel-filtration column (22 mm ⁇ 250 mm). The plasmid-fusion protein complexes elute in the void volume. The void volume (30 ml) is concentrated with two Centriprep® 100 concentrators, as described above. After adjusting the Na glutamate concentration of the concentrate, one carries out the remainder of the procedure in the same manner as with the first method.
  • the plasmids were dissociated from the beads by phenol extraction, and after adding 20 ⁇ g of glycogen (Boehringer Mannheim), the DNA was precipitated with an equal volume of isopropanol. The pellet was washed with 75% ethanol, and the DNA was resuspended in either 4 ⁇ l (panned DNA) or 400 ⁇ l (pre-panned DNA) of H 2 O. Strain MC1061 was transformed using 2 ⁇ l each of the DNA solutions to permit counts of recovered plasmids and amplification of the selected plasmids. The results of the panning are shown below in Table 1.
  • An ELISA was used to test MC1061 transformants from the second, third, and fourth rounds for D32.39-specific ligands (see Example 3).
  • the ELISA was performed in a 96-well plate (Beckman). Single colonies of transformants obtained from panning were grown overnight in LB/100 ⁇ g/ml ampicillin at 37° C. The overnight cultures were diluted 1/10 in 3 ml LB/100 ⁇ g/ml ampicillin and grown 1 hr. The expression of the lac repressor-peptide fusions was induced by the addition of arabinose to a final concentration of 0.2%.
  • the cells were lysed as described above in 1 ml of lysis buffer plus lysozyme and stored at -70° C. Thawed crude lysate was added to each of 2 wells (100 ⁇ l/well), and the plate was incubated at 37° C. After 45 min, 100 ⁇ l of 1% BSA in PBS (10 mM NaPO4, pH 7.4, 120 mM NaCl, and 2.7 mM KCl) were added for an additional 15 min. at 37° C., followed by 3 washes with PBS/0.05% Tween 20. Each well then was blocked with 1% BSA in PBS (200 ⁇ l/well) for 30 min. at 37° C., and the wells were washed as before.
  • PBS 10 mM NaPO4, pH 7.4, 120 mM NaCl, and 2.7 mM KCl
  • the primary antibody D32.39 (100 ⁇ l of antibody at 1 ⁇ g/ml in PBS/0.1% BSA) was added to each well, the plate was incubated at room temperature for 1 hr., and then each well was washed as before.
  • the secondary antibody alkaline phosphatase-conjugated Goat-anti-rabbit antibody (Gibco-BRL), was diluted 1/3000 in PBS/0.1% BSA and added to each well (100 ⁇ l/well); the plate was then incubated for 1 hr at room temperature.
  • the ELISA was developed with 4 mg/ml p-nitrophenyl phosphate in 1M diethanolamine/HCl pH 9.8, 0.24 mM MgCl 2 (200 ⁇ l/well).
  • the reaction was stopped after 6 min. by the addition of 2M NaOH (50 ⁇ l/well), and the absorbance at 405 nm was measured on a plate reader (a Biomek, from Beckman).
  • the positive control for the ELISA was MC1061 transformed with pMC3, encoding the lac repressor-dynorphin B fusion.
  • the negative controls were wells not coated with lysate. Background variability was calculated from the wells containing lysates from 16 colonies selected at random from the library, none of which scored significantly above the negative controls. Wells were scored as positive if the measured absorbance was at least two standard deviations above background.
  • plasmids from both ELISA positive and ELISA negative colonies obtained after panning were sequenced.
  • Double stranded plasmid DNA, isolated from strain XL1-Blue, was sequenced using Sequenase® (US Biochemicals) according to the instructions supplied by the manufacturer.
  • the preferred recognition sequence for the D32.39 antibody apparently covers a six amino acid region of the dynorphin B peptide (RQFKVV) (SEQ. ID NO. 80).
  • RQFKVV dynorphin B peptide
  • arginine is invariant for all of the ELISA positive clones. No strong bias was evident for residues in the second position.
  • five amino acids phenylalanine, histidine, asparagine, tyrosine, and tryptophan, in order of frequency
  • the aromatic amino acids comprise 74% of this total.
  • the fourth position shows a strong bias for the positively charged residues lysine (69%) and arginine (21%).
  • the fifth position is occupied almost exclusively by hydrophobic residues, most of which are valine (81%). Valine and threonine predominate in the sixth position (76%), with serine and isoleucine accounting for most of the remaining amino acids.
  • Plasmid pDimer1 was constructed to provide a monovalent display system.
  • the plasmid encodes a lac headpiece dimer linked to a dynorphin B antibody epitope (RQFKVVT) (SEQ. ID NO. 81); a random linker is encoded between the headpieces and between the second headpiece and the dynorphin B epitope.
  • RQFKVVT dynorphin B antibody epitope
  • This vector was used in the affinity enrichment protocol with anti-dynorphin B antibody to determine the optimum linker sequences, as discussed below.
  • Plasmid pDimer1 was constructed from plasmid pMC5 by first using plasmid pMC5 as a PCR template for amplification with oligonucleotide primers ON-929 and ON-930. These oligonucleotides are shown below. ##STR7## The amplified DNA resulting from the PCR amplification was digested with restriction enzymes BamHI and ApaI and then ligated with the large BamHI-ApaI fragment of plasmid pMC5 to yield plasmid pMC5dlacI. This process resulted in a deletion of all but about the first 60 codons (the lac headpiece coding sequence) of the lacI gene coding sequence from plasmid pMC5.
  • plasmid pMC5 was used as a template for PCR amplification with oligonucleotide primers ON-938 and ON-940 (to encode a five amino acid random linker between the two headpieces) and ON-939 and ON-940 (to encode a four amino acid random linker between the two headpieces). These oligonucleotides are shown below (M is A or C). ##STR8## The amplified DNA from each reaction was digested with restriction enzymes SstI and HindIII and then ligated to the large SstI-HindIII fragment of plasmid pMC5dlacI. The resulting plasmids were designated pDimer1 and were then transformed into E. coli host cells as a mixture.
  • the resulting library of transformants was panned in accordance with the procedure of Example 6, except that HEK buffer rather than HEKL buffer was used in the lysis and column purification steps.
  • the cells were grown either in LB broth with 0.1% glucose and supplemented with L-arabinose to 0.2% about 30 minutes before harvesting the plasmids or in LB broth without glucose and supplemented with L-arabinose to 0.2% about 15 minutes before harvesting the plasmids. Both protocols yielded similar results.
  • Four rounds of affinity enrichment were completed; in the latter two rounds, about 5 to 10 ⁇ g/ml of an oligonucleotide encoding lacO S was added during the lysis and panning steps to increase the stringency of selection for tight-binding derivatives. This oligonucleotide is shown below in single-stranded form but is used in double-stranded form. ##STR9##
  • This Example provides a standard protocol for the method of the present invention with any receptor that can be immobilized on a microtiter dish with an immobilizing antibody. To practice the method, the following reagents will be helpful.
  • HEK buffer is identical to HE buffer but also contains KCl at a final concentration of 50 mM.
  • HEKL buffer is identical to HEK buffer but also contains alpha-lactose, which may require warming to go into solution, at a final concentration of 0.2M.
  • Lysis buffer (6 ml) is prepared by mixing 4.2 ml of HE buffer with 1 ml of 50% glycerol, 750 ⁇ l of protease free BSA at 10 mg/ml in PBS, 10 ⁇ l of 0.5M DTT, and 12.5 ⁇ l of 0.1M PMSF in isopropanol.
  • HEK/BSA buffer is prepared by dissolving 5 g of BSA, fraction V, in 500 ml of HEK buffer.
  • the process can be conveniently carried out over a two day period, as shown below.
  • steps A-O should also be carried out.

Abstract

A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also contain a binding site for the DNA binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a continuation-in-part of U.S. patent application Ser. No. 07/778,233, filed Oct. 16, 1991, now U.S. Pat. No. 5,270,170, and is related to copending U.S. patent application Ser. No. 07/517,659, filed May 1, 1990, and to copending Ser. No. 07/541,108, filed Jun. 20, 1990, and to copending Ser. No. 07/718,577, filed Jun. 20, 1991, each of which is incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates generally to methods for selecting peptide ligands to receptor molecules of interest and, more particularly, to methods for generating and screening large peptide libraries for peptides with desired binding characteristics.
BACKGROUND OF THE INVENTION
The isolation of ligands that bind biological receptors is fundamental to understanding signal transduction and to discovering new therapeutics. The ability to synthesize DNA chemically has made possible the construction of extremely large collections of nucleic acid and peptide sequences as potential ligands. Recently developed methods allow efficient screening of libraries for desired binding activities (see Pluckthun and Ge, 1991, Angew. Chem. Int. Ed. Engl. 30:296-298). For example, RNA molecules with the ability to bind a particular protein (see Tuerk and Gold, 1990, Science 249:505-510) or a dye (see Ellington and Szostak, 1990, Nature 346:818-822) have been selected by alternate rounds of affinity selection and PCR amplification. A similar technique was used to determine the DNA sequences that bound a human transcription factor (see Thiesen and Bach, 1990, Nucl. Acids Res. 18:3203-3209).
Application of efficient screening techniques to peptides requires the establishment of a physical or logical connection between each peptide and the nucleic acid that encodes the peptide. After rounds of affinity enrichment, such a connection allows identification, usually by amplification and sequencing, of the genetic material encoding interesting peptides. Several phage based systems for screening proteins and polypeptides have been described. The fusion phage approach of Parmley and Smith, 1988, Gene 73:305-318, can be used to screen proteins. Others have described phage based systems in which the peptide is fused to the pIII coat protein of filamentous phage (see Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science 249:404-406; and Cwirla et al., 1990, Proc. Natl. Acad. Sci. USA 87:6378-6382; each of which is incorporated herein by reference).
In these latter publications, the authors describe expression of a peptide at the amino terminus of or internal to the pIII protein. The connection between peptide and the genetic material that encodes the peptide is established, because the fusion protein is part of the capsid enclosing the phage genomic DNA. Phage encoding peptide ligands for receptors of interest can be isolated from libraries of greater than 108 peptides after several rounds of affinity enrichment followed by phage growth. Other non-phage based systems that could be suggested for the construction of peptide libraries include direct screening of nascent peptides on polysomes (see Tuerk and Gold, supra) and display of peptides directly on the surface of E. coli. As in the filamentous phage system, all of these methods rely on a physical association of the peptide with the nucleic acid that encodes the peptide.
There remains a need for methods of constructing peptide libraries in addition to the methods described above. For instance, the above methods do not provide random peptides with a free carboxy terminus, yet such peptides would add diversity to the peptide structures now available for receptor binding. In addition, prior art methods for constructing random peptide libraries cannot tolerate stop codons in the degenerate region coding for the random peptide, yet stop codons occur with frequency in degenerate oligonucleotides. Prior art methods involving phage fusions require that the fusion peptide be exported to the periplasm and so are limited to fusion proteins that are compatible with the protein export apparatus and the formation of an intact phage coat.
The present invention provides random peptide libraries and methods for generating and screening those libraries with significant advantages over the prior art methods.
SUMMARY OF THE INVENTION
The present invention provides random peptide libraries and methods for generating and screening those libraries to identify peptides that bind to receptor molecules of interest. The peptides can be used for therapeutic, diagnostic, and related purposes, e.g., to bind the receptor or an analogue of the receptor and so inhibit or promote the activity of the receptor.
The peptide library of the invention is constructed so that the peptide is expressed as a fusion product; the peptide is fused to a DNA binding protein. The peptide library is constructed so that the DNA binding protein can bind to the recombinant DNA expression vector that encodes the fusion product that contains the peptide of interest. The method of generating the peptide library of the invention comprises the steps of (a) constructing a recombinant DNA vector that encodes a DNA binding protein and contains a binding site for the DNA binding protein; (b) inserting into the coding sequence of the DNA binding protein in the vector of step (a) a coding sequence for a peptide such that the resulting vector encodes a fusion protein composed of the DNA binding protein and the peptide; (c) transforming a host cell with the vector of step (b); and (d) culturing the host cell transformed in step (c) under conditions suitable for expression of the fusion protein.
The screening method of the invention comprises the steps of (a) lysing the cells transformed with the peptide library under conditions such that the fusion protein remains bound to the vector that encodes the fusion protein; (b) contacting the fusion proteins of the peptide library with a receptor under conditions conducive to specific peptide-receptor binding; and (c) isolating the vector that encodes a peptide that binds to said receptor. By repetition of the affinity selection process one or more times, the plasmids encoding the peptides of interest can be enriched. By increased stringency of the selection, peptides of increasingly higher affinity can be identified.
The present invention also relates to recombinant DNA vectors useful for constructing the random peptide library, the random peptide library, host cells transformed with the recombinant vectors of the library, and fusion proteins expressed by those host cells.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a recombinant vector of a random peptide library of the invention. In this embodiment of the invention, the DNA binding protein is the lacI gene product, the fusion protein forms a tetramer, and the tetramer interacts with the vector and immobilized receptor, as shown in the Figure. The library plasmid carries the lacI gene with random coding sequence fused to the 3' end of the coding sequence of the gene, as well as two lacO sequences. The lac repressor-peptide fusions produced by the hybrid genes bind to the lacO sites on the same plasmid that encodes them. After lysis of cells containing the random library, those plasmid-repressor-peptide complexes that specifically bind a chosen receptor are enriched by avidity panning against the immobilized receptor. Transformation of E. coli with recovered plasmids allows additional rounds of panning or sequencing of isolated clones.
FIG. 2 (SEQ. ID NOS.:1-6) shows a partial restriction site, DNA sequence, and function map of plasmid pMC5. Hybridization of oligonucleotide ON-332 to oligonucleotides ON-369 and ON-370 produces a fragment with cohesive ends compatible with SfiI, HindIII digested plasmid pMC5. The ligation product adds sequence coding for twelve random amino acids to the end of lacI through a six codon linker. The library plasmid also contains: the rrnB transcriptional terminator, the bla gene to permit selection on ampicillin, the M13 phage intragenic region to permit rescue of single-stranded DNA, a plasmid replication origin (ori), two lacOS sequences, and the araC gene to permit positive and negative regulation of the araB promoter that drives expression of the lacI fusion gene.
FIGS. 3A and 3B (SEQ. ID NOS.:7-64) shows sequences isolated by panning with the D32.39 antibody. Each sequence is listed with a clone number, the panning round in which the clone was isolated, and the result of the ELISA with D32.39 antibody. The sequences are aligned to show the D32.39 epitope that they share (box).
FIG. 4 shows the linker sequences from vectors pJS141 and pJS142.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
For purposes of clarity and a complete understanding of the invention, the following terms are defined.
"DNA Binding Protein" refers to a protein that specifically interacts with deoxyribonucleotide strands. Those of skill in the art will recognize that, for purposes of the present invention, the DNA binding protein must bind specifically to a recombinant DNA vector and, in a preferred embodiment, bind to a specific sequence of DNA contained in the vector. In embodiments of the invention in which RNA vectors are used, DNA binding protein can also refer to an RNA binding protein.
"Epitope" refers to that portion of an antigen that interacts with an antibody.
"Host Cell" refers to a eukaryotic or procaryotic cell or group of cells that can be or has been transformed by a recombinant DNA vector. For purposes of the present invention, a host cell is typically a bacterium, such as an E. coli K12 cell or an E. coli B cell.
"Ligand" refers to a molecule, such as a random peptide, that is recognized by a particular receptor.
"Ligand Fragment" refers to a portion of a gene encoding a ligand and to the portion of the ligand encoded by that gene fragment.
"Ligand Fragment Library" refers not only to a set of recombinant DNA vectors that encodes a set of ligand fragments, but also to the set of ligand fragments encoded by those vectors, as well as the fusion proteins containing those ligand fragments.
"Linker" or "spacer" refers to a molecule or group of molecules that connects two molecules, such as a DNA binding protein and a random peptide, and serves to place the two molecules in a preferred configuration, e.g., so that the random peptide can bind to a receptor with minimal steric hindrance from the DNA binding protein.
"Peptide" or "polypeptide" refers to a polymer in which the monomers are alpha amino acids joined together through amide bonds. Peptides are two or often more amino acid monomers long. Standard abbreviations for amino acids are used herein (see Stryer, 1988, Biochemistry, Third Ed., incorporated herein by reference.)
"Random Peptide" refers to an oligomer composed of two or more amino acid monomers and constructed by a stochastic or random process. A random peptide can include framework or scaffolding motifs, as described below.
"Random Peptide Library" refers not only to a set of recombinant DNA vectors that encodes a set of random peptides, but also to the set of random peptides encoded by those vectors, as well as the fusion proteins containing those random peptides.
"Receptor" refers to a molecule that has an affinity for a given ligand. Receptors can be naturally occurring or synthetic molecules. Receptors can be employed in an unaltered state or as aggregates with other species. Receptors can be attached, covalently or noncovalently, to a binding member, either directly or via a specific binding substance. Examples of receptors include, but are not limited to, antibodies, including monoclonal antibodies and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials), cell membrane receptors, enzymes, and hormone receptors.
"Recombinant DNA Vector" refers to a DNA or RNA molecule that encodes a useful function and can be used to transform a host cell. For purposes of the present invention, a recombinant DNA vector typically is a phage or plasmid and can be extrachromosomally maintained in a host cell or controllably integrated into and excised from a host cell chromosome.
The present invention provides random peptide libraries and methods for generating and screening those libraries to identify either peptides that bind to receptor molecules of interest or gene products that modify peptides or RNA in a desired fashion. The peptides are produced from libraries of random peptide expression vectors that encode peptides attached to a DNA binding protein. A method of affinity enrichment allows a very large library of peptides to be screened and the vector carrying the desired peptide(s) to be selected. The nucleic acid can then be isolated from the vector and sequenced to deduce the amino acid sequence of the desired peptide. Using these methods, one can identify a peptide as having a desired binding affinity for a molecule. The peptide can then be synthesized in bulk by conventional means.
By identifying the peptide de novo, one need not know the sequence or structure of the receptor molecule or the sequence or structure of the natural binding partner of the receptor. Indeed, for many "receptor" molecules a binding partner has not yet been identified. A significant advantage of the present invention is that no prior information regarding an expected ligand structure is required to isolate peptide ligands of interest. The peptide identified will have biological activity, which is meant to include at least specific binding affinity for a selected receptor molecule and, in some instances, will further include the ability to block the binding of other compounds, to stimulate or inhibit metabolic pathways, to act as a signal or messenger, to stimulate or inhibit cellular activity, and the like.
The number of possible receptor molecules for which peptide ligands may be identified by means of the present invention is virtually unlimited. For example, the receptor molecule may be an antibody (or a binding portion thereof). The antigen to which the antibody binds may be known and perhaps even sequenced, in which case the invention may be used to map epitopes of the antigen. If the antigen is unknown, such as with certain autoimmune diseases, for example, sera, fluids, tissue, or cell from patients with the disease can be used in the present screening method to identify peptides, and consequently the antigen, that elicits the autoimmune response. One can also use the present screening method to tailor a peptide to a particular purpose. Once a peptide has been identified, that peptide can serve as, or provide the basis for, the development of a vaccine, a therapeutic agent, a diagnostic reagent, etc.
The present invention can be used to identify peptide ligands for a wide variety of receptors in addition to antibodies. These ligands include, by way of example and not limitation, growth factors, hormones, enzyme substrates, interferons, interleukins, intracellular and intercellular messengers, lectins, cellular adhesion molecules, and the like. Peptide ligands can also be identified by the present invention for molecules that are not peptides or proteins, e.g., carbohydrates, non-protein organic compounds, metals, etc. Thus, although antibodies are widely available and conveniently manipulated, antibodies are merely representative of receptor molecules for which peptide ligands can be identified by means of the present invention.
The peptide library is constructed so that the DNA binding protein-random peptide fusion product can bind to the recombinant DNA expression vector that encodes the fusion product that contains the peptide of interest. The method of generating the peptide library comprises the steps of (a) constructing a recombinant DNA vector that encodes a DNA binding protein and contains binding sites for the DNA binding protein; (b) inserting into the coding sequence of the DNA binding protein in a multiplicity of vectors of step (a) coding sequences for random peptides such that the resulting vectors encode different fusion proteins, each of which is composed of the DNA binding protein and a random peptide; (c) transforming host cells with the vectors of step (b); and (d) culturing the host cells transformed in step (c) under conditions suitable for expression of the fusion proteins. Typically, a random peptide library will contain at least 106 to 108 different members, although library sizes of 108 to 1013 can be achieved.
The peptide library produced by this method is especially useful in screening for ligands that bind to a receptor of interest. This screening method comprises the steps of (a) lysing the cells transformed with the peptide library under conditions such that the fusion protein remains bound to the vector that encodes the fusion protein; (b) contacting the fusion proteins of the peptide library with a receptor under conditions conducive to specific peptide-receptor binding; and (c) isolating the vector that encodes a peptide that binds to said receptor. By repetition of the affinity selection process one or more times, the vectors that encode the peptides of interest may be enriched. By increased stringency of the selection, peptides of increasingly higher affinity can be identified. If the presence of cytoplasmic or periplasmic proteins interferes with binding of fusion protein to receptor, then partial purification of fusion protein-plasmid complexes by gel filtration, affinity, or other purification methods can be used to prevent such interference. For instance, purification of the cell lysate on a column (such as the Sephacryl S-400 HR column) that removes small proteins and other molecules may be useful.
The recombinant vectors of the random peptide library are constructed so that the random peptide is expressed as a fusion product; the peptide is fused to a DNA binding protein. A DNA binding protein of the invention must exhibit high avidity binding to DNA and have a region that can accept insertions of amino acids without interfering with the DNA binding activity. The half-life of a DNA binding protein-DNA complex produced by practice of the present method must be long enough to allow screening to occur. Typically, the half-life will be one to four hours or longer.
Suitable DNA binding proteins for purposes of the present invention include proteins selected from a large group of known DNA binding proteins including transcriptional regulators and proteins that serve structural functions on DNA. Examples include: proteins that recognize DNA by virtue of a helix-turn-helix motif, such as the phage 434 repressor, the lambda phage cI and cro repressors, and the E. coli CAP protein from bacteria and proteins from eukaryotic cells that contain a homeobox helix-turn-helix motif; proteins containing the helix-loop-helix structure, such as myc and related proteins; proteins with leucine zippers and DNA binding basic domains such as fos and jun; proteins with `POU` domains such as the Drosophila paired protein; proteins with domains whose structures depend on metal ion chelation such as Cys2 His2 zinc fingers found in TFIIIA, Zn2 (Cys)6 clusters such as those found in yeast Ga14, the Cys3 His box found in retrovital nucleocapsid proteins, and the Zn2 (Cys)8 clusters found in nuclear hormone receptor-type proteins; the phage P22 Arc and Mnt repressors (see Knight et al., 1989, J. Biol. Chem. 264(7):3639-3642 and Bowie and Sauer, 1989, J. Biol. Chem. 264(13):7596-7602, each of which is incorporated in by reference); and others. Proteins that bind DNA in a non-sequence-specific manner could also be used, for example, histones, protamines, and HMG type proteins. In addition, proteins could be used that bind to DNA indirectly, by virtue of binding another protein bound to DNA. Examples of these include yeast Ga180 and adenovirus E1A protein.
Although many DNA binding proteins can be used in the construction of the libraries of the invention, the lac repressor is preferred for several reasons. The lac repressor, a 37 kDa protein, is the product of the E. coli lacI gene and negatively controls transcription of the lacZYA operon by binding to a specific DNA sequence called lacO. Structure-function relationships in the lac repressor have been studied extensively through the construction of thousands of amino acid substitution variants of the protein (see Gordon et al., 1988, J. Mol. Biol. 200:239-251, and Kleina and Miller, 1990, J. Mol. Biol. 212:295-318). The repressor exists as a tetramer in its native form with two high affinity DNA binding domains formed by the amino termini of the subunits (see Beyreuther, 1980, The Operon (Miller and Reznikoff, eds., Cold Spring Harbor Laboratory), pp. 123-154). The two DNA binding sites exhibit strong cooperativity of binding to DNA molecules with two lacO sequences. A single tetramer can bind to suitably spaced sites on a plasmid, forming a loop of DNA between the two sites, and the resulting complex is stable for days (see Besse et al., 1986, EMBO J. 1377-1381; Flashner and Gralla, 1988, Proc. Natl. Acad. Sci. USA 85:8968-8972; Hsieh et al. 1987 J. Biol. Chem. 262:14583-14591; Kramer et al., 1987, EMBO J. 6:1481-1491; Mossing and Record, 1986, Science 233:889-892; and Whitson et al., 1987, J. Biol. Chem. 262:14592-14599).
The carboxy terminal domains of the lac repressor form the dimer and tetramer contacts, but significantly, fusions of proteins as large as α-galactosidase can be made to the carboxy terminus without eliminating the DNA binding activity of the repressor (see Muller-Hill and Kania, 1974, Nature 249:561-563; and Brake et al., 1978, Proc. Natl. Acad. Sci. USA 75:4824-4827). The lac repressor fusion proteins of the present invention include not only carboxy terminus fusions but also amino terminus fusions and peptide insertions in the lac repressor. Substitutions of other sequences, including eukaryotic nuclear localization signals, transcriptional activation domains, and nuclease domains, have been made at both the amino and carboxy termini of the lac repressor without serious disruption of specific DNA binding (see Hu and Davidson, 1991, Gene 99:141-150; Labow et al., 1990, Mol. Cell. Biol. 10:3343-3356; and Panayotatos et al., 1989, J. Biol. Chem. 264:15066-15069).
The binding of the lac repressor to a single wild-type lacO is both tight and rapid, with a dissociation constant of 10-13 M, an association rate constant of 7×109 M-1 s-1, and a half-life for the lac repressor-lacO complex of about 30 min. (see Barkley and Bourgeois, 1980, The Operon (Miller and Reznikoff, eds., Cold Spring Harbor Laboratory), pp 177-220) The high stability of the lac repressor-DNA complex has permitted its use in methods for identifying DNA binding proteins (see Levens and Howley, 1985, Mol. Cell. Biol. 2307-2315), for quantifying PCR-amplified DNA (see Lundeberg et al., 1991, Bio/Tech. 10:68-75), and for cleavage of the E. coli and yeast genomes at a single site (see Koob and Szybalski 1990, Science 250:271-273). This stability is important for purposes of the present invention, because, for the affinity selection or "panning" step of the screening process to succeed, the connection between the fusion protein and the plasmid that encodes the fusion protein must remain intact for at least a portion of the complexes throughout the panning step.
In fact, for purposes of the present invention, a longer half-life is preferred. A variety of techniques can be used to increase the stability of the DNA binding protein-DNA complex. These techniques include altering the amino acid sequence of the DNA binding protein, altering the DNA sequence of the DNA binding site, increasing the number of DNA binding sites on the vector, adding compounds that increase the stability of the complex (such as lactose or ONPF for the lac system), and various combinations of each of these techniques.
An illustrative random peptide library cloning vector of the invention, plasmid pMC5, demonstrates some of these techniques. Plasmid pMC5 has two lacO sequences to take advantage of the strong cooperative interaction between a lac repressor tetramer and two lac repressor binding sites, and each of these sequences is the symmetric variant of the lacO sequence, called lacOS or lacOid, which has about ten fold higher affinity for repressor than the wild-type sequence (see Sadler et al., 1983, Proc. Natl. Acad. Sci. USA 80:6785-6789, and Simons et al., 1984, Proc. Natl. Acad. Sci. USA 81:1624-1628 ). Other "tight-binding" lac repressors and coding sequences for those repressors that can be used for purposes of the present invention are described in Maurizot and Grebert, 1988, FEBS Lettrs. 239(1):105-108, incorporated herein by reference. See also Lehming et al., 1987 EMBO J. 6(10):3145-3153.
Plasmid pMC5 is shown in FIGS. 1 and 2, and details of the construction of the plasmid are in Example 1, below. This library plasmid contains two major functional elements in a vector that permits replication and selection in E. coli. The lacI gene is expressed under the control of the araB promoter and has a series of restriction enzyme sites at the 3' end of the gene. Synthetic oligonucleotides cloned into these sites fuse the lac repressor protein coding sequence to additional random peptide coding sequence.
Once a vector such as pMC5 is constructed, one need only clone peptide coding sequences in frame with the DNA binding protein coding sequences to obtain a random peptide library of the invention. Thus, the random peptide library of the invention is constructed by cloning an oligonucleotide that contains the random peptide coding sequence (and any spacers, framework determinants, etc., as discussed below) into a selected cloning site of a vector that encodes a DNA binding protein and binding sites for that protein.
Using known recombinant DNA techniques (see generally, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference), one can synthesize an oligonucleotide that, inter alia, removes unwanted restriction sites and adds desired ones, reconstructs the correct portions of any sequences that have been removed, inserts the spacer, conserved, or framework residues, if any, and corrects the translation frame (if necessary) to produce an active fusion protein comprised of a DNA binding protein and random peptide. The central portion of the oligonucleotide will generally contain one or more random peptide coding sequences (variable region domain) and spacer or framework residues. The sequences are ultimately expressed as peptides (with or without spacer or framework residues) fused to or in the DNA binding protein.
The variable region domain of the oligonucleotide encodes a key feature of the library: the random peptide. The size of the library will vary according to the number of variable codons, and hence the size of the peptides, that are desired. Generally, the library will be at least 106 to 108 or more members, although smaller libraries may be quite useful in some circumstances. To generate the collection of oligonucleotides that forms a series of codons encoding a random collection of amino acids and that is ultimately cloned into the vector, a codon motif is used, such as (NNK)x, where N may be A, C, G, or T (nominally equimolar), K is G or T (nominally equimolar), and x is typically up to about 5, 6, 7, or 8 or more, thereby producing libraries of penta-, hexa-, hepta-, and octa-peptides or more. The third position may also be G or C, designated "S". Thus, NNK or NNS (i) code for all the amino acids, (ii) code for only one stop codon, and (iii) reduce the range of codon bias from 6:1 to 3:1. There are 32 possible codons resulting from the NNK motif: 1 for each of 12 amino acids, 2 for each of 5 amino acids, 3 for each of 3 amino acids, and only one of the three stop codons. With longer peptides, the size of the library that is generated can become a constraint in the cloning process, but the larger libraries can be sampled, as described below. The expression of peptides from randomly generated mixtures of oligonucleotides in recombinant vectors is discussed in Oliphant et al., 1986, Gene 44:177-183, incorporated herein by reference.
An exemplified codon motif (NNK)x produces 32 codons, one for each of 12 amino acids, two for each of five amino acids, three for each of three amino acids and one (amber) stop codon. Although this motif produces a codon distribution as equitable as available with standard methods of oligonucleotide synthesis, it results in a bias against peptides containing one-codon residues. For example, a complete collection of hexacodons contains one sequence encoding each peptide made up of only one-codon amino acids, but contains 729 (36) sequences encoding each peptide with three-codon amino acids.
An alternate approach that minimizes the bias against one-codon residues involves the synthesis of 20 activated trinucleotides, each representing the codon for one of the 20 genetically encoded amino acids. These trinucleotides are synthesized by conventional means, removed from the support with the base and 5-OH-protecting groups intact, and activated by the addition of 3'-O-phosphoramidite (and phosphate protection with beta-cyanoethyl groups) by the method used for the activation of mononucleosides, as generally described in McBride and Caruthers, 1983, Tetr. Letters 22:245, which is incorporated herein by reference.
Degenerate "oligocodons" are prepared using these trimers as building blocks. The trimers are mixed at the desired molar ratios and installed in the synthesizer. The ratios will usually be approximately equimolar, but may be a controlled unequal ratio to obtain the over- to under-representation of certain amino acids coded for by the degenerate oligonucleotide collection. The condensation of the trimers to form the oligocodons is done essentially as described for conventional synthesis employing activated mononucleosides as building blocks. See generally, Atkinson and Smith, 1984, Oligonucleotide Synthesis (M. J. Gait, ed.), pp. 35-82. This procedure generates a population of oligonucleotides for cloning that is capable of encoding an equal distribution (or a controlled unequal distribution) of the possible peptide sequences. This approach may be especially useful in generating longer peptide sequences, because the range of bias produced by the (NNK)x motif increases by three-fold with each additional amino acid residue.
When the codon motif is (NNK)x, as defined above, and when x equals 8, there are 2.6×1010 possible octapeptides. A library containing most of the octapeptides may be produced, but a sampling of the octapeptides may be more conveniently constructed by making only a subset library using about 0.1%, and up to as much as 1%, 5%, or 10%, of the possible sequences, which subset of recombinant vectors is then screened. As the library size increases, smaller percentages are acceptable. If desired, to extend the diversity of a subset library the recovered vector subset may be subjected to mutagenesis and then subjected to subsequent rounds of screening. This mutagenesis step may be accomplished in two general ways: the variable region of the recovered phage may be mutagenized or additional variable amino acids may be added to the regions adjoining the initial variable sequences.
The process of constructing a random peptide encoding oligonucleotide is described in Example 2, below. In brief, a library can be constructed in pMC5 using the half-site cloning strategy of Cwirla et al., supra. A random dodecamer peptide sequence, connected to the C-terminus of the lac repressor through a linker peptide GADGGA (GADGA [SEQ. ID NO.:65]) would also be an acceptable linker), can be specified by a degenerate oligonucleotide population containing twelve codons of the form NNK, where N is any base, and K is G or T. Transformation of E. coli strain MC1061 using 4 μg of pMC5 ligated to a four fold molar excess of annealed oligonucleotides yielded a test library of 5.5×108 independent clones.
Once the library is constructed, host cells are transformed with the library vectors. The successful transformants are typically selected by growth in a selective medium or under selective conditions, e.g., an appropriate antibiotic, which, in the case of plasmid pMC5 derivatives, is preferably ampicillin. This selection may be done on solid or in liquid growth medium. For growth on solid medium, the cells are grown at a high density (- 108 to 109 transformants per m2) on a large surface of, for example, L-agar containing the selective antibiotic to form essentially a confluent lawn. For growth in liquid culture, cells may be grown in L-broth (with antibiotic selection) through about 10 or more doublings. Growth in liquid culture may be more convenient because of the size of the libraries, while growth on solid media likely provides less chance of bias during the amplification process.
For best results with the present method, one should control the ratio of fusion proteins to vectors so that vectors are saturated with fusion proteins, without a vast excess of fusion protein. Too little fusion protein could result in vectors with free binding sites that might be filled by fusion protein from other cells in the population during cell lysis, thus breaking the connection between the genetic information and the peptide ligand. Too much fusion protein could lead to titration of available receptor sites during panning by fusion protein molecules not bound to plasmid. To control this ratio, one can use any of a variety of origin of replication sequences to control vector number and/or an inducible promoter, such as any of the promoters selected from the group consisting of the araB, lambda pL, (which can be either nalidixic acid or heat inducible or both), trp, lac, T7, T3, and tac or trc (these latter two are trp/lac hybrids) promoters to control fusion protein number. A regulated promoter is also useful to limit the amount of time that the peptide ligands are exposed to cellular proteases. By inducing the promoter a short time before lysing the cells containing a library, one can minimize the time during which proteases act.
The araB promoter normally drives expression of the enzymes of the E. coli araBAD operon, which are involved in the catabolism of L-arabinose. The araB promoter is regulated both positively and negatively, depending on the presence of L-arabinose in the growth medium, by the AraC protein. This promoter can be catabolite repressed by adding glucose to the growth medium and induced by adding L-arabinose to the medium. Plasmid pMC5 encodes and can drive expression of the AraC protein (see Lee, 1980, The Operon (Miller and Reznikoff, eds., Cold Spring Harbor Laboratory), pp. 389-409). The araB promoter is also regulated by the CAP protein, an activator involved in the E. coli system of catabolite repression.
The expression level of the lacI fusion gene under the control of the araB promoter in plasmid pMC5 can be controlled over a very wide range through changes in the growth medium. One can construct a vector to measure expression of a fusion protein encoding gene to determine the growth conditions needed to maintain an acceptable ratio of repressors to vectors. Plasmid pMC3 is such a vector and can be constructed by attaching an oligonucleotide that encodes a short peptide linker (GADGA [SEQ. ID NO.:65]) followed by dynorphin B (YGGFLRRQFKVVT [SEQ. ID NO.:66]) to the lacI gene in plasmid pMC5. Monoclonal antibody D32.39 binds to dynorphin B, a 13 amino acid opioid peptide (see Barrett and Goldstein, 1985, Neuropeptides 2:113-120, incorporated herein by reference). These same reagents, plasmids pMC3 and pMC5 and receptor D32.39, provide a test receptor and positive and negative controls for use in panning experiments, described below. Growth of E. coli transformants harboring plasmid pMC3 in LB broth (10 g of tryptone, 5 g of NaCl, and 5 g of yeast extract per liter) allowed detection in a Western blot of a faint band of the expected molecular weight, while addition of 0.2% glucose rendered this band undetectable. Growth in LB plus 0.2% L-arabinose led to the production of a very heavy band on a stained gel, representing greater than 25% of the total cell protein.
To prevent overproduction of the fusion protein encoded by a plasmid pMC5 derivative (or any other vector of the present invention that has an inducible promoter), one can grow the transformants first under non-inducing conditions (to minimize exposure of the fusion protein to cellular proteases and to minimize exposure of the cell to the possibly deleterious effects of the fusion protein) and then under "partial induction" conditions. For the araB promoter, partial induction can be achieved with as little as 3.3×10-5 % of L-arabinose (as demonstrated by increased repression in the assay described below). A preferred way to achieve partial induction consists of growing the cells in 0.1% glucose until about 30 min. before the cells are harvested; then, 0.2 to 0.5% L-arabinose is added to the culture to induce expression of the fusion protein. Other methods to express the protein controllably are available.
One can estimate the lacI expression level necessary to fill the available binding sites in a typical plasmid pMC5 derivative by observing the behavior of strain ARI 20 (lacI- lacZYA+) transformed with pMC3 or pMC5 (encoding only the linker peptide GADGA [SEQ. ID NO.:65]). Because the lacO sites in plasmids pMC3 and pMC5 have higher affinity than those in the lacZYA operon, the available repressor should fill the plasmid sites first. Substantial repression of lacZYA should be observed only if there is an excess of repressor beyond the amount needed to fill the plasmid sites. As shown by color level on X-gal indicator plates and direct assays of β-galactosidase (see Miller, J. H., 1972, Experiments in Molecular Genetics (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.), incorporated herein by reference), the amount of repressor produced by pMC5 is sufficient to fill the lacO sites and repress greater than 200 fold lacZYA in ARI 20 host cells during growth in normal LB medium (2.4 units compared to 500 units from ARI 20 transformed with vector pBAD18, which has no lacI). The repressor encoded by pMC3 was partially inactivated by the addition of the dynorphin B tail, allowing about 10 fold higher expression of lacZYA (37 units). Because of the apparent excess production of repressor under these conditions, LB is a preferred medium for expressing similar fusion proteins of the invention.
At some point during the growth of the transformants, the fusion protein will be expressed. Because the random peptide vector also contains DNA binding sites for the DNA binding protein, fusion proteins will bind to the vectors that encode them. After these complexes form, the cells containing a library are lysed, and the complexes are partially purified away from cell debris. Following cell lysis, one should avoid cross reaction between unbound fusion proteins of one cell with heterologous DNA molecules of another cell. The presence of high concentrations of the DNA binding site for the DNA binding protein will minimize this type of cross reaction. Thus, for the lac system, one can synthesize a DNA duplex encoding the lacO or a mutated lacO sequence for addition to the cell lysis solution. The compound ONPF, as well as lactose, is known to strengthen the binding of the lac repressor to lacO, so one can also, or alternatively, add ONPF or lactose to the cell lysis solution to minimize this type of cross reaction.
After cell lysis, in a process called panning, plasmid-peptide complexes that bind specifically to immobilized receptors are separated from nonbinding complexes, which are washed away. Bulk DNA can be included during the lysis and panning steps to compete for non-specific binding sites and to lower the background of non-receptor-specific binding to the immobilized receptor. A variety of washing procedures can be used to enrich for retention of molecules with desired affinity ranges. For affinity enrichment of desired clones, from about 102 to 106 library equivalents (a library equivalent is one of each recombinant; 104 equivalents of a library of 109 members is 1013 vectors), but typically 103 to 104 library equivalents, are incubated with a receptor (or portion thereof) for which a peptide ligand is desired. The receptor is in one of several forms appropriate for affinity enrichment schemes. In one example the receptor is immobilized on a surface or particle, and the library is then panned on the immobilized receptor generally according to the procedure described below.
A second example of receptor presentation is receptor attached to a recognizable ligand (which may be attached via a spacer). A specific example of such a ligand is biotin. The receptor, so modified, is incubated with the library, and binding occurs with both reactants in solution. The resulting complexes are then bound to streptavidin (or avidin) through the biotin moiety. See PCT patent publication No. 91/07087. The streptavidin may be immobilized on a surface such as a plastic plate or on particles, in which case the complexes (vector/DNA binding protein/peptide/receptor/biotin/streptavidin) are physically retained; or the streptavidin may be labelled, with a fluorophore, for example, to tag the active fusion protein for detection and/or isolation by sorting procedures, e.g., on a fluorescence-activated cell sorter.
Vectors that express peptides without the desired specificity are removed by washing. The degree and stringency of washing required will be determined for each receptor/peptide of interest. A certain degree of control can be exerted over the binding characteristics of the peptides recovered by adjusting the conditions of the binding incubation and the subsequent washing. The temperature, pH, ionic strength, divalent cation concentration, and the volume and duration of the washing will select for peptides within particular ranges of affinity for the receptor. Selection based on slow dissociation rate, which is usually predictive of high affinity, is the most practical route. This may be done either by continued incubation in the presence of a saturating amount of free ligand, or by increasing the volume, number, and length of the washes. In each case, the rebinding of dissociated peptide-vector is prevented, and with increasing time, peptide-vectors of higher and higher affinity are recovered. Additional modifications of the binding and washing procedures may be applied to find peptides that bind receptors under special conditions.
Although the screening method is highly specific, the procedure generally does not discriminate between peptides of modest affinity (micromolar dissociation constants) and those of high affinity (nanomolar dissociation constants or greater). The ability to select peptides with relatively low affinity may be the result of multivalent interaction between a vector/fusion protein complex and a receptor. For instance, when the receptor is an IgG antibody, each complex may bind to more than one antibody binding site, either by a single complex binding through the multiple peptides displayed to both sites of a single IgG molecule or by forming a network of complex-IgG. Multivalent interaction produces a high avidity and tenacious adherence of the vector during washing. Multivalent interactions can be mimicked by using a high density of immobilized monovalent receptor.
To enrich for the highest affinity peptide ligands, a substantially monovalent interaction between vector and the receptor (typically immobilized on a solid phase) may be appropriate. The screening (selection) with substantially monovalent interaction can be repeated as part of additional rounds of amplification and selection of vectors. Monovalent interactions may be achieved by employing low concentrations of receptor, such as the Fab binding fragment of an antibody molecule.
A strategy employing a combination of conditions favoring multivalent or monovalent interactions can be used to advantage in producing new peptide ligands for receptor molecules. By conducting the first rounds of screening under conditions to promote multivalent interactions, one can then use high stringency washing to reduce greatly the background of non-specifically bound vectors. This high avidity step may select a large pool of peptides with a wide range of affinities, including those with relatively low affinity. Subsequent screening under conditions favoring increasingly monovalent interactions and isolation of phage based on a slow dissociation rate may then allow the identification of the highest affinity peptides.
The present invention also provides univalent display vectors. As noted above, the lac operator is an inverted DNA repeat, and two separate lac repressor proteins bind to the operator. However, only a portion of the lac repressor protein binds to the operator. This portion, called the "headpiece," can be made as a recombinant protein (see Kaptein et al., 1990, Bioch. Pharmacol. 40:89-96). The present invention provides a recombinant DNA vector that encodes two or more fused lac headpieces and contains a site into which random peptide coding sequences can be introduced. This vector, described in Example 5, provides a monovalent display system, although a more preferred version of the system would comprise only one lacO sequence per vector (the vector in Example 5 has two lacO sequences). One can also construct derivatives of such vectors that encode 3, 4, 5, or more headpieces or encode mutated headpieces or binding sites (for instance, by using the His1 repressor headpiece and the 344 operator mutants described in Lehming et al., 1987, EMBO J. 6(10):3145-3153, incorporated herein by reference) to increase the affinity of the repressor for the operator.
In another aspect of the present invention, one can determine the relative affinity of a series of related peptide ligands by measuring the dissociation rate for a peptide of interest and the selected receptor molecule under substantially monovalent conditions. For example, one can measure the dissociation of a Fab fragment from vector/fusion protein complexes immobilized on particles. This procedure avoids the necessity and inconvenience of separately determining binding affinities for a selected peptide, which could be especially burdensome if a large number of peptides have been selected.
After washing the receptor-fusion protein-vector complexes to select for peptides of the desired affinity, the vector DNA is then released from bound complexes by, for example, treatment with high salt or extraction with phenol, or both. For the lac system, one can use IPTG, a compound known to decrease the stability of the lac repressor-lacO complex, to dissociate the plasmid from the fusion protein. In a preferred embodiment, the elution buffer includes 1 mM IPTG, 10 μg/mL of a double-stranded oligonucleotide that encodes lacOS, and 0.05 to 0.2M KCl. Once released from bound complexes, the plasmids are reintroduced into E. coli by transformation. Because of the high efficiency, the preferred method of transformation is electroporation. Using this new population of transformants, one can repeat additional cycles of panning to increase the proportion of peptides in the population that are specific for the receptor. The structure of the binding peptides can then be determined by sequencing the 3' region of the lacI fusion gene.
As noted above, antibody D32.39 and the pMC3 complex serves as a receptor-ligand positive control in panning experiments to determine ability to recover plasmids based on the sequence of the fusion peptide. Useful negative controls are pMC5, which encodes only the linker fusion peptide (GADGA [SEQ. ID NO.:65]), and pMC1, which encodes the dynorphin B peptide, but lacks the lacO sequences carreid by pMC3 and pMC5. Lysates of E. coli strains carrying each plasmid were panned on D32.39 immobilized on polystyrene petri dishes. After washing, plasmids were recovered from complexes bound to the plates by phenol extraction, followed by transformation of E. coli.
The results with pure lysates demonstrated about 100 fold more transformants recovered from pMC3 lysates as compared to the negative controls. The results with mixed lysates revealed enrichment of pMC3 versus controls among the population of recovered plasmids. The results with cells that were mixed before lysis yielded similar results. These results show that the plasmid-lacI-peptide complexes were sufficiently stable to allow enrichment of plasmids on the basis of the peptide the plasmids encode.
The random dodecapeptide library in pMC5 described above was used in the screening method of the invention to identify vectors that encode a fusion protein that comprised a peptide that would bind to D32.39 antibody coupled to sheep antimouse antibody coated magnetic beads. The number of complexes added to the beads at each round of panning yielded the equivalent of 1010 to 1011 transformants (see Example 3). After panning, the recovered plasmids yielded transformants ranging in number from about 108 in early rounds to almost 1011 in the fourth and final round. Compared to the number of transformants from antibody panned complexes, panning against unmodified polystyrene beads produced orders of magnitude fewer transformants.
The above results demonstrate that the DNA binding activity of lac repressor can act as a link between random peptides and the genetic material encoding them and so serve as the base on which to construct large peptide ligand libraries that can be efficiently screened. In the screening process, plasmid-repressor-peptide complexes are isolated by panning on immobilized receptor, the plasmids are amplified after transformation of E. coli, and the procedure is repeated to enrich for plasmids encoding peptides specific for the receptor. The repressor binds to the library plasmid with sufficient avidity to allow panning of the library on immobilized receptor without problematic levels of dissociation. This system can be used to identify a series of related peptides that bind to a monoclonal antibody whose epitope has not been characterized and to identify peptide ligands for other receptors.
Once a peptide ligand of interest has been identified, a variety of techniques can be used to diversify a peptide library to construct ligands with improved properties. In one approach, the positive vectors (those identified in an early round of panning) are sequenced to determine the identity of the active peptides. Oligonucleotides are then synthesized based on these peptide sequences, employing all bases at each step at concentrations designed to produce slight variations of the primary oligonucleotide sequences. This mixture of (slightly) degenerate oligonucleotides is then cloned into the random peptide library expression vector as described herein. This method produces systematic, controlled variations of the starting peptide sequences but requires, however, that individual positive vectors be sequenced before mutagenesis. This method is useful for expanding the diversity of small numbers of recovered vectors.
Another technique for diversifying a selected peptide involves the subtle misincorporation of nucleotide changes in the coding sequence for the peptide through the use of the polymerase chain reaction (PCR) under low fidelity conditions A protocol described in Leung et al., 1989, Technique 1:11-15, utilizes altered ratios of nucleotides and the addition of manganese ions to produce a 2% mutation frequency.
Yet another approach for diversifying a selected random peptide vector involves the mutagenesis of a pool, or subset, of recovered vectors. Recombinant host cells transformed with vectors recovered from panning are pooled and isolated. The vector DNA is mutagenized by treating the cells with, e.g., nitrous acid, formic acid, hydrazine, or by use of a mutator strain as described below. These treatments produce a variety of mutations in the vector DNA. The segment containing the sequence encoding the variable peptide can optionally be isolated by cutting with restriction nuclease(s) specific for sites flanking the variable region and then recloned into undamaged vector DNA. Alternatively, the mutagenized vectors can be used without recloning of the mutagenized random peptide coding sequence.
In the second general approach for diversifying a set of peptide ligands, that of adding additional amino acids to a peptide or peptides found to be active, a variety of methods are available. In one, the sequences of peptides selected in early panning are determined individually and new oligonucleotides, incorporating all or part of the determined sequence and an adjoining degenerate sequence, are synthesized. These are then cloned to produce a secondary library.
In another approach that adds a second variable region to a pool of random peptide expression vectors, a restriction site is installed next to the primary variable region. Preferably, the enzyme should cut outside of its recognition sequence, such as BspMI, which cuts leaving a four base 5' overhang, four bases to the 3' side of the recognition site. Thus, the recognition site may be placed four bases from the primary degenerate region. To insert a second variable region, a degenerately synthesized oligonucleotide is then ligated into this site to produce a second variable region juxtaposed to the primary variable region. This secondary library is then amplified and screened as before.
While in some instances it may be appropriate to synthesize peptides having contiguous variable regions to bind certain receptors, in other cases it may be desirable to provide peptides having two or more regions of diversity separated by spacer residues. For example, the variable regions may be separated by spacers that allow the diversity domains of the peptides to be presented to the receptor in different ways. The distance between variable regions may be as little as one residue or as many as five to ten to up to about 100 residues. For probing a large binding site, one may construct variable regions separated by a spacer containing 20 to 30 amino acids. The number of spacer residues, when present, will preferably be at least two to three or more but usually will be less than eight to ten. An oligonucleotide library having variable domains separated by spacers can be represented by the formula: (NNK)y --(abc)n --(NNK)z, where N and K are as defined previously (note that S as defined previously may be substituted for K); y+z is equal to about 5, 6, 7, 8, or more; a, b and c represent the same or different nucleotides comprising a codon encoding spacer amino acids; and n is up to about 20 to 30 codons or more.
The spacer residues may be somewhat flexible, comprising polyglycine, for example, to provide the diversity domains of the library with the ability to interact with sites in a large binding site relatively unconstrained by attachment to the DNA binding protein. Rigid spacers, such as, e.g., polyproline, may also be inserted separately or in combination with other spacers, including glycine residues. The variable domains can be close to one another with a spacer serving to orient the one variable domain with respect to the other, such as by employing a turn between the two sequences, as might be provided by a spacer of the sequence Gly-Pro-Gly, for example. To add stability to such a turn, it may be desirable or necessary to add Cys residues at either or both ends of each variable region. The Cys residues would then form disulfide bridges to hold the variable regions together in a loop, and in this fashion may also serve to mimic a cyclic peptide. Of course, those skilled in the art will appreciate that various other types of covalent linkages for cyclization may also be accomplished.
The spacer residues described above can also be encoded on either or both ends of the variable nucleotide region. For instance, a cyclic peptide coding sequence can be made without an intervening spacer by having a Cys codon on both ends of the random peptide coding sequence. As above, flexible spacers, e.g., polyglycine, may facilitate interaction of the random peptide with the selected receptors. Alternatively, rigid spacers may allow the peptide to be presented as if on the end of a rigid arm, where the number of residues, e.g., Pro, determines not only the length of the arm but also the direction for the arm in which the peptide is oriented. Hydrophilic spacers, made up of charged and/or uncharged hydrophilic amino acids, (e.g., Thr, His, Asn, Gln, Arg, Glu, Asp, Met, Lys, etc.), or hydrophobic spacers made up of hydrophobic amino acids (e.g., Phe, Leu, Ile, Gly, Val, Ala, etc.) may be used to present the peptides to binding sites with a variety of local environments.
The present invention can be used to construct improved spacer molecules. For example, one can construct a random peptide library that encodes a DNA binding protein, such as the lac repressor or a cysteine depleted lac repressor (described below), a random peptide of formula NNK5 (sequences up to and including NNK10 or NNK15 could also be used), and a peptide ligand of known specificity. One would then screen the library for improved binding of the peptide ligand to the receptor specific for the ligand using the method of the present invention; fusion proteins that exhibit improved specificity would be isolated together with the vector that encodes them, and the vector would be sequenced to determine the structure of the spacer responsible for the improved binding.
Unless modified during or after synthesis by the translation machinery, recombinant peptide libraries consist of sequences of the 20 normal L-amino acids. While the available structural diversity for such a library is large, additional diversity can be introduced by a variety of means, such as chemical modifications of the amino acids. For example, as one source of added diversity a peptide library of the invention can be subjected to carboxy terminal amidation. Carboxy terminal amidation is necessary to the activity of many naturally occurring bioactive peptides. This modification occurs in vivo through cleavage of the N-C bond of a carboxy terminal Gly residue in a two-step reaction catalyzed by the enzymes peptidylglycine alpha-amidation monooxygenase (PAM) and hydroxyglycine aminotransferase (HGAT). See, Eipper et al., 1991, J. Biol. Chem. 266:7827-7833; Mizuno et al., 1986, Biochem. Biophys. Res. Comm. 137(3):984-991; Murthy et al., 1986, J. Biol. Chem. 261(4):1815-1822; Katopodis et al., 1990, Biochemistry 29:6115-6120; and Young and Tamburini, 1989, J. Am. Chem. Soc. 111:1933-1934, each of which are incorporated herein by reference.
Amidation can be performed by treatment with enzymes, such as PAM and HGAT, in vivo or in vitro, and under conditions conducive to maintaining the structural integrity of the fusion protein/vector complex. In a random peptide library of the present invention, amidation will occur on a library subset, i.e., those peptides having a carboxy terminal Gly. A library of peptides designed for amidation can be constructed by introducing a Gly codon at the end of the variable region domain of the library. After amidation, an enriched library serves as a particularly efficient source of ligands for receptors that preferentially bind amidated peptides. Many of the C-terminus amidated bioactive peptides are processed from larger pro-hormones, where the amidated peptide is flanked at its C-terminus by the sequence -Gly-Lys-Arg-X . . . (SEQ. ID NO. 67) (where X is any amino acid). Oligonucleotides encoding the sequence -Gly-Lys-Arg-X-Stop (SEQ. ID NO. 67) can be placed at the 3' end of the variable oligonucleotide region. When expressed, the Gly-Lys-Arg-X (SEQ. ID NO. 67) is removed by in vivo or in vitro enzymatic treatment, and the peptide library is carboxy terminal amidated as described above.
Conditions for C-terminal amidation of the libraries of the invention were developed using a model system that employed an antibody specific for the amidated C-terminus of the peptide cholecystokinin (CCK). The reaction conditions to make the peptide alpha-amidating monooxygenase (PAM) enzyme active when used to amidate the libraries were developed using an 125 I labeled small peptide substrate and an ELISA with a positive control glycine extended CCK octamer peptide fused to the lac repressor. The E. coli strain used in the experiment carried plasmid pJS129, which encodes the cysteine free lac repressor (described below) fused to the CCK substrate peptide (DYMGWMDFG) (SEQ. ID NO. 79).
A panning lysate was made from this strain using the standard panning protocol (see Example 6). After concentration of the column fractions in a Centriprep 100, four samples were prepared, each containing 0.25 ml of lysate and 0.25 ml of 2x PAM buffer (prepared by mixing 0.2 ml of 1M HEPES, pH 7.4 (with KOH), 0.9 ml of 20% lactose, 3.65 ml of H2 O, and 0.1 ml of a solution composed of 20 mg/ml catalase, 100 μl of 20 mM CuSO4, 16.6 μl of 6M NaI, and 150 μl of 0.1M ascorbic acid). PAM enzyme was added to the tubes in different amounts and incubated at 37° C. for 30 minutes. Then, 120 μl of 5% BSA in HEKL buffer and 6 μl of 10 mg/ml herring DNA were added to each tube; the contents of each tube were then added to 6 microtiter wells that had been coated with 2 μg/well anti-CCK antibody and blocked with BSA. The microtiter plate was agitated at 4° C. for 150 minutes, washed 5× with cold HEKL, washed for 10 minutes with a solution composed of HEKL, 1% BSA, and 0.1 mg/ml herring DNA, and washed again 5× with cold HEKL. The plasmids were eluted using the standard protocol and used to transform E. coli host cells. The results showed a dramatic increase in the recovery of plasmid transformants with increasing amounts of PAM enzyme, demonstrating that the amidation reaction worked.
Other modifications found in naturally occurring peptides and proteins can be introduced into the libraries to provide additional diversity and to contribute to a desired biological activity. For example, the variable region library can be provided with codons that code for amino acid residues involved in phosphorylation, glycosylation, sulfation, isoprenylation (or the addition of other lipids), etc. Modifications not catalyzed by naturally occurring enzymes can be introduced by chemical means (under relatively mild conditions) or through the action of, e.g., catalytic antibodies and the like. In most cases, an efficient strategy for library construction involves specifying the enzyme (or chemical) substrate recognition site within or adjacent to the variable nucleotide region of the library so that most members of the library are modified. The substrate recognition site added can be simply a single residue (e.g., serine for phosphorylation) or a complex consensus sequence, as desired.
Conformational constraints, or scaffolding, can also be introduced into the structure of the peptide libraries. A number of motifs from known protein and peptide structures can be adapted for this purpose. The method involves introducing nucleotide sequences that code for conserved structural residues into or adjacent to the variable nucleotide region so as to contribute to the desired peptide structure. Positions nonessential to the structure are allowed to vary.
A degenerate peptide library as described herein can incorporate the conserved frameworks to produce and/or identify members of families of bioactive peptides or their binding receptor elements. Several families of bioactive peptides are related by a secondary structure that results in a conserved "framework," which in some cases is a pair of cysteines that flank a string of variable residues. This results in the display of the variable residues in a loop closed by a disulfide bond, as discussed above.
In some cases, a more complex framework that contributes to the bioactivity of the peptides is shared among members of a peptide family. An example of this class is the conotoxins: peptide toxins of 10 to 30 amino acids produced by venomous molluscs known as predatory cone snails. The conotoxin peptides generally possess a high density of disulfide crosslinking. Of those that are highly crosslinked, most belong to two groups, mu and omega, that have conserved primary frameworks as follows (C is Cys): ##STR1## The number of residues flanked by each pair of Cys residues varies from 2 to 6 in the peptides reported to date. The side chains of the residues that flank the Cys residues are apparently not conserved in peptides with different specificity, as in peptides from different species with similar or identical specificities. Thus, the conotoxins have exploited a conserved, densely crosslinked motif as a framework for hypervariable regions to produce a huge array of peptides with many different pharmacological effects.
The mu and omega classes (with 6 Cys residues) have 15 possible combinations of disulfide bonds. Usually only one of these conformations is the active ("correct") form. The correct folding of the peptides may be directed by a conserved 40 residue peptide that is cleaved from the N-terminus of the conopeptide to produce the small, mature bioactive peptides that appear in the venom.
With 2 to 6 variable residues between each pair of Cys residues, there are 125 (53) possible framework arrangements for the mu class (2,2,2, to 6,6,6), and 625 (54) possible for the omega class (2,2,2,2 to 6,6,6,6). Randomizing the identity of the residues within each framework produces 1010 to >1030 peptides. "Cono-like" peptide libraries are constructed having a conserved disulfide framework, varied numbers of residues in each hypervariable region, and varied identity of those residues. Thus, a sequence for the structural framework for use in the present invention comprises Cys-Cys-Y-Cys-Y-Cys-Cys, or Cys-Y-Cys-Y-Cys-Cys-Y-Cys-Y-Cys, where Y is (NNK)x or (NNS)x ; N is A, C, G or T; K is G or T; S is G or C; and x is from 2 to 6.
Framework structures that require the formation of one or more disulfide bonds under oxidizing conditions may create problems with respect to the natural lac repressor, which has 3 cysteine residues. All 3 of these residues, however, can be changed to other amino acids without a serious effect on the function of the molecule (see Kleina and Miller, supra). Plasmid pJS123 is derived from plasmid pMC5 by site specific mutagenesis and encodes a lac repressor identical to the lac repressor encoded on plasmid pMC5, except the cysteine codon at position 107 has been changed to an serine codon; the cysteine codon at position 140 has been changed to an alanine codon (alanine works better than serine at this position); and the cysteine codon at position 281 has been changed to a serine codon. Plasmid pJS123 (available in strain ARI 161 from the American Type Culture Collection under the accession number ATCC No. 68819) is therefore preferred for constructing random peptide libraries involving cysteine-linked framework structures.
The lac repressor coding sequence in plasmid pJS123 can be subjected to mutagenesis to improve the binding of the mutant protein with lacO type sequences. A preferred method for performing this mutagenesis involves the construction of a coding sequence in plasmid pJS123 that encodes a fusion protein comprised of the cysteine depleted lac repressor, a spacer peptide, and a peptide ligand of known specificity. The resulting vector is subjected to mutagenesis by any of a variety of methods; a preferred method involves transformation of an E. coli mutator strain such as mutD5 (see Schaaper, 1988, Proc. Natl. Acad. Sci. USA 85:8126-8130, incorporated herein by reference) and culture of the transformants to produce the fusion protein encoded by the vector. The fusion proteins are screened by the present method to find vectors that have been mutated to increase the binding affinity of the cysteine depleted lac repressor to the lacO sequence. One could combine this method with the method of constructing improved spacers, described above, to select for an improved cysteine depleted lac repressor-peptide spacer molecule.
In such a fashion, plasmid pJS123 was modified to include a D32.39 antibody epitope to create plasmid pJS128, which was then introduced into a mutD mutator strain. Oligonucleotides were then cloned into the mutagenized vector to encode a D32.39 epitope joined to repressor via a random region of 5, 10, or 15 amino acids. This library was panned on D32.39 antibody for 5 rounds under increasingly stringent conditions. Individual clones were selected from the population of plasmids surviving after the fifth round and tested by a variety of assays. These assays included: (1) tests for ability to repress the chromosomal lac operon (a test of DNA binding affinity); (2) tests for plasmid copy number; (3) ELISA with D32.39 antibody to test for display of the peptide epitope; and (4) tests of plasmid recovery during panning. Several of these plasmids were sequenced in the random tail region to determine the structure of the linker peptide. A series of subcloning experiments were also conducted to determine regions of the plasmids that determined the observable properties of the plasmids. Finally, plasmids carrying a higher copy number replication origin and encoding one of the linker regions were constructed and sequenced to ascertain that no base changes in the cysteine free repressor gene, as compared to the starting plasmid, were introduced. The linker tail of this plasmid and the cloning strategy for random libraries is shown in FIG. 4. Two versions of the vector were constructed, one with the cysteine-free lac repressor gene (ARI246/pJS141; ATCC No. 69088) and one with the wild-type lac repressor gene (ARI280/pJS142; ATCC No.69087).
ARI246 has the genotype E. coli B lon-11 sulA1 hsdR17 Δ(ompT-fepC) ΔclpA319::kan lacI42::Tn10 lacZU118. The lon-11, Δ(ompT-fepC), and ΔclpA319::kan mutations destroy three genes involved in proteolysis, so this strain should allow greater diversity of peptides to be expressed on the library particles. The sulA1 mutation suppresses the filamentation phenotype caused by the lon-11 allele. The hsdR17 mutation destroys the restriction system to allow more efficient transformation of unmodified DNA. The lacI42::Tn10 mutation eliminates expression of the chromosomal lac repressor gene to prevent competition of wild-type repressor for binding sites on the library plasmids. The lacZU118 allele stops expression of β-galactosidase, which would otherwise be constitutive in the lacI42::Tn10 background, leading to unnecessary use of cell resources and reducing growth rates. E. coli B cells grow more quickly than K12 cells and yield excellent electrocompetent cells for transformation. Transformation frequencies of around 5×1010 tf/μg of Bluescript plasmid DNA can be frequently observed with ARI246 cells. ARI280 has the same genotype as ARI246, except that the lacI mutation has been converted to a deletion by selecting for loss of the Tn10 insertion, and a recA::cat mutation has been introduced. The recA::cat mutation is useful to prevent homologous recombination between plasmids. As a consequence, the library plasmids exist more frequently as monomers, rather than multimeric forms that can be observed in ARI246. The monomers are better for two reasons: monomers reduce the valency of peptides per library particle, allowing more stringent selection for higher affinity peptide ligands; and growth as monomers increases the number of plasmids per amount of DNA, increasing the number of library equivalents that can be panned against receptors. The recA::cat mutation makes the strain less healthy, so growth rates are slower, and the transformation frequency is reduced to about 2×1010 tf/μg.
Other changes can be introduced to provide residues that contribute to the peptide structure, around which the variable amino acids are encoded by the library members. For example, these residues can provide for alpha helices, a helix-turn-helix structure, four helix bundles, a beta-sheet, or other secondary or tertiary structural (framework or scaffolding) motifs. See U.S. patent application Ser. No. 07/718,577, filed Jun. 20, 1991, incorporated herein by reference. DNA binding peptides, such as those that correspond to the transcriptional transactivators referred to as leucine zippers, can also be used as a framework, provided the DNA binding peptide is distinct from the DNA binding protein component of the fusion protein and the library vector does not contain the binding site for the DNA binding peptide. In these peptides, leucine residues are repeated every seven residues in the motifs, and the region is adjacent to an alpha helical region rich in lysines and arginines and characterized by a conserved helical face and a variable helical face.
Other specialized forms of structural constraints can also be used in the present invention. For example, certain serine proteases are inhibited by small proteins of conserved structure (e.g., pancreatic trypsin inhibitor). This conserved framework can incorporate degenerate regions as described herein to generate libraries for screening for novel protease inhibitors.
In another aspect related to frameworks for a peptide library, information from the structure of known ligands can be used to find new peptide ligands having features modified from those of the known ligand. In this embodiment, fragments of a gene encoding a known ligand, prepared by, e.g., limited DNAse digestion into pieces of 20 to 100 base pairs, are subcloned into a variable nucleotide region system as described herein either singly or in random combinations of several fragments. The fragment library is then screened in accordance with the procedures herein for binding to the receptor to identify small peptides capable of binding to the receptor and having characteristics which differ as desired from the parental peptide ligand. This method is useful for screening for any receptor-ligand interaction where one or both members are encoded by a gene, e.g., growth factors, hormones, cytokines and the like, such as insulin, interleukins, insulin-like growth factor, etc. In this embodiment of the invention, the peptide library can contain as few as 10 to 100 different members, although libraries of 1000 or more members will generally be used.
Thus, the present invention can be used to construct peptide ligands of great diversity. The novel features of the preferred embodiment of the invention, called "peptides on plasmids", in which the lac repressor is the DNA binding protein and a plasmid vector encodes the fusion protein, are distinct from those of the previously described phage libraries. The random peptides of the present libraries can be displayed with a free carboxy terminus instead of being displayed at the amino terminus or internal to the carrier protein and so add diversity to the peptide structures available for receptor binding. The presentation of peptide ligands at the carboxy terminus also facilitates amidation, as discussed above. This mode of display also ensures that stop codons in the degenerate region, which occur more often in longer degenerate oligonucleotides, shorten rather than destroy individual clones. The presence of stop codons in the random peptide coding sequence actually serves to create additional diversity, by creating peptides of differing lengths. The lac repressor fusions of the invention also allow the display of potential ligands with a wide range of sizes.
In addition, these lac repressor fusions are cytoplasmic proteins, unlike the phage fusions, which are exported to the periplasm. The use of both fusion methods increases total available peptide diversity, because the two types of libraries are exposed to different cellular compartments and so are exposed to different sets of E. coli proteases and to different reduction/oxidation environments. There is no need, however, for peptides fused to the lac repressor to be compatible with the protein export apparatus and the formation of an intact phage coat. The peptides need simply be compatible with the formation of at least a repressor dimer, which is the smallest form of the protein that can bind DNA (see Daly and Matthews, 1986, Biochem. 25:5474-5478, and Kania and Brown, 1976, Proc. Natl. Acad, Sci. USA 73:3529-3533).
As in the phage system, the lac repressor fusion library displays multiple copies of the peptide on each library particle. Each repressor tetramer, in principle, displays four peptides that are available for binding to receptors. In addition, each plasmid monomer can bind up to two tetramers (if no loop is formed), and multimers of the plasmid can display higher multiples of two tetramers. This multivalent display allows the isolation of ligands with moderate affinity (micromolar Kd, see Cwirla et al., supra). For receptors with known, high affinity peptide ligands, these moderate affinity ligands can obscure the high affinity ones simply because of their greater numbers. This problem can be overcome by immobilizing monovalent receptors at low density, which allows high affinity (nanomolar Kd) ligands to be identified, as discussed above. For receptors whose normal ligands are not small peptides, however, this multivalency of display will be an advantage for identifying initial families of moderate affinity ligands, which can then be optimized by additional rounds of screening under monovalent conditions. The multivalency of ligand display therefore allows the isolation of peptides with a wide range of affinities, depending on the density of the receptor during the panning procedure.
Libraries of peptides produced and screened according to the present invention are particularly useful for mapping antibody epitopes. The ability to sample a large number of potential epitopes as described herein has clear advantages over the methods based on chemical synthesis now in use and described in, among others, Geysen et al., 1987, J. Immunol. Meth. 102:259-274. In addition, these libraries are useful in providing new ligands for important binding molecules, such as hormone receptors, adhesion molecules, enzymes, and the like.
The present libraries can be generalized to allow the screening of a wide variety of peptide and protein ligands. In addition, the vectors are constructed so that screening of other ligands encoded by the plasmid is possible. For example, the system can be simply modified to allow screening of RNA ligands. A known RNA binding protein (e.g., a ribosomal protein) is fused to the DNA binding protein. A promoter elsewhere on the vector drives expression of an RNA molecule composed of the known binding site for the RNA binding protein followed by random sequence. The DNA-RNA binding fusion protein would link the genetic information of the vector with each member of a library of RNA ligands. These RNA ligands could then be screened by panning techniques.
Another large class of possible extensions to this technique is to use a modified version of the vector to isolate genes whose products modify peptides, proteins, or RNA in a desired fashion. This requires the availability of a receptor that binds specifically to the modified product. For the general case, a connection is made between the plasmid and the substrate peptide, protein, or RNA, as described above. The plasmid is then used as a cloning vector to make libraries of DNA or cDNA from a source with the potential to contain the desired modification gene (specific organisms, PCR amplified antibody genes, etc.) under the control of a promoter that functions in E. coli. Plasmids carrying the gene in question could then be isolated by panning lysates of the library with the receptor specific for the modified product.
For example, a gene encoding an enzyme that cleaves a particular amino acid sequence could be isolated from libraries of DNA from organisms that might have such a protease or from amplified antibody cDNA. An antibody for use as the receptor would first be made to the peptide that would remain after the desired cleavage reaction had taken place. Many such antibodies will not bind to that peptide unless it is exposed at the N- or C-termius of the protein. The coding sequence for the uncleaved substrate sequence would be attached to the DNA binding protein coding sequence in a vector. This vector would be used to make an expression library from an appropriate source. Members of this library containing a gene that encoded an enzyme able to cleave the peptide would cleave only the peptide attached to the plasmid with that gene. Panning of lysates of the library would preferentially isolate those plasmids with active genes. As can be appreciated from the disclosure above, the present invention has a wide variety of applications. Accordingly, the following examples are offered by way of illustration, not by way of limitation.
EXAMPLE 1 Construction of Plasmids pMC3 and pMC5
The bacterial strains used were E. coli K12 strains MC1061 (araD139 Δ(araABC-leu)7696 thr ΔlacX74 galU galK hsdR mcrB rpsL(strA) thi), ARI 20 (F' lac+ pro+ lacIqL8 lacIam74 // Δ(lac-pro) thi rpsL(strA) recA::cat), and XL1-Blue (F' proAB lacIq lacZΔM15 Tn10 // recA1 endA1 gyrA96 thi hsdR17 supE44 relA1 lac), and E. coli B strain ARI 161 (lon-11, sulA1, hsdR17, Δ(ompT-fepC), ΔclpA319::kan). ARI 161 is a protease deficient strain and serves to minimize proteolysis of the peptides in the library, which would reduce the available diversity for panning. Mutations known to reduce proteolysis include degP, lon, htpR, ompT, and clpA,P.
The library plasmid pMC5 was constructed in several steps using plasmid pBAD18 as the starting plasmid. Plasmid pBAD18 contains the araB promoter followed by a polylinker and a terminator under the control of the positive/negative regulator AraC, also specified by the plasmid. Plasmid pBAD18 also contains a modified plasmid pBR322 origin and the bla gene to permit replication and selection in E. coli, as well as the phage M13 intragenic region to permit rescue of single-stranded DNA for sequencing.
The lacI gene was modified for cloning into plasmid pBAD18 using the GeneAmp® PCR amplification kit (Perkin-Elmer Cetus Instruments) with oligonucleotides ON-286 and ON-287, shown below:
______________________________________                                    
ON-286 5'-GCG GGC TAG CTA ACT AAT GGA GGA                                 
       TAC ATA AAT GAA ACC AGT AAC GTT ATA                                
       CG-3' (SEQ. ID NO. 68)                                             
ON-287 5'-CGT TCC GAG CTC ACT GCC CGC TCT CGA                             
       GTC GGG AAA CCT GTC GTG C-3'                                       
       (SEQ. ID NO. 69).                                                  
______________________________________                                    
The amplification reaction was carried out according to the manufacturer's instructions, except for the use of Vent™ DNA polymerase (New England Biolabs). ON-286 contains a nonhomologous 5' region that adds an NheI site, a consensus ribosome binding site (see Gold and Stormo, 1990, Methods in Enzymology (Goeddel, ed., Boston: Academic Press), pp. 89-103, incorporated herein by reference), and changes the initiation codon of lacI from GTG to ATG. ON-287 changes codons 356 and 357 of lacI to an XhoI site through two silent mutations, and adds a SacI site after the lacI stop codon.
Cloning of the NheI, SacI digested amplification product into plasmid pBAD18 produced vector pJS100. Two lacOS sequences were added to this vector, with their centers spaced 326 bp apart, by amplifying an unrelated sequence (the human D2 dopamine receptor gene (see England et al., 1991, FEBS Lett. 279:87-90, and U.S. patent application Ser. No. 07/645,029, filed Jan. 22, 1991, now U.S. Pat. No. 5,264,565, both of which are incorporated herein by reference), with oligonucleotides ON-295 and ON-296, shown below: ##STR2## ON-295 adds an NdeI site and a lacOS sequence at one end of the amplified fragment, and ON-296 adds a ClaI site and lacOS at the other end. Cloning of the NdeI to ClaI fragment into pJS100 produced plasmid pJS102.
Plasmid pMC3, encoding the dynorphin B-tailed lac repressor, was constructed by cloning complementary oligonucleotides ON-312 and ON-313 to replace the XhoI to XbaI fragment at the 3' end of lacI in pJS102. These oligonucleotides add sequence encoding a five amino acid spacer (GADGA [SEQ. ID NO.:65]) and dynorphin B (YGGFLRRQFKVVT [SEQ. ID NO.:66]) to the end of the wild-type lacI sequence, introduce an SfiI site in the sequence encoding the spacer, and are shown below: ##STR3##
The library plasmid pMC5 was constructed by cloning complementary oligonucleotides ON-335 and ON-336 to replace the SfiI to HindIII dynorphin B segment of pMC3, as shown in FIG. 2. Oligonucleotides ON-335 and ON-336 are shown below: ##STR4## Plasmid pMC3 is available in strain ARI161 from the American Type Culture Collection under the accession number ATCC No. 68818.
EXAMPLE 2 Construction of a Random Dodecamer Peptide Library
Oligonucleotide ON-332 was synthesized with the sequence: ##STR5## where N is A, C, G, or T (equimolar) and K is G or T (see Cwirla et al., supra). The oligonucleotide was purified by HPLC and phosphorylated with T4 kinase (New England Biolabs). The two half-site oligonucleotides ON-369 and ON-370 were phosphorylated during synthesis and are shown below: ##STR6## ON-369 and ON-370 annealed to ON-332 produce SfiI and HindIII-compatible ends, respectively, but the ligated product does not have either recognition sequence (see FIG. 2).
Four hundred pmoles of each oligonucleotide were annealed in a 25 μl reaction buffer (10 mM Tris, pH 7.4, 1 mM EDTA, 100 mM NaCl), by heating to 65° C. for 10 min. and cooling for 30 min. to room temperature. Vector pMC5 was digested to completion with SfiI and HindIII, the vector backbone was isolated by 4 rounds of washing with TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA) in a Centricon 100 microconcentrator (Amicon) by the manufacturer's instructions, followed by phenol extraction and ethanol precipitation. The annealed oligonucleotides were added to 64 micrograms of digested pMC5 at a 4:1 molar ratio in a 3.2 ml ligation reaction containing 5% PEG, 3200 units of HindIII, 194 Weiss units of T4 ligase (New England Biolabs), 1 mM ATP, 20 mM Tris, pH 7.5, 10 mM MgCl2, 0.1 mM EDTA, 50 μg/ml BSA, and 2 mM DTT. The reaction was split equally into 8 tubes and incubated overnight at 15° C.
After ethanol precipitation, 1/16 of the ligated DNA (4 μg) was introduced into MC1061 (80 μl) by electropotation (Dower et al., 1988, Nucl. Acids Res. 16:6127-6145, incorporated herein by reference), to yeild 5.5×108 independent transformants. The library was amplified approximately 1000-fold in 1 liter of LB/100 μg/ml ampicillin by growth of the transformants at 37° C. to an A600 of 1. The cells containing the library were concentrated by centrifugation at 5500 x g for 6 min., washed once in ice-cold 50 mM Tris (pH 7.6), 10 mM EDTA, 100 mM KCl, followed by a wash in ice-cold 10 mM Tris, 0.1 mM EDTA, 100 mM KCl. The final pellet was resuspended in 16 ml of HEG buffer (35 mM HEPES/KOH pH 7.5, 0.1 mM EDTA, 100 mM Na Glutamate), distributed into 19 tubes of 1.0 ml each, frozen on dry ice, and stored at -70° C.
EXAMPLE 3 Panning the Library
One aliquot (1.0 ml) of the library prepared in Example 2 was thawed on ice and added to 9 ml of lysis buffer (35 mM HEPES {pH 7.5 with KOH}, 0.1 mM EDTA, 100 mM Na glutamate, 5% glycerol, 0.3 mg/ml BSA, 1 mM DTT, and 0.1 mM PMSF). Lysozyme was added (0.3 ml at 10 mg/ml in HEG), and the mixture was incubated on ice for 1 hr.
The cellular debris was removed by centrifugation of the lysate at 20,000 x g for 15 min., and the supernatant was concentrated by centrifugation in a Centriprep® 100 concentrator (Amicon) at 500 x g for 40 min. The concentrated supernatant (about 0.5 ml) was washed with 10 ml of HEG buffer and centrifuged as before. A sample (5%) of the total lysate was removed to determine the pre-panned input of plasmid complexes.
An alternate method for partially purifying and concentrating the lysate is as follows. About 2.0 ml of the frozen cells in HEG are thawed on ice, and then 8 ml of lysis buffer without Na glutamate (high ionic strength inhibits lysozyme; DTT is optional) are added to the cells, and the mixture is incubated on ice for 1 hr. The cellular debris is removed from the lysate by centrifugation at 20,000 x g for 15 min., and the supernatant is loaded onto a Sephacryl® S-400 High Resolution (Pharmacia) gel-filtration column (22 mm×250 mm). The plasmid-fusion protein complexes elute in the void volume. The void volume (30 ml) is concentrated with two Centriprep® 100 concentrators, as described above. After adjusting the Na glutamate concentration of the concentrate, one carries out the remainder of the procedure in the same manner as with the first method.
Half of the remaining concentrated lysate was added to D32.39-antibody-coated sheep-anti-mouse (Fc)-coupled magnetic beads (10 μg of D32.39 added to 5 mg Dynal beads for 1 hr. at 25° C. followed by 6 washes with HEG), and half was added to uncoated beads. After incubating the lysates with the beads at 0° C. for 1 hr. with shaking, the beads were washed three times with 5 ml of cold HEG/0.1% BSA and then three times with HEG using a MACS 0.6 tesla magnet (Miltenyi Biotec GmBH) to immobilize the beads. The plasmids were dissociated from the beads by phenol extraction, and after adding 20 μg of glycogen (Boehringer Mannheim), the DNA was precipitated with an equal volume of isopropanol. The pellet was washed with 75% ethanol, and the DNA was resuspended in either 4 μl (panned DNA) or 400 μl (pre-panned DNA) of H2 O. Strain MC1061 was transformed using 2 μl each of the DNA solutions to permit counts of recovered plasmids and amplification of the selected plasmids. The results of the panning are shown below in Table 1.
              TABLE 1                                                     
______________________________________                                    
       Number of Transformants                                            
Panning               Ab D32.39 Uncoated                                  
Round    Input        Beads     Beads                                     
______________________________________                                    
1        1.6 × 10.sup.10                                            
                        9 × 10.sup.7                                
                                1.7 × 10.sup.5                      
2        1.4 × 10.sup.11                                            
                      6.1 × 10.sup.7                                
                                1.2 × 10.sup.4                      
3        1.7 × 10.sup.11                                            
                      2.0 × 10.sup.9                                
                                40                                        
4        --           .sup. 1.6 × 10.sup.11                         
                                  4 × 10.sup.4                      
______________________________________                                    
EXAMPLE 4 ELISA Analysis of the Library
An ELISA was used to test MC1061 transformants from the second, third, and fourth rounds for D32.39-specific ligands (see Example 3). The ELISA was performed in a 96-well plate (Beckman). Single colonies of transformants obtained from panning were grown overnight in LB/100 μg/ml ampicillin at 37° C. The overnight cultures were diluted 1/10 in 3 ml LB/100 μg/ml ampicillin and grown 1 hr. The expression of the lac repressor-peptide fusions was induced by the addition of arabinose to a final concentration of 0.2%.
The cells were lysed as described above in 1 ml of lysis buffer plus lysozyme and stored at -70° C. Thawed crude lysate was added to each of 2 wells (100 μl/well), and the plate was incubated at 37° C. After 45 min, 100 μl of 1% BSA in PBS (10 mM NaPO4, pH 7.4, 120 mM NaCl, and 2.7 mM KCl) were added for an additional 15 min. at 37° C., followed by 3 washes with PBS/0.05% Tween 20. Each well then was blocked with 1% BSA in PBS (200 μl/well) for 30 min. at 37° C., and the wells were washed as before.
The primary antibody, D32.39 (100 μl of antibody at 1 μg/ml in PBS/0.1% BSA) was added to each well, the plate was incubated at room temperature for 1 hr., and then each well was washed as before. The secondary antibody, alkaline phosphatase-conjugated Goat-anti-rabbit antibody (Gibco-BRL), was diluted 1/3000 in PBS/0.1% BSA and added to each well (100 μl/well); the plate was then incubated for 1 hr at room temperature. After three washes with PBS/0.05% Tween 20 and two with TBS (10 mM Tris pH 7.5, 150 mM NaCl), the ELISA was developed with 4 mg/ml p-nitrophenyl phosphate in 1M diethanolamine/HCl pH 9.8, 0.24 mM MgCl2 (200 μl/well).
The reaction was stopped after 6 min. by the addition of 2M NaOH (50 μl/well), and the absorbance at 405 nm was measured on a plate reader (a Biomek, from Beckman). The positive control for the ELISA was MC1061 transformed with pMC3, encoding the lac repressor-dynorphin B fusion. The negative controls were wells not coated with lysate. Background variability was calculated from the wells containing lysates from 16 colonies selected at random from the library, none of which scored significantly above the negative controls. Wells were scored as positive if the measured absorbance was at least two standard deviations above background.
Of randomly picked colonies, 35 of 58 (60%) tested positive by ELISA: 11 of 20 from round two, 12 of 16 from round three, and 12 of 22 from round four. None of 16 random colonies from the unpanned library scored significantly above background. These data demonstrate the rapid enrichment of specific ligands achieved by the present invention: after only two rounds of panning, the majority of plasmids encoded peptides with affinity for the D32.39 antibody.
To determine the structure of the peptide ligands obtained by the present method, plasmids from both ELISA positive and ELISA negative colonies obtained after panning were sequenced. Double stranded plasmid DNA, isolated from strain XL1-Blue, was sequenced using Sequenase® (US Biochemicals) according to the instructions supplied by the manufacturer.
The translated peptide sequence for all ELISA positive colonies examined shared the consensus sequence shown in FIG. 3. The preferred recognition sequence for the D32.39 antibody apparently covers a six amino acid region of the dynorphin B peptide (RQFKVV) (SEQ. ID NO. 80). In the first position, arginine is invariant for all of the ELISA positive clones. No strong bias was evident for residues in the second position. In the third position, however, five amino acids (phenylalanine, histidine, asparagine, tyrosine, and tryptophan, in order of frequency) account for 98% of the residues. Of these, the aromatic amino acids comprise 74% of this total. The fourth position shows a strong bias for the positively charged residues lysine (69%) and arginine (21%). The fifth position is occupied almost exclusively by hydrophobic residues, most of which are valine (81%). Valine and threonine predominate in the sixth position (76%), with serine and isoleucine accounting for most of the remaining amino acids.
Of the ELISA negative clones obtained after panning, greater than half showed peptide sequence similarity to the consensus motif (FIG. 3). None of 19 isolates sequenced from the unpanned library showed any such similarity. Some of these ELISA negative sequences differ enough from the consensus that their affinity for the antibody may be insufficient to permit detection in the ELISA. There are, however, ELISA negative sequences identical in the five conserved amino acids of the consensus region to clones that scored positive (e.g., #28 and #57). There may be amino acids outside the consensus region that affect binding of the peptide to antibody or its susceptibility to E. coli proteases, or its availability in the ELISA. That even the ELISA negative clones frequently have an obvious consensus sequence demonstrates the utility of the present invention for isolating ligands for biological receptors.
EXAMPLE 5 Construction of Plasmid pDimer1
Plasmid pDimer1 was constructed to provide a monovalent display system. The plasmid encodes a lac headpiece dimer linked to a dynorphin B antibody epitope (RQFKVVT) (SEQ. ID NO. 81); a random linker is encoded between the headpieces and between the second headpiece and the dynorphin B epitope. This vector was used in the affinity enrichment protocol with anti-dynorphin B antibody to determine the optimum linker sequences, as discussed below.
Plasmid pDimer1 was constructed from plasmid pMC5 by first using plasmid pMC5 as a PCR template for amplification with oligonucleotide primers ON-929 and ON-930. These oligonucleotides are shown below. ##STR7## The amplified DNA resulting from the PCR amplification was digested with restriction enzymes BamHI and ApaI and then ligated with the large BamHI-ApaI fragment of plasmid pMC5 to yield plasmid pMC5dlacI. This process resulted in a deletion of all but about the first 60 codons (the lac headpiece coding sequence) of the lacI gene coding sequence from plasmid pMC5.
To generate the second headpiece-encoding region, plasmid pMC5 was used as a template for PCR amplification with oligonucleotide primers ON-938 and ON-940 (to encode a five amino acid random linker between the two headpieces) and ON-939 and ON-940 (to encode a four amino acid random linker between the two headpieces). These oligonucleotides are shown below (M is A or C). ##STR8## The amplified DNA from each reaction was digested with restriction enzymes SstI and HindIII and then ligated to the large SstI-HindIII fragment of plasmid pMC5dlacI. The resulting plasmids were designated pDimer1 and were then transformed into E. coli host cells as a mixture.
The resulting library of transformants was panned in accordance with the procedure of Example 6, except that HEK buffer rather than HEKL buffer was used in the lysis and column purification steps. The cells were grown either in LB broth with 0.1% glucose and supplemented with L-arabinose to 0.2% about 30 minutes before harvesting the plasmids or in LB broth without glucose and supplemented with L-arabinose to 0.2% about 15 minutes before harvesting the plasmids. Both protocols yielded similar results. Four rounds of affinity enrichment were completed; in the latter two rounds, about 5 to 10 μg/ml of an oligonucleotide encoding lacOS was added during the lysis and panning steps to increase the stringency of selection for tight-binding derivatives. This oligonucleotide is shown below in single-stranded form but is used in double-stranded form. ##STR9##
After the fourth round of affinity enrichment, a number of individual plasmids were sequenced to determine the identity of the linker between the two headpieces and the second headpiece and the dynorphin B sequence. Both four and five amino acid linkers were observed between the two headpieces; about 25% of the isolates examined had the sequence GRCR between the two headpieces and the sequence GPNQ between the second headpiece and the dynorphin B sequence. These results show that the two headpiece system can be used to screen ligands for ability to bind to receptors.
EXAMPLE 6 Standard Protocol
This Example provides a standard protocol for the method of the present invention with any receptor that can be immobilized on a microtiter dish with an immobilizing antibody. To practice the method, the following reagents will be helpful.
______________________________________                                    
Items              Vendor     Catalog #                                   
______________________________________                                    
BSA, fraction V, RIA grade                                                
                   USB        10868                                       
BSA, protease free USB        10867                                       
Bulk DNA, sonicated, phenol                                               
                   Amicon     4308                                        
extracted Centriprep 100                                                  
concentrator, 5-15 ml                                                     
Chromatography column, G22X250                                            
                   Amicon     95220                                       
Coomassie Plus protein assay                                              
                   Pierce     23236                                       
reagent                                                                   
DTT                                                                       
EDTA, disodium, dihydrate                                                 
                   Sigma      E-5134                                      
Ethyl alcohol, 200 proof                                                  
                   Gold Shield                                            
                   Chem.                                                  
Glycerol           Sigma      G-5516                                      
Glycogen, molecular biology grade                                         
                   Boehringer 901 393                                     
HEPES free acid, molecular                                                
                   Sigma      H-0891                                      
biology grade                                                             
Isopropanol, HPLC grade                                                   
                   Aldrich    27,049-0                                    
IPTG               Bachem     SISO10                                      
alpha-Lactose, monohydrate                                                
                   Sigma      L-3625                                      
Lysozyme, from hen egg white                                              
                   Boehringer 837 059                                     
Microtiter plate, Immulon 4, flat                                         
                   Dynatech   011-010-3850                                
bottom                                                                    
PBS                Sigma      1000-3                                      
PMSF                                                                      
Phenol, equlibrated                                                       
                   USB        20072                                       
Phenol: chloroform: Isoamyl                                               
                   USB        20081                                       
alcohol                                                                   
Potassium hydroxide solution, 8.0N                                        
                   Sigma      17-8                                        
Potassium chloride Sigma      P-9541                                      
Sodium chloride    Sigma      S-3014                                      
Sephacryl S-400, high resolution                                          
                   Pharmacia  17-0609-01                                  
Tubes w/ screw cap, 13 ml                                                 
                   Sarstedt   60.540                                      
______________________________________                                    
The various buffers and other preparations referred to in the protocol are shown below.
HE buffer is prepared at pH=7.5 (adjusted with KOH) by adding 8.34 g of HEPES, free acid (use a better grade than Sigma's standard; the final concentration is 35 mM), to 200 μl of 0.5M EDTA, pH 8.0 (final concentration is 0.1 mM) and adding water to a final volume of 1 L.
HEK buffer is identical to HE buffer but also contains KCl at a final concentration of 50 mM.
HEKL buffer is identical to HEK buffer but also contains alpha-lactose, which may require warming to go into solution, at a final concentration of 0.2M.
Lysis buffer (6 ml) is prepared by mixing 4.2 ml of HE buffer with 1 ml of 50% glycerol, 750 μl of protease free BSA at 10 mg/ml in PBS, 10 μl of 0.5M DTT, and 12.5 μl of 0.1M PMSF in isopropanol.
HEK/BSA buffer is prepared by dissolving 5 g of BSA, fraction V, in 500 ml of HEK buffer.
WTEK buffer is prepared at pH=7.5 by adding 7.53 g of Tris, pH=7.5 (final concentration of 50 mM), to 20 ml of 0.5M EDTA (final concentration of 10 mM) and 7.45 g of KCl (final concentration of 100 mM) and adding water to a final volume of 1 L.
TEK buffer is prepared at pH=7.5 by adding 1.51 g of Tris, pH=7.5 (final concentration of 10 mM), to 200 μl of 0.5M EDTA (final concentration of 0.1 mM) and 7.45 g of KCl (final concentration of 100 mM) and adding water to a final volume of 1 L.
The process can be conveniently carried out over a two day period, as shown below.
Day 1
1. Coat two sets of 12 microtiter wells with the appropriate amount of immobilizing antibody in 100 μl of PBS, for panning and negative control; let the coated plate incubate at 37° C. for 1 hr. Consider using all 24 wells as "plus receptor" wells in the first round, i.e., no negative control in the first round.
2. Wash the plate four times (4×) with HEK/BSA.
3. Block wells by adding 200 μl of HEK/BSA to each well; let the plate incubate at 37° C. for 1 hr.
4. Wash the plate 4× with HEK/BSA.
5. Dilute the receptor preparation in cold HEK/BSA (or appropriate binding buffer) as necessary.
6. Add the diluted receptor preparation to the wells at 100 μl per well; let the plate incubate at 4° C. for 1 hr. with agitation.
7. Wash the plate 2× with cold HEK/BSA.
8. Add 100 μl of 0.1 mg/ml bulk DNA in HEK/BSA to each well; incubate the plate at 4° C. for at least 10 minutes.
On day 1, steps A-O should also be carried out.
A. Begin equilibrating column with cold HEKL (- 1 hr, flow rate is set to collect 5 ml fractions every 2 to 3 minutes).
B. Prepare 1 ml of lysozyme at 10 mg/ml in cold HE.
C. Thaw and combine sub-libraries (2 ml final volume) in a 13 ml Sarstedt screw cap tube.
D. Add 6 ml of lysis buffer and 150 μl of lysozyme solution (Boehringer lysozyme is preferred over Sigma lysozyme); mix by inverting gently; and incubate on ice for 5 minutes, although less time is often satisfactory.
E. Add 2 ml of 20% lactose and 250 μl of 2M KCl, and mix by inverting gently.
F. Spin at 14.5K for 15 minutes in a Beckman JA-20 rotor.
G. Transfer supernatant by pipetting into a new tube.
H. Load raw lysate onto the equilibrated column.
I. After lysate is loaded, collect ten 5 ml fractions.
J. Perform the coomassie protein assay as follows: (1) to 10 microtiter wells, add 100 μl of coomassie reagent and 20 μl from each fraction, and mix; (2) select 4 consecutive fractions which correspond to 1 brown and 3 blue wells from the assay (light blue counts as blue).
K. Combine selected fractions in a Centriprep100. Two centripreps may be used to speed up the process. The maximum capacity of each centriprep is about 15 ml.
L. Spin in Beckman J-6B centrifuge at 1500 rpm.
M. Rinse the column with cold HEK for 1 hr.
N. Empty liquid from the inner chamber every 15 minutes until final volume <2 ml (- 1 hr.).
O. Determine lysate volume, and remove 1% as "Pre" sample; keep Pre sample on ice.
Returning to the numbered steps, one proceeds as follows.
9. Wash plate 2× with cold HEK/BSA.
10. Bring the volume of the concentrated lysate up to 2400 μl by adding HEKL/BSA; add bulk DNA to a final concentration of 0.1 mg/ml. The activity of the receptor in this buffer should be verified.
11. Add lysate at 100 μl per well; incubate the plate at 4° C. for 1 hr. with agitation.
12. Wash plate 4× with cold HEKL/BSA.
13. Add 100 μl of 0.1 mg/ml bulk DNA in HEKL/BSA to each well; incubate at 4° C. for 30 minutes with agitation.
14. Wash plate 4× with cold HEKL.
15. Quickly wash plate 1× with cold HEK.
16. Elute by adding to each well 100 μl of a solution composed of 1 mM IPTG, 10 μg/ml of ON-413, and 0.2M KCl in HE; incubate at room temperature for 30 minutes with agitation. 50 mM KCl may also be used.
17. Remove all eluants; a phenol/CHC13 extraction is optional.
18. Add one-tenth volume of 5M NaCl and 1 μl of 20 mg/ml glycogen as carrier.
19. Precipitate plasmids in equal volume of isopropanol at room temperature.
20. Spin 10 minutes; carefully remove supernatant, spin again, and remove remaining supernatant.
21. Wash with 200 μl of 70% EtOH.
22. Spin and remove traces of supernatant as above.
23. Resuspend plasmids in water (suggested volumes: 100 μl for Pre; and 4 μl each for the panning and negative control wells; use more than 4 μl for panning and negative control samples in later rounds to retain as backups).
Day 2
24. Chill 4 sterile 0.2 cm electrode gap cuvettes on ice. The panning sample is divided equally into 2 cuvettes to prevent complete loss of sample during electroporation.
25. To three 16 ml sterile culture tubes, add 1 ml SOC medium (2% Bacto-Tryptone, 0.5% Bacto-yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM Glucose) plus 10 mM NaCitrate to two tubes and 2 ml to one tube. Label the two 1 ml tubes as "Pre" and "NC" (for "negative control"), and label the 2 ml tube as "Pan" (for "panning").
26. Thaw 200 μl of high efficiency electro-competent cells.
27. Transfer 40 μl aliquots of cells to 4 chilled sterile eppendorf tubes; incubate the tubes on ice.
28. Add 2 μl of each plasmid to each Pre and NC tube and 4 μl to the Pan tube and mix gently.
29. Transfer cells/plasmids mixtures into their corresponding cuvettes; keep the cuvettes on ice.
30. Set the BioRad Gene Pulser apparatus to 2.5 kV, 25 μFD capacity, and set the Pulser Controller unit to 200 ohms.
31. Apply one pulse (time constant=4-5 msec).
32. Immediately add the room temperature SOC-Citrate medium to resuspend cells in the cuvette.
33. Transfer cell suspension back to the culture tube.
34. Incubate the culture tube at 37° C. for 1 hr. with agitation.
35. To 200 ml of LB broth, add 2 ml of 1M sodium citrate and 0.4 ml of 50 mg/ml ampicillin prewarmed to 37° C.
36. Remove 10 to 100 μl of the "Pan" library culture for plating, and transfer the rest (2 ml) to the prewarmed LB broth. Plate out several dilutions of each sample on LB plates containing ampicillin. Suggested plate dilutions are as follows: Pre--10-5, 10-6 and 10-7 ; and Pan/NC--10-3, 10-4, 10-5 and 10-6.
37. Grow "Pan" library at 37° C. for about 4-5 hr. until the OD600 =0.5-1.0.
38. Chill the flask rapidly in ice water for at least 10 minutes.
39. Centrifuge cells in 250 ml sterile bottle at 6K for 6 minutes in a Beckman JA-14 rotor.
40. Wash by vortexing cells in 100 ml of cold WTEK.
41. Centrifuge at 6K for 6 minutes.
42. Wash by vortexing cells in 50 ml cold TEK.
43. Centrifuge at 6K for 6 minutes.
44. Resuspend cells in 4 ml of HEK and store in two 2 ml vials at -70° C. Use one tube for the next round; keep the other as a backup.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
__________________________________________________________________________
SEQUENCE LISTING                                                          
(1) GENERAL INFORMATION:                                                  
(iii) NUMBER OF SEQUENCES: 91                                             
(2) INFORMATION FOR SEQ ID NO:1:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 14 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                   
Gly AlaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaa                               
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:2:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 54 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: DNA (genomic)                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                   
GTGGCGCCNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKNNKTAAGGTCTCG54                  
(2) INFORMATION FOR SEQ ID NO:3:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 11 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: DNA (genomic)                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                   
TGCCACCGCGG11                                                             
(2) INFORMATION FOR SEQ ID NO:4:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 14 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: DNA (genomic)                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                   
ATTCCAGAGCTCGA14                                                          
(2) INFORMATION FOR SEQ ID NO:5:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 10 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: Peptide                                              
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                   
LeuGluSerGlyGlnGlyAlaAspGlyAla                                            
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:6:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 45 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
 (D) TOPOLOGY: linear                                                     
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                   
CTCGAGAGCGGGCAGGGGGCCGACGGGGCCTAATTAATTAAGCTT45                           
(2) INFORMATION FOR SEQ ID NO:7:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 13 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
 (D) TOPOLOGY: linear                                                     
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: dynB 1.0                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                   
TyrGlyGlyPheLeuArgArgGlnPheLysValValThr                                   
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:8:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
 (A) LENGTH: 12 amino acids                                               
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 21 4 1.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                                   
ThrGlyLysArgGlyPheLysValValCysAsnSer                                      
1 510                                                                     
(2) INFORMATION FOR SEQ ID NO:9:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 22 4 1.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                                   
Ly sArgAsnPheLysValValGlySerProCysGly                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:10:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 28 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 10 4 0.3                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:                                  
SerAspSerGlyAsnGlyLeuGlyIleArgArgPheLysValSerSer                          
151015                                                                    
LeuAla ValLeuAlaAspGluArgArgPheSerAla                                     
2025                                                                      
(2) INFORMATION FOR SEQ ID NO:11:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii ) IMMEDIATE SOURCE:                                                  
(B) CLONE: 30 4 0.9                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:                                  
GluThrArgProPheLysValSerGluTyrIleLeu                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:12:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 28 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 35 4 0.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:                                  
SerLeuLysAspGluAsnAsnLysArgArgIlePheLysValSerSer                          
15 1015                                                                   
LeuAlaValLeuAlaAspGluArgArgPheSerAla                                      
2025                                                                      
(2) INFORMATION FOR SEQ ID NO:13:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
 (C) STRANDEDNESS: single                                                 
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 57 3 0.9                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:                                  
SerTyrLeuArgArgGluPheLysValSerGlyVal                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:14:                                         
 (i) SEQUENCE CHARACTERISTICS:                                            
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 24 4 0.9                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:                                  
GlyTrpArgSerCysProArgGlnPheLysValThr                                      
 1510                                                                     
(2) INFORMATION FOR SEQ ID NO:15:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 45 3 0.9                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:                                  
IleLysArgGlyPheLysIleThrSerAlaMetSer                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:16:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: peptide                                              
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 47 3 0.8                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:                                  
ValArgPheIleAlaArgProPheArgIleThrGly                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:17:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 71 2 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:                                  
AlaArgAlaPheArgValThrArgIleAlaGlyVal                                      
15 10                                                                     
(2) INFORMATION FOR SEQ ID NO:18:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 74 2 0.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:                                  
LysAsnGluThr ArgArgProPheArgGlnThrAla                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:19:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
 (B) CLONE: 68 2 0.6                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:                                  
ValAsnHisArgArgPheSerValValHisSerTyr                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:20:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
 (C) STRANDEDNESS: single                                                 
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 48 3 0.4                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:                                  
ValSerSerSerArgThrPheAsnValThrArgArg                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:21:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 46 3 0.3                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:                                  
GlyArgSerPheHisValThrSerPheGlySe rVal                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:22:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 4 4 1.1                                                        
( xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:                                 
ArgSerThrThrValArgGlnHisLysValValGly                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:23:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
( D) TOPOLOGY: linear                                                     
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 15 4 1.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:                                  
GluArgProAsnArgLeuHisLysValValHisAla                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:24:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
 (A) LENGTH: 12 amino acids                                               
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 73 2 0.5                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:                                  
TrpGlnAsnArgThrHisLysValValSerGlyArg                                      
1 510                                                                     
(2) INFORMATION FOR SEQ ID NO:25:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 7 amino acids                                                 
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 78 2 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:                                  
AlaArgLy sHisLysValThr                                                    
15                                                                        
(2) INFORMATION FOR SEQ ID NO:26:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 11 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 40 3 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:                                  
ArgGlnValThrArgLeuHisLysValIleHis                                         
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:27:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(i i) MOLECULE TYPE: peptide                                              
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 11 4 1.0                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:                                  
CysProGlyGluArgMetHisLysAlaValArgAla                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:28:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
 (B) TYPE: amino acid                                                     
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 2 4 1.0                                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:                                  
SerArgCysArgAsnHisArgValValThrSerGln                                      
15 10                                                                     
(2) INFORMATION FOR SEQ ID NO:29:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 26 4 0.8                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:                                  
AsnAspGlyArgProHis ArgValValArgCysGly                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:30:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
 (B) CLONE: 9 4 0.8                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:                                  
GluIleArgArgHisArgValThrGluArgValAsp                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:31:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
 (C) STRANDEDNESS: single                                                 
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 56 3 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:                                  
LeuArgArgLeuHisArgValThrAsnThrMetThr                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:32:                                         
 (i) SEQUENCE CHARACTERISTICS:                                            
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 69 2 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:                                  
ValLysGlnArgLeuHisSerValValArgProGly                                      
 1510                                                                     
(2) INFORMATION FOR SEQ ID NO:33:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 7 4 1.1                                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:                                  
ValThrGlnArgValArgSerAsnLysValValSer                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:34:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: peptide                                              
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 20 4 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:                                  
HisValGluLysIleLysArgLeuAsnLysValVal                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:35:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 23 4 1.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:                                  
ArgLeuLysThrArgLeuAsnLysValValMetAsp                                      
15 10                                                                     
(2) INFORMATION FOR SEQ ID NO:36:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 63 2 0.4                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:                                  
ValArgMetAsnL ysValValCysGluLysLeuTrp                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:37:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 11 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
 (B) CLONE: 49 3 0.3                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:                                  
AspLeuLysArgLeuAsnArgValValGlyHis                                         
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:38:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
 (C) STRANDEDNESS: single                                                 
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 19 4 0.8                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:                                  
ArgIleArgAsnAsnLysValIleAlaArgProVal                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:39:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 36 4 0.5                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:                                  
SerArgValArgSerAsnLysValIleMetSerIle                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:40:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 77 2 0.6                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:                                  
SerCysArgLeuAsnLysValIleAlaArgProVal                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:41:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 33 4 0.5                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:                                  
ArgAlaLeuSerLysAspArgLeuAsnLysValThr                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:42:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A ) LENGTH: 12 amino acids                                               
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 58 3 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:                                  
CysThrThrGluArgSerArgGlnTrpLysValThr                                      
15 10                                                                     
(2) INFORMATION FOR SEQ ID NO:43:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 16 4 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:                                  
AlaArgProTrp LysIleThrArgAsnGluProGly                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:44:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 72 2 0.3                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:                                  
GlyValSerGluCysArgLysTrpLysIleValGln                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:45:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
 (C) STRANDEDNESS: single                                                 
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 6 4 1.2                                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:                                  
ThrThrLeuArgArgTyrLysValThrGlyGluArg                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:46:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 34 4 1.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:                                  
IleAlaAspArgArgProTyrArgValThrA rgPro                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:47:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 76 2 1.2                                                       
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:                                 
AlaGlyLysValLeuArgAlaTyrLysIleValGlu                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:48:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
 (D) TOPOLOGY: linear                                                     
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 8 4 1.0                                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:                                  
GlnLysArgLeuMetLysValIlePheGluGlyArg                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:49:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
 (A) LENGTH: 12 amino acids                                               
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 55 3 1.0                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:                                  
GluValProHisArgPheArgTrpThrLysHisMet                                      
1 510                                                                     
(2) INFORMATION FOR SEQ ID NO:50:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 24 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 13 4 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:                                  
SerThrT hrGluArgArgSerPheLysValSerSerLeuAlaValLeu                         
151015                                                                    
AlaAspGluArgArgPheSerAla                                                  
20                                                                        
(2) INFORMATION FOR SEQ ID NO:51:                                         
( i) SEQUENCE CHARACTERISTICS:                                            
(A) LENGTH: 23 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 14 4 0.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:                                  
ArgLeuProGlyArgMetPheLysValSerSerLeuAlaVal LeuAla                         
151015                                                                    
AspGluArgArgPheSerAla                                                     
20                                                                        
(2) INFORMATION FOR SEQ ID NO:52:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
 (C) STRANDEDNESS: single                                                 
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 28 4 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:                                  
ValGlySerPheLysArgThrPheLysValSerCys                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:53:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 21 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 29 4 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:                                  
ArgGlyArgMetPheLysValSerSerLeuAlaVal LeuAlaAspGlu                         
151015                                                                    
ArgArgPheSerAla                                                           
20                                                                        
(2) INFORMATION FOR SEQ ID NO:54:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 29 amino acids                                                
(B) TYPE: amino acid                                                      
 (C) STRANDEDNESS: single                                                 
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 54 3 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:                                  
ProGlyArgTrpValArgGlyValGlyIleArgCysPheLysValSer                          
15 1015                                                                   
SerLeuAlaValLeuAlaAspGluArgArgPheSerAla                                   
2025                                                                      
(2) INFORMATION FOR SEQ ID NO:55:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 22 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 60 2 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:                                  
ArgMetSerArgLeuPheLysValSerSerLeuAlaValLeuAlaAsp                          
1510 15                                                                   
GluArgArgPheSerAla                                                        
20                                                                        
(2) INFORMATION FOR SEQ ID NO:56:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 28 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
 (B) CLONE: 1 4 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:                                  
ProAspValLeuArgAlaValAlaThrArgGlnHisLysValSerSer                          
151015                                                                    
LeuAlaValLeuAlaAspGluA rgArgPheSerAla                                     
2025                                                                      
(2) INFORMATION FOR SEQ ID NO:57:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 27 4 0.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:                                  
ArgValArgGlyHisArgValValMetTyrAsnGlu                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:58:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
 (D) TOPOLOGY: linear                                                     
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 64 2 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:                                  
GluCysLeuHisArgArgValHisLysIleLeuSer                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:59:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 61 2 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:                                  
GlyLeuLysCysArgProMetLysValAsnAlaAsp                                      
1 510                                                                     
(2) INFORMATION FOR SEQ ID NO:60:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 50 3 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:                                  
A rgHisArgProPheGlyTrpValAsnLysArgSer                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:61:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 52 3 0.2                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:                                  
AlaAlaArgLeuPheSerGlnIleArgArgPhePro                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:62:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
 (B) TYPE: amino acid                                                     
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 53 3 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:                                  
ArgValArgTrpHisMetValThrGlyAspLysGly                                      
15 10                                                                     
(2) INFORMATION FOR SEQ ID NO:63:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
(B) CLONE: 31 4 0.1                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:                                  
ArgPheArgAsnCysSerIle IleSerAlaArgGly                                     
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:64:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(vii) IMMEDIATE SOURCE:                                                   
 (B) CLONE: 62 2 0.1                                                      
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:                                  
TyrGlyValProArgIlevalAlaHisGlnLeuMet                                      
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:65:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 5 amino acids                                                 
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:                                  
GlyAlaAspGlyAla                                                           
15                                                                        
(2) INFORMATION FOR SEQ ID NO:66:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 13 amino acids                                                
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: peptide                                              
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:                                  
TyrGlyGlyPheLeuArgArgGlnPheLysValValThr                                   
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:67:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 4 amino acids                                                 
(B) TYPE: amino acid                                                      
 (C) STRANDEDNESS: single                                                 
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:                                  
GlyLysArgXaa                                                              
(2) INFORMATION FOR SEQ ID NO:68:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 53 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:                                 
GCGGGCTAGCTAACTAATGGAGGATACATAAATGAAACCAGTAACGTTATACG53                   
(2) INFORMATION FOR SEQ ID NO:69:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 46 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:                                  
CGTTCCGAGCTCACTGCCCGCTCTCGAGTCGGGAAACCTGTCGTGC46                          
(2) INFORMATION FOR SEQ ID NO:70:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 51 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:                                  
CCTCCATATGAATTGTGAGCGCTCACAATTCGGTACAGCCCCATCCCACCC51                     
(2) INFORMATION FOR SEQ ID NO:71:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 51 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:                                  
CAGCATCGATCAATTGTGAGCGCTCACAATTCAGGATGTGTGTGATGAAGA51                     
(2) INFORMATION FOR SEQ ID NO:72:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 72 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(i i) MOLECULE TYPE: DNA (genomic)                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:                                  
TCGAGAGCGGGCAGGGGGCCGACGGGGCCTACGGTGGTTTCCTGCGTCGTCAGTTCAAAG60            
TTGTAACCTAAT72                                                            
(2) INFORMATION FOR SEQ ID NO:73:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
 (A) LENGTH: 72 base pairs                                                
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:                                  
CTAGATTAGGTTACAACTTTGAACTGACGACGCAGGAAACCACCGTAGGCCCCGTCGGCC60            
CCCTGCCCGCTC 72                                                           
(2) INFORMATION FOR SEQ ID NO:74:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 15 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:                                  
GGGCCTAATTAATTA 15                                                        
(2) INFORMATION FOR SEQ ID NO:75:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 22 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:                                  
AGCTTAATTAATTAGGCC CCGT22                                                 
(2) INFORMATION FOR SEQ ID NO:76:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 54 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:                                  
GTGGCGCCNNKNNKNN KNNKNNKNNKNNKNNKNNKNNKNNKNNKTAAGGTCTCG54                 
(2) INFORMATION FOR SEQ ID NO:77:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 11 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:                                  
GGCGCCACCGT 11                                                            
(2) INFORMATION FOR SEQ ID NO:78:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 14 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:                                  
AGCTCGAGACCT TA14                                                         
(2) INFORMATION FOR SEQ ID NO:79:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 9 amino acids                                                 
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:                                  
AspTyr MetGlyTrpMetAspPheGly                                              
15                                                                        
(2) INFORMATION FOR SEQ ID NO:80:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 6 amino acids                                                 
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:                                  
ArgGlnPheLy sValVal                                                       
15                                                                        
(2) INFORMATION FOR SEQ ID NO:81:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 7 amino acids                                                 
(B) TYPE: amino acid                                                      
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: peptide                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:                                  
ArgGlnPheLysValValThr                                                     
 15                                                                       
(2) INFORMATION FOR SEQ ID NO:82:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 21 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:                                  
TATTTGCACGGCGTCACACTT 21                                                  
(2) INFORMATION FOR SEQ ID NO:83:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 47 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:                                  
CCGCGCCTGGGCCCAGGGAATGTAATTGAGCTCCGCCATCGCCGCT T47                        
(2) INFORMATION FOR SEQ ID NO:84:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 62 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:                                  
CGATGGCGGAGCTCAATTACATTCCCNNKNNKNNKNNKNNKAAA CCAGTAACGTTATACG60           
AT62                                                                      
(2) INFORMATION FOR SEQ ID NO:85:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 59 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: DNA (genomic)                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:                                  
CGATGGCGGAGCTCAATTACATTCCCNNKNNKNNKNNKAAACCAGTAACGTTATACGAT59             
(2) INFORMATION FOR SEQ ID NO:86:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 72 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: DNA (genomic)                                        
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:                                  
CGCCCGCCAAGCTTAGGTTACAACTTTGAACTGACGMNNMNNMNNMNNGGGAATGTAATT60            
CAGCTCCGCCAT72                                                            
(2) INFORMATION FOR SEQ ID NO:87:                                         
(i ) SEQUENCE CHARACTERISTICS:                                            
(A) LENGTH: 32 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:                                  
GAATTCAATTGTGAGCGCTCACAATTGAATTC32                                        
(2) INFORMATION FOR SEQ ID NO:88:                                         
 (i) SEQUENCE CHARACTERISTICS:                                            
(A) LENGTH: 93 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(ix) FEATURE:                                                             
(A) NAME/KEY: CDS                                                         
(B) LOCATION: 1..85                                                       
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:                                  
CTCGAGAGCGGGCAGGTGGTGCATGGGGAGCAG GTGGGTGGTGAGGCC48                       
LeuGluSerGlyGlnValValHisGlyGluGlnValGlyGlyGluAla                          
151015                                                                    
TCCGGGGCCGTTAACGGCCGTGGCCTAGCTGGC CAATAAGTCGAC93                          
SerGlyAlaValAsnGlyArgGlyLeuAlaGlyGln                                      
2025                                                                      
(2) INFORMATION FOR SEQ ID NO:89:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 28 amino acids                                                
(B) TYPE: amino acid                                                      
(D) TOPOLOGY: linear                                                      
 (ii) MOLECULE TYPE: protein                                              
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:                                  
LeuGluSerGlyGlnValValHisGlyGluGlnValGlyGlyGluAla                          
151015                                                                    
SerGlyAlaValAsnGlyArgGlyLeuAlaGlyGl n                                     
2025                                                                      
(2) INFORMATION FOR SEQ ID NO:90:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 93 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(ix) FEATURE:                                                             
(A) NAME/KEY: CDS                                                         
(B) LOCATION: 1..60                                                       
 (ix) FEATURE:                                                            
(A) NAME/KEY: miscfeature                                                 
(B) LOCATION: 61..63                                                      
(D) OTHER INFORMATION: /note: "NNK can appear up to n times               
where n=5,6,7,8 or more"                                                  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:                                  
CTCGAGAGCGGGCAGGTGGTGCATGGGGAGCAGGTGGGTGGTGAGGCC48                        
LeuGluSerGlyG lnValValHisGlyGluGlnValGlyGlyGluAla                         
151015                                                                    
TCCGGAGGTGGTNNKTAACTAAGTAAAGCTGGCCAATAAGTCGAC93                           
SerGlyGlyGly Xaa                                                          
20                                                                        
(2) INFORMATION FOR SEQ ID NO:91:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 21 amino acids                                                
(B) TYPE: amino acid                                                      
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: protein                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:                                  
LeuGluSerGlyGlnValValHisGlyGluGlnValGlyGlyGluAla                          
1 51015                                                                   
SerGlyGlyGlyXaa                                                           
20                                                                        

Claims (13)

What is claimed is:
1. A method for generating and screening a random peptide library, said method comprising the steps of:
(a) transforming host cells with at least 106 different vectors, each of which (i) encodes a fusion protein composed of a random peptide linked to a DNA binding protein consisting essentially of two lac headpieces joined by a linker; and (ii) contains a lacO or a derivative lacO binding site, and culturing the resultant transformed host cells under conditions such that said fusion protein is produced and binds to a vector that encodes the fusion protein;
(b) lysing the cells transformed in step (a) under conditions such that the fusion protein remains bound to the vector that encodes the fusion protein;
(c) contacting the fusion proteins with a receptor under conditions conducive to specific peptide-receptor binding; and
(d) isolating the vector that encodes a peptide that binds to said receptor.
2. The method of claim 1, wherein said random peptide is located at the carboxy terminus of said fusion protein.
3. The method of claim 1 further comprising the steps of:
(e) transforming host cells with the vectors obtained in step (d); and repeating steps (b), (c), and (d) with the host cells transformed in step (e).
4. The method of claim 3, wherein said host cells are E. coli.
5. The method of claim 4, wherein said binding site is lacOS.
6. The method of claim 4, wherein said vector is a plasmid that contains only one binding site.
7. A mixture of recombinant host cells transformed with a random peptide library composed of at least 106 different members, wherein each member is a recombinant DNA vector that (i) encodes a DNA binding protein consisting essentially of two lac headpieces joined by a linker; (ii) contains a lacO or derivative lacO binding site; and (iii) comprises a coding sequence for a random peptide inserted into the coding sequence of the DNA binding protein such that the resulting vector encodes a fusion protein that is composed of the DNA binding protein and the random peptide; and wherein each different member differs from other members with respect to the coding sequence of the random peptide.
8. A mixture of recombinant host cells transformed with a ligand fragment library composed of at least 10 different members, wherein each member is a recombinant DNA vector that (i) encodes a DNA binding protein consisting essentially of two lac headpieces joined by a linker; (ii) contains a lacO or derivative lacO binding site; and (iii) comprises a coding sequence for a ligand fragment inserted into the coding sequence of the DNA binding protein, such that the resulting vector encodes a fusion protein that is composed of the DNA binding protein and the ligand fragment; and wherein each different member differs from other members with respect to the coding sequence of the ligand fragment.
9. A recombinant DNA vector comprising:
(a) a DNA sequence encoding a DNA binding protein consisting essentially of two lac headpieces joined by a linker;
(b) a promoter positioned so as to drive transcription of said DNA binding protein coding sequence;
(c) a lacO or derivative lacO binding site; and
(d) a coding sequence for a peptide inserted in said DNA binding protein coding sequence so that said coding sequences can be transcribed to produce a fusion protein composed of said peptide and said DNA binding protein capable of binding to said binding site.
10. The vector of claim 9, wherein said binding site is lacOS.
11. The vector of claim 9 that is pDimer1.
12. A recombinant E. coli host cell transformed with a vector of claim 9.
13. The transformed host cell of claim 12 that is E. coli/pDimer1.
US07/963,321 1991-10-16 1992-10-15 Peptide library and screening method Expired - Lifetime US5338665A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US07/963,321 US5338665A (en) 1991-10-16 1992-10-15 Peptide library and screening method
US08/290,641 US5498530A (en) 1991-10-16 1994-08-15 Peptide library and screening method
US08/548,540 US5733731A (en) 1991-10-16 1995-10-26 Peptide library and screening method
US09/010,216 US6156511A (en) 1991-10-16 1998-01-21 Peptide library and screening method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/778,233 US5270170A (en) 1991-10-16 1991-10-16 Peptide library and screening method
US07/963,321 US5338665A (en) 1991-10-16 1992-10-15 Peptide library and screening method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/778,233 Continuation-In-Part US5270170A (en) 1991-10-16 1991-10-16 Peptide library and screening method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/290,641 Continuation US5498530A (en) 1991-10-16 1994-08-15 Peptide library and screening method

Publications (1)

Publication Number Publication Date
US5338665A true US5338665A (en) 1994-08-16

Family

ID=25112696

Family Applications (3)

Application Number Title Priority Date Filing Date
US07/778,233 Expired - Lifetime US5270170A (en) 1991-10-16 1991-10-16 Peptide library and screening method
US07/963,321 Expired - Lifetime US5338665A (en) 1991-10-16 1992-10-15 Peptide library and screening method
US08/290,641 Expired - Lifetime US5498530A (en) 1991-10-16 1994-08-15 Peptide library and screening method

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US07/778,233 Expired - Lifetime US5270170A (en) 1991-10-16 1991-10-16 Peptide library and screening method

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/290,641 Expired - Lifetime US5498530A (en) 1991-10-16 1994-08-15 Peptide library and screening method

Country Status (6)

Country Link
US (3) US5270170A (en)
EP (1) EP0610448B1 (en)
AT (1) ATE213772T1 (en)
AU (1) AU3759693A (en)
DE (1) DE69232439D1 (en)
WO (1) WO1993008278A1 (en)

Cited By (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006188A1 (en) * 1994-08-18 1996-02-29 Cytogen Corporation Peptide librairies as a source of syngenes
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
WO1997037220A1 (en) * 1996-04-03 1997-10-09 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
WO1998015649A1 (en) * 1996-10-04 1998-04-16 Universität Heidelberg A method of purifying dna
US5741462A (en) 1995-04-25 1998-04-21 Irori Remotely programmable matrices with memories
US5751629A (en) 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
WO1998051325A2 (en) * 1997-05-15 1998-11-19 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US5942422A (en) * 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US5961923A (en) * 1995-04-25 1999-10-05 Irori Matrices with memories and uses thereof
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US6025129A (en) * 1995-04-25 2000-02-15 Irori Remotely programmable matrices with memories and uses thereof
US6100026A (en) * 1995-04-25 2000-08-08 Irori Matrices with memories and uses thereof
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6187536B1 (en) 1997-02-18 2001-02-13 Thomas Jefferson University Methods of identifying and detecting pancreatic cancer
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6284459B1 (en) 1995-04-25 2001-09-04 Discovery Partners International Solid support matrices with memories and combinatorial libraries therefrom
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US6331273B1 (en) 1995-04-25 2001-12-18 Discovery Partners International Remotely programmable matrices with memories
US20020061287A1 (en) * 1996-01-04 2002-05-23 Wolff Jon A. Process of making a compound by forming a polymer from a template drug
US6416714B1 (en) 1995-04-25 2002-07-09 Discovery Partners International, Inc. Remotely programmable matrices with memories
US20020110843A1 (en) * 2000-05-12 2002-08-15 Dumas David P. Compositions and methods for epitope mapping
WO2002068453A2 (en) * 2001-02-22 2002-09-06 Xencor Methods and compositions for the construction and use of fusion libraries using computational protein design methods
US20020146780A1 (en) * 2000-12-12 2002-10-10 Roland Carlsson Method for in vitro molecular evolution of protein function
US6465430B1 (en) 1995-06-07 2002-10-15 Smithkline Beecham Corporation Peptides and compounds that bind to a thrombopoietin receptor
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030148353A1 (en) * 1998-06-16 2003-08-07 Borrebaeck Carl Arne Krister Method for in vitro molecular evolution of protein function
US20030158116A1 (en) * 1996-06-07 2003-08-21 Dower William J. Peptides and compounds that bind to a receptor
US20030176352A1 (en) * 2001-10-11 2003-09-18 Hosung Min Peptides and related compounds having thrombopoietic activity
US20030195156A1 (en) * 2001-05-11 2003-10-16 Amgen Inc. Peptides and related molecules that bind to TALL-1
US6653151B2 (en) 1999-07-30 2003-11-25 Large Scale Proteomics Corporation Dry deposition of materials for microarrays using matrix displacement
US20030219826A1 (en) * 1999-09-01 2003-11-27 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US6703362B1 (en) 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
US20040077022A1 (en) * 1998-10-23 2004-04-22 Ulrich Feige Modified peptides as therapeutic agents
US6743778B2 (en) 2000-04-21 2004-06-01 Amgen Inc. Apo-AI/AII peptide derivatives
US6767704B2 (en) 2000-03-27 2004-07-27 Thomas Jefferson University Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expression
US20040258687A1 (en) * 2003-02-10 2004-12-23 Thomas Jefferson University Use of GCC ligands
US20050048589A1 (en) * 2003-08-25 2005-03-03 Moncef Jendoubi Lung cancer specific gene products: their coding sequence, their antibodies and their use in diagnostic, therapeutic and disease management of lung cancer
US20050064464A1 (en) * 1998-02-11 2005-03-24 Maxygen, Inc., A Delaware Corporation Optimization of immunomodulatory properties of genetic vaccines
US20050074884A1 (en) * 1999-09-01 2005-04-07 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and /or nuclear transport of proteins, DNA and viruses
US20050080014A1 (en) * 1998-10-23 2005-04-14 Chuan-Fa Liu Thrombopoietic compounds
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US20050100895A1 (en) * 2000-09-18 2005-05-12 Waldman Scott A. Compositions and methods for identifying and targeting stomach and esophageal cancer cells
US20050137133A1 (en) * 2003-08-28 2005-06-23 Macdonald Brian R. Peptides and compounds that bind to a receptor
US6953663B1 (en) 1995-11-29 2005-10-11 Affymetrix, Inc. Polymorphism detection
US20060008806A1 (en) * 1986-07-17 2006-01-12 University Of Washington Method for producing novel DNA sequence with biological activity
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
US20060040866A1 (en) * 2003-08-28 2006-02-23 Macdonald Brian R Peptides and compounds that bind to a receptor
US20060057105A1 (en) * 2004-08-20 2006-03-16 Stern Michael E Methods of treating ocular inflammation and allergy
US7053177B1 (en) 1997-05-15 2006-05-30 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US20060140934A1 (en) * 2004-09-24 2006-06-29 Colin Gegg Modified Fc molecules
US20060166198A1 (en) * 2002-05-17 2006-07-27 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US20060234307A1 (en) * 1998-10-23 2006-10-19 Amgen Inc. Modified peptides as therapeutic agents
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
GB2401433B (en) * 2001-12-17 2006-10-25 Tao Chen Codon-based sequence analysis
US7135457B1 (en) 1997-05-15 2006-11-14 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US7135333B1 (en) 1997-08-07 2006-11-14 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US20060269477A1 (en) * 1993-10-26 2006-11-30 Waldman Scott A ST receptor binding compounds and methods of using the same
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US20080070840A1 (en) * 2006-06-19 2008-03-20 Hosung Min Thrombopoietic compounds
US20080131431A1 (en) * 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
US20080213277A1 (en) * 2007-02-02 2008-09-04 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
US20080254020A1 (en) * 2004-07-08 2008-10-16 Amgen Inc. Therapeutic Peptides
US20080267983A1 (en) * 2004-08-23 2008-10-30 Yeda Research And Development Co. Ltd. Peptide Inhibitors for Mediating Stress Responses
US20080279908A1 (en) * 2004-11-29 2008-11-13 The Regents Of The University Of California Hydroxyapatite-Binding Peptides for Bone Growth and Inhibition
EP2070944A1 (en) 2001-10-11 2009-06-17 Amgen Inc. Specific binding agents of human angiopoietin-2
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US20090203572A1 (en) * 2005-11-19 2009-08-13 Karin Haraldsson Method for in Vitro Molecular Evolution of Protein Function
US20090233809A1 (en) * 2008-03-04 2009-09-17 Affymetrix, Inc. Resequencing methods for identification of sequence variants
US20090258017A1 (en) * 2006-04-21 2009-10-15 Callahan William J Lyophilized therapeutic peptibody Formulations
US7662551B2 (en) 2000-12-22 2010-02-16 Alligator Bioscience Ab Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US20100239579A1 (en) * 2006-05-15 2010-09-23 Viral Logic Systems Technology Corp. CD47 Related Compositions and Methods for Treating Immunological Diseases and Disorders
EP2246363A1 (en) 2002-11-15 2010-11-03 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2010132609A2 (en) 2009-05-12 2010-11-18 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
EP2275816A2 (en) 2006-03-22 2011-01-19 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8067367B2 (en) 2002-09-18 2011-11-29 Janssen Pharmaceutica, N.V. Methods of increasing platelet and hematopoietic stem cell production
EP2397549A2 (en) 1999-02-04 2011-12-21 BP Corporation North America Inc. Non-stochastic generation of genetic vaccines and enzymes
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012094173A1 (en) 2011-01-06 2012-07-12 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring ampk activation
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US20120252701A1 (en) * 1994-02-17 2012-10-04 Codexis, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013096926A1 (en) 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2666473A1 (en) 2002-09-19 2013-11-27 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP2671891A2 (en) 2008-06-27 2013-12-11 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2014089269A1 (en) 2012-12-07 2014-06-12 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
WO2014201265A1 (en) 2013-06-14 2014-12-18 Pacific Biosciences Of California, Inc. Bis-biotinylation tags
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
WO2016164305A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10106579B2 (en) 2014-06-12 2018-10-23 Ra Pharmaceuticals, Inc. Modulation of complement activity
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US10288622B2 (en) 2011-05-23 2019-05-14 Yeda Research And Development Co. Ltd. Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US10421823B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
US10421824B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1
EP3669881A1 (en) 2014-01-28 2020-06-24 Buck Institute for Research on Aging Compositions for use in the treatment of senescence-assiocated disease and disorders
US10835574B2 (en) 2015-12-16 2020-11-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11123399B2 (en) 2016-12-07 2021-09-21 Ra Pharmaceuticals, Inc. Modulators of complement activity

Families Citing this family (397)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
AU1248292A (en) * 1990-12-06 1992-07-08 Affymax Technologies N.V. Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US6469158B1 (en) * 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
DK0728015T3 (en) * 1992-06-18 2006-07-17 Creagen Inc Combinatorial polypeptide antigens
US5840484A (en) * 1992-07-17 1998-11-24 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
US6303297B1 (en) 1992-07-17 2001-10-16 Incyte Pharmaceuticals, Inc. Database for storage and analysis of full-length sequences
US6114114A (en) * 1992-07-17 2000-09-05 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
US6503759B1 (en) 1992-10-01 2003-01-07 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5565324A (en) * 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5721099A (en) * 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
IT1270939B (en) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio PROCEDURE FOR THE PREPARATION OF IMMUNOGEN AND DIAGNOSTIC REAGENTS, AND IMMUNOGEN AND DIAGNOSTIC REAGENTS SO OBTAINABLE.
US5514774A (en) * 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5432155A (en) * 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
JPH09500625A (en) 1993-07-09 1997-01-21 スミスクライン・ビーチャム・コーポレイション Cyclic semi-random peptide library
CN1525171A (en) * 1993-10-01 2004-09-01 ŦԼ�и��ױ��Ǵ�ѧ���� Complex combinatorial chemical libraries encoded with tags
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5492807A (en) * 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
ZA95260B (en) * 1994-01-13 1995-09-28 Univ Columbia Synthetic receptors libraries and uses thereof
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US20050084885A1 (en) * 1994-01-18 2005-04-21 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6936477B2 (en) * 1994-04-13 2005-08-30 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5856083A (en) * 1994-05-06 1999-01-05 Pharmacopeia, Inc. Lawn assay for compounds that affect enzyme activity or bind to target molecules
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5525734A (en) * 1994-06-22 1996-06-11 Affymax Technologies N.V. Methods for synthesizing diverse collections of pyrrolidine compounds
NZ271488A (en) * 1994-07-12 1998-01-26 Human Genome Sciences Inc Connective tissue growth factor-2 (ctgf-2)
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
EP2022856B1 (en) * 1994-08-20 2011-09-14 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5712096A (en) * 1994-08-23 1998-01-27 University Of Massachusetts Medical Center Oligoribonucleotide assays for novel antibiotics
US5856090A (en) * 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
US5463564A (en) * 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
CA2200684A1 (en) * 1994-09-21 1996-03-28 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US6015668A (en) * 1994-09-30 2000-01-18 Life Technologies, Inc. Cloned DNA polymerases from thermotoga and mutants thereof
JP3398749B2 (en) * 1994-11-10 2003-04-21 オーキッド バイオ サイエンシズ, インコーポレイテッド Liquid distribution system
US5585069A (en) * 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5603351A (en) * 1995-06-07 1997-02-18 David Sarnoff Research Center, Inc. Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device
US6341256B1 (en) * 1995-03-31 2002-01-22 Curagen Corporation Consensus configurational bias Monte Carlo method and system for pharmacophore structure determination
US6309820B1 (en) * 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
US5925562A (en) * 1995-04-25 1999-07-20 Irori Remotely programmable matrices with memories
US5834184A (en) * 1995-05-17 1998-11-10 Harada; Kazuo In vivo selection of RNA-binding peptides
US5747453A (en) 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
US5874562A (en) * 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US7041801B1 (en) 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
WO1997001755A2 (en) * 1995-06-26 1997-01-16 Perseptive Biosystems, Inc. High speed, automated, continuous flow, multi-dimensional molecular selection and analysis
US5948614A (en) * 1995-09-08 1999-09-07 Life Technologies, Inc. Cloned DNA polymerases from thermotoga maritima and mutants thereof
CA2238995A1 (en) * 1995-12-18 1997-06-26 Praecis Pharmaceuticals Incorporated Methods for identifying compounds that bind to a target
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
JP2001509661A (en) 1996-01-23 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Method for screening trans-dominant intracellular factor peptide and RNA molecule
US6031071A (en) * 1996-01-24 2000-02-29 Biophage, Inc. Methods of generating novel peptides
WO1997027559A1 (en) * 1996-01-26 1997-07-31 Patterson David E Method of creating and searching a molecular virtual library using validated molecular structure descriptors
US6185506B1 (en) 1996-01-26 2001-02-06 Tripos, Inc. Method for selecting an optimally diverse library of small molecules based on validated molecular structural descriptors
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US6432635B1 (en) 1996-03-21 2002-08-13 Helsinki University Licensing Ltd. Oy Cystatin B mutants
WO1997044491A1 (en) * 1996-05-22 1997-11-27 The Johns Hopkins University Methods of detection utilizing modified bacteriophage
WO1997045538A1 (en) * 1996-05-31 1997-12-04 Medigene Ag Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6083693A (en) 1996-06-14 2000-07-04 Curagen Corporation Identification and comparison of protein-protein interactions that occur in populations
SE9603466D0 (en) * 1996-09-23 1996-09-23 Astra Ab New compounds
US6838238B1 (en) * 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US20020022227A1 (en) * 1996-10-17 2002-02-21 Short Jay M. Morphatides: novel shape and structure libraries
US6453246B1 (en) 1996-11-04 2002-09-17 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for representing proximity data in a multi-dimensional space
US6571227B1 (en) 1996-11-04 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Method, system and computer program product for non-linear mapping of multi-dimensional data
AU732397B2 (en) 1996-11-04 2001-04-26 3-Dimensional Pharmaceuticals, Inc. System, method and computer program product for identifying chemical compounds having desired properties
KR100566859B1 (en) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Selection of proteins using rna-protein fusions
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6087115A (en) * 1997-01-22 2000-07-11 Cornell Research Foundation, Inc. Methods of identifying negative antagonists for G protein coupled receptors
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
US6306588B1 (en) * 1997-02-07 2001-10-23 Invitrogen Corporation Polymerases for analyzing or typing polymorphic nucleic acid fragments and uses thereof
GB9703369D0 (en) * 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) * 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6368877B1 (en) * 1997-06-25 2002-04-09 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions
DK1496120T3 (en) * 1997-07-07 2007-07-30 Medical Res Council In vitro sorting method
FR2767135B1 (en) * 1997-08-06 2002-07-12 Genset Sa LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF
GB9718455D0 (en) * 1997-09-02 1997-11-05 Mcgregor Duncan P Chimeric binding peptide library screening method
US6607878B2 (en) 1997-10-06 2003-08-19 Stratagene Collections of uniquely tagged molecules
WO1999024075A2 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Affinity markers for human serum albumin
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
AU746454B2 (en) * 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
EP1064369B1 (en) 1998-03-17 2006-08-16 Gendaq Limited Nucleic acid binding proteins
AU3363399A (en) * 1998-03-27 1999-10-18 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
JP4278872B2 (en) 1998-08-17 2009-06-17 フィロス インク. Identification of compound-protein interaction using protein-nucleic acid fusion molecule library
US20070178475A1 (en) * 1998-09-17 2007-08-02 Nehls Michael C Novel human polynucleotides and polypeptides encoded thereby
DE19845420C2 (en) * 1998-10-02 2000-11-16 Deutsches Krebsforsch Intercellular spread of recombinant DNA
EP1127120B1 (en) * 1998-11-04 2008-05-28 Serono Genetics Institute S.A. Genomic and complete cdna sequences of human adipocyte-specific apm1 and biallelic markers thereof
AU1619400A (en) 1998-11-10 2000-05-29 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes
IL143238A0 (en) 1998-12-02 2002-04-21 Phylos Inc Dna-protein fusions and uses thereof
GB9900298D0 (en) * 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
AU2004242526B2 (en) * 1999-01-07 2007-08-30 United Kingdom Research And Innovation Optical Sorting Method
US7013219B2 (en) * 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
DE60041912D1 (en) 1999-02-10 2009-05-14 Serono Genetics Inst Sa POLYMORPHE MARKERS OF THE LSR GENE
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20020110809A1 (en) * 1999-04-30 2002-08-15 Nehls Michael C. Novel human polynucleotides and polypeptides encoded thereby
US20020095031A1 (en) * 1999-05-04 2002-07-18 Nehls Michael C. Novel human polynucleotides and polypeptides encoded thereby
US6485690B1 (en) 1999-05-27 2002-11-26 Orchid Biosciences, Inc. Multiple fluid sample processor and system
US20110104675A1 (en) * 1999-08-09 2011-05-05 Pacific Northwest Research Institute Methods and Compositions for Diagnosing Carcinomas
CA2382483A1 (en) * 1999-08-20 2001-03-01 Johns Hopkins University School Of Medicine Methods and compositions for the construction and use of fusion libraries
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
DE60035218D1 (en) 1999-11-18 2007-07-26 Dendreon Corp NUCLEIC ACIDS THAT CODE ENDOTHELIAS, ENDOTHELIASES, AND THEIR USE
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
IL149809A0 (en) * 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) * 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US20020058617A1 (en) * 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) * 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
DE60126913T2 (en) * 2000-01-24 2007-06-28 Gendaq Ltd. NUCLEIC ACID BINDING POLYPEPTIDE IS IDENTIFIED BY FLEXIBLE LINKER-LINKED NUCLEIC ACID ACID
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
CA2396810A1 (en) 2000-01-24 2001-07-26 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US6489466B2 (en) 2000-01-28 2002-12-03 Linden Technologies, Inc. C-3′ protected monomeric nucleotides and synthesis of oligonucleotides on solid support
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2001234980A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Methods of preparing and using a viral vector library
US7416524B1 (en) 2000-02-18 2008-08-26 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. System, method and computer program product for fast and efficient searching of large chemical libraries
WO2001062981A1 (en) * 2000-02-25 2001-08-30 Montclair Group Platform for the discovery of the bacterial genes involved in rna modification
WO2001065462A2 (en) 2000-02-29 2001-09-07 3-Dimensional Pharmaceuticals, Inc. Method and computer program product for designing combinatorial arrays
AU2001247627A1 (en) 2000-03-22 2001-10-03 3-Dimensional Pharmaceuticals, Inc. System, method, and computer program product for representing object relationships in a multidimensional space
AU2001249805A1 (en) 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for representing object relationships in a multidimensional space
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
PT1360500E (en) * 2000-04-14 2010-04-19 Genencor Int Methods for selective targeting
US6248541B1 (en) 2000-04-21 2001-06-19 Genencor International, Inc. Screening under nutrient limited conditions
US6534292B1 (en) 2000-05-08 2003-03-18 Genencor International, Inc. Methods for forming recombined nucleic acids
AU2001265154A1 (en) * 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US20040168209A1 (en) * 2000-06-12 2004-08-26 Alejandro Abuin Novel murine polynucleotide sequences and mutant cells and mutant animals defined thereby
EP2014303A2 (en) 2000-07-27 2009-01-14 Genentech, Inc. APO-2L receptor agonist and CPT-11 synergism
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
CA2419600A1 (en) * 2000-08-22 2002-02-28 3-Dimensional Pharmaceuticals, Inc. Method, system, and computer program product for determining properties of combinatorial library products from features of library building blocks
US6980674B2 (en) * 2000-09-01 2005-12-27 Large Scale Proteomics Corp. Reference database
US6539102B1 (en) * 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
ES2335861T3 (en) 2000-09-08 2010-04-06 Universitat Zurich GROUPS OF REPETITIVE PROTEINS THAT INCLUDE REPETITIVE MODULES.
AU2001292740A1 (en) * 2000-09-20 2002-04-02 Dimitris K. Agrafiotis Method, system, and computer program product for encoding and building products of a virtual combinatorial library
US6582914B1 (en) 2000-10-26 2003-06-24 Genencor International, Inc. Method for generating a library of oligonucleotides comprising a controlled distribution of mutations
US20020155439A1 (en) * 2000-12-04 2002-10-24 Ana Rodriguez Method for generating a library of mutant oligonucleotides using the linear cyclic amplification reaction
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
CA2431517A1 (en) 2000-12-12 2002-08-01 University Of Connecticut Polynucleotides encoding cellular transporters and methods of use thereof
US20030082647A1 (en) * 2000-12-12 2003-05-01 Reenan Robert A. Transporter protein
US7572575B2 (en) * 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
US20030124537A1 (en) * 2000-12-14 2003-07-03 Yuan-Chin Liu Procaryotic libraries and uses
US6933109B2 (en) * 2000-12-22 2005-08-23 Large Scale Proteomics Corporation Rapid particle detection
US20030009293A1 (en) * 2001-01-09 2003-01-09 Anderson Norman G. Reference database
WO2002057293A2 (en) * 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US7054757B2 (en) * 2001-01-29 2006-05-30 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Method, system, and computer program product for analyzing combinatorial libraries
US20020168640A1 (en) * 2001-02-22 2002-11-14 Min Li Biochips comprising nucleic acid/protein conjugates
AU2002306777C1 (en) 2001-03-19 2008-04-24 President And Fellows Of Harvard College Evolving new molecular function
US7309783B2 (en) * 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
US20050164515A9 (en) * 2001-06-05 2005-07-28 Belcher Angela M. Biological control of nanoparticle nucleation, shape and crystal phase
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
MXPA03011985A (en) 2001-06-20 2004-03-26 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
RU2004101289A (en) 2001-06-20 2005-07-10 Нуэволюшн А/С (Dk) METHOD FOR SYNTHESIS OF THE MOLECULE ON THE MATRIX
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030007973A1 (en) * 2001-06-22 2003-01-09 Lynes Michael A. Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
CA2450236A1 (en) * 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
EP1476180A4 (en) * 2001-08-13 2005-04-20 Univ Southern California Interleukin-2 mutants with reduced toxicity
ES2390531T3 (en) 2001-09-18 2012-11-13 Genentech, Inc. Compositions and procedures for the diagnosis and treatment of tumor
US20030073104A1 (en) * 2001-10-02 2003-04-17 Belcher Angela M. Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
WO2005049075A2 (en) 2003-11-17 2005-06-02 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
GB0127564D0 (en) 2001-11-16 2002-01-09 Medical Res Council Emulsion compositions
KR100623128B1 (en) 2002-01-02 2006-09-14 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
US7262054B2 (en) * 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
AU2003233489B2 (en) 2002-04-08 2008-10-02 Pioneer Hi-Bred International, Inc. Enhanced silk exsertion under stress
KR20040101502A (en) 2002-04-16 2004-12-02 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
WO2003102157A2 (en) * 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003263937B2 (en) * 2002-08-19 2010-04-01 The President And Fellows Of Harvard College Evolving new molecular function
US7361635B2 (en) * 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
CA2499123A1 (en) 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
US20050147962A1 (en) * 2002-11-19 2005-07-07 Wagstrom Christopher R. Display of dimeric proteins on phage
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004067753A2 (en) 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
US7323305B2 (en) 2003-01-29 2008-01-29 454 Life Sciences Corporation Methods of amplifying and sequencing nucleic acids
US8017323B2 (en) 2003-03-26 2011-09-13 President And Fellows Of Harvard College Free reactant use in nucleic acid-templated synthesis
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
PL2272868T4 (en) 2003-06-05 2016-07-29 Genentech Inc Combination therapy for B cell disorders
US20050136429A1 (en) * 2003-07-03 2005-06-23 Massachusetts Institute Of Technology SIRT1 modulation of adipogenesis and adipose function
US8048627B2 (en) 2003-07-05 2011-11-01 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
HUE045709T2 (en) 2003-07-08 2020-01-28 Genentech Inc Antagonist antibodies to IL-17A/F heterologous polypeptides
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050164969A1 (en) * 2003-11-19 2005-07-28 Massachusetts Institute Of Technology Method of extending life span
EP2287341B1 (en) 2003-12-01 2013-02-13 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
WO2005080432A2 (en) 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
US7323347B2 (en) * 2004-05-27 2008-01-29 Sensata Technologies, Inc. Biosensor surface structures and methods
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
PL3530673T3 (en) 2004-09-03 2022-08-01 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
WO2006056009A1 (en) * 2004-11-23 2006-06-01 Hepgenics Pty Ltd Peptides having adhesive properties for use in solid phase assay and chemical polymer synthesis regimes.
PL1699826T3 (en) 2005-01-05 2009-08-31 F Star Biotechnologische Forschungs Und Entw M B H Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
BRPI0607985A2 (en) 2005-03-10 2009-10-27 Genentech Inc dscr1 modulator, treatment methods, side effect amelioration method and tumor growth inhibition method
US20100240770A1 (en) * 2005-03-11 2010-09-23 Jifa Qi Synthesis and use of colloidal III-V nanoparticles
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
TW200716174A (en) 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
WO2007011722A2 (en) 2005-07-15 2007-01-25 President And Fellows Of Harvard College Reaction discovery system
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
JP5808070B2 (en) * 2005-12-02 2015-11-10 ジェネンテック, インコーポレイテッド Binding polypeptides and uses thereof
PL1971366T3 (en) 2005-12-29 2015-01-30 Janssen Biotech Inc Human anti-il-23 antibodies, compositions, methods and uses
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
JP5162476B2 (en) 2006-02-13 2013-03-13 ドナルドソン カンパニー,インコーポレイティド Web containing fine fibers and bioactive particulates and uses thereof
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
JP2009536527A (en) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド Binding polypeptide with optimized scaffold
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2007133710A2 (en) 2006-05-11 2007-11-22 Raindance Technologies, Inc. Microfluidic devices and methods of use thereof
US20100240029A1 (en) * 2006-06-06 2010-09-23 Massachusetts Institute Of Technology Cholesterol-Regulating Complex of SIRT1 and LXR and Methods of Use
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
BRPI0715580A2 (en) 2006-10-12 2014-06-10 Genentech Inc '' ANTI-LINFOTOXIN-a (LTa) ANTIBODY ISOLATED, HUMANIZED ANTIBODY, ANTI-LINFOTOXIN-a ANTIBODIES, ANTIBODY COMPOSITION, ANTIBODY, HYBRIDOMA, ANTIBODY, NUCLEIC ACID ISOLATED, HYDROPLE CULUS, OF AN ANTIBODY, METHOD FOR INHIBITING LTA-ACTIVATED CELL PROLIFERATION, METHOD FOR TREATING AN AUTOMUNE DISORDER, MANUFACTURED ARTICLES, METHOD FOR DISCLOSING ANTIBODY AND METHOD FOR PACKING 'ANTIBODY'
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
NZ578701A (en) 2007-02-09 2012-02-24 Genentech Inc Anti-robo4 antibodies and uses therefor
DK2140021T3 (en) 2007-02-22 2012-05-07 Genentech Inc Methods for Detecting Inflammatory Bowel Disease.
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
BRPI0721707A2 (en) * 2007-05-17 2013-01-15 Genentech Inc crystal structures of neuropillin fragments and neuropillin-antibody complexes
EP2158220B1 (en) 2007-06-26 2017-04-19 F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H Display of binding agents
CN101802012B (en) 2007-07-16 2014-08-06 健泰科生物技术公司 Anti-CD79b antibodies and immunoconjugates and methods of use
JP2010533495A (en) 2007-07-16 2010-10-28 ジェネンテック, インコーポレイテッド Humanized CD79b antibodies and immunoconjugates and their use
JP2010534664A (en) 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Methods and compositions for treatment of fibrosis related diseases using IL-17 antagonists
JP2011500715A (en) 2007-10-16 2011-01-06 ザイモジェネティクス, インコーポレイテッド Combination of BLyS inhibitor and anti-CD20 agent for the treatment of autoimmune disease
WO2009067580A2 (en) 2007-11-20 2009-05-28 Pioneer Hi-Bred International, Inc. Maize ethylene signaling genes and modulation of same for improved stress tolerance in plants
TWI580694B (en) * 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
DK2078750T3 (en) * 2008-01-09 2017-01-02 Univ Muenchen Ludwig Maximilians Fluorescent two-hybrid (F2H) assay for direct visualization of protein interactions in living cells
EP2247620B1 (en) 2008-01-31 2016-05-18 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CN102124030B (en) * 2008-06-20 2015-06-17 国立大学法人冈山大学 Antibody against oxidized ldl/ss2gpi complex and use of the same
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
JP5623401B2 (en) 2008-08-14 2014-11-12 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Anti-IL-12 / IL-23 antibody
WO2010047515A2 (en) 2008-10-20 2010-04-29 광주과학기술원 Bipodal peptide binder
CA3149920A1 (en) 2008-10-31 2010-05-06 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
ES2836948T3 (en) 2008-11-03 2021-06-28 Molecular Partners Ag Binding proteins that inhibit VEGF-A receptor interaction
EP3929216A1 (en) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP2012516350A (en) * 2009-01-28 2012-07-19 アンティジェン・エクスプレス・インコーポレーテッド Ii-Key hybrid peptide that regulates immune response to influenza
MX2011008566A (en) 2009-02-12 2011-11-29 Janssen Biotech Inc Fibronectin type iii domain based scaffold compositions, methods and uses.
WO2010101818A1 (en) 2009-03-02 2010-09-10 Pioneer Hi-Bred International, Inc. Nac transcriptional activators involved in abiotic stress tolerance
EP3415235A1 (en) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation of microfluidic droplets
MA33256B1 (en) 2009-04-01 2012-05-02 Genentech Inc Antibody ,,, fcrh5 and methods of use
EP2272939B1 (en) 2009-07-03 2012-09-12 BP Corporation North America Inc. Alkene oligomerization process
US20110035843A1 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
JP5885664B2 (en) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド Screening method
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
AU2010324686B2 (en) 2009-11-30 2016-05-19 Genentech, Inc. Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
EP2506861A1 (en) 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
AR080154A1 (en) 2010-02-10 2012-03-14 Immunogen Inc CD20 ANTIBODIES AND ITS USE
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US8535889B2 (en) 2010-02-12 2013-09-17 Raindance Technologies, Inc. Digital analyte analysis
BR112012017405A2 (en) 2010-02-18 2018-08-14 Genentech Inc method to increase tumor recurrence time in cancer patient
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
AR081361A1 (en) 2010-04-30 2012-08-29 Molecular Partners Ag MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CA2803792A1 (en) 2010-07-09 2012-01-12 Genentech, Inc. Anti-neuropilin antibodies and methods of use
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
CA2818969C (en) 2010-11-26 2020-04-14 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
EP2474612A1 (en) 2011-01-05 2012-07-11 University College Dublin, National University of Ireland Dublin Affinity separation means, and uses thereof to separate, purify or concentrate a target molecule
EP3412778A1 (en) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Methods for forming mixed droplets
EP3736281A1 (en) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
AU2012230899A1 (en) 2011-03-21 2013-10-10 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
JP2014519808A (en) 2011-04-29 2014-08-21 ヤンセン バイオテツク,インコーポレーテツド Repetitive proteins that bind to IL4 / IL13 and uses
WO2012167142A2 (en) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
RU2014109395A (en) 2011-09-15 2015-10-20 Дженентек, Инк. WAYS TO STIMULATE DIFFERENTIATION
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
CN103906835A (en) 2011-10-25 2014-07-02 先锋国际良种公司 Methods to alter plant cell wall composition for improved biofuel production and silage digestibility
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
CN104718220A (en) 2012-02-11 2015-06-17 霍夫曼-拉罗奇有限公司 R-spondin translocations and methods using the same
MX2014010953A (en) 2012-03-16 2014-10-13 Hoffmann La Roche Methods of treating melanoma with pak1 inhibitors.
WO2013137920A1 (en) 2012-03-16 2013-09-19 Genentech, Inc. Engineered conformationally-stabilized proteins
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
JP6302460B2 (en) 2012-04-25 2018-03-28 バイオデシー, インコーポレイテッド Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
MX2014015825A (en) 2012-06-28 2015-08-10 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor.
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
RU2015137610A (en) 2013-03-06 2017-04-10 Дженентек, Инк. METHODS FOR TREATMENT AND PREVENTION OF DRUG RESISTANCE OF MALIGNANT TUMORS
BR112015022604A2 (en) 2013-03-14 2017-10-24 Genentech Inc Uses of a Chromatin Modifier Modulator and an Egfr Antagonist
CA2903297A1 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Modulation of acc deaminase expression
JP2016520528A (en) 2013-03-15 2016-07-14 ジェネンテック, インコーポレイテッド Cancer treatment and anticancer drug resistance prevention method
NZ712314A (en) 2013-03-15 2021-07-30 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
JP6440055B2 (en) * 2013-05-10 2018-12-19 国立大学法人 東京大学 Method for producing peptide library, peptide library, and screening method
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
MX369173B (en) 2013-12-24 2019-10-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments.
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
RU2713327C2 (en) 2014-05-05 2020-02-04 Регенерон Фармасьютикалз, Инк. Humanised animals by c5 and c3
BR112016025040A2 (en) 2014-05-23 2018-02-20 Genentech Inc methods to determine mit biomarker expression, to treat cancer, to identify an individual with cancer, to predict whether an individual with cancer is more or less likely to respond effectively to treatment, to inhibit cell proliferation, and to treat nccrcc in an individual
EP3154589A1 (en) 2014-06-13 2017-04-19 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN114057857A (en) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 CHAGASIN-based scaffold compositions, methods and uses
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
EP3286227A2 (en) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Multispecific antigen-binding proteins
MX2017016647A (en) 2015-06-24 2019-04-25 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments.
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN108137681A (en) 2015-09-23 2018-06-08 豪夫迈·罗氏有限公司 The variant of the optimization of anti-VEGF antibodies
JP2019502753A (en) 2015-12-23 2019-01-31 ムーンショット ファーマ エルエルシー Induction of immune response by suppression of nonsense mutation-dependent mRNA degradation mechanism
WO2017139329A1 (en) 2016-02-09 2017-08-17 Alexander Krantz Site-selective functionalization of proteins using traceless affinity lables
CN116920085A (en) 2016-02-12 2023-10-24 詹森药业有限公司 anti-VISTA (B7H 5) antibodies
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20190063458A (en) 2016-07-15 2019-06-07 포세이다 테라퓨틱스, 인크. The chimeric antigen receptor (CARS) specific to MUC1 and its use
RU2019104074A (en) 2016-07-15 2020-08-18 Посейда Терапьютикс, Инк. CHIMERIC ANTIGEN RECEPTORS AND METHODS OF THEIR APPLICATION
JP2019534858A (en) 2016-09-09 2019-12-05 ジェネンテック, インコーポレイテッド Selective peptide inhibitor of FRIZZLED
KR20190059305A (en) 2016-09-30 2019-05-30 얀센 바이오테크 인코포레이티드 A safe and effective way to treat psoriasis with anti-IL23-specific antibodies
KR20190078648A (en) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 Methods for treating psoriasis with anti-IL23 specific antibodies
MX2019008989A (en) 2017-01-30 2019-10-09 Janssen Biotech Inc Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis.
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
JP7169979B2 (en) 2017-02-27 2022-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Method for evaluating therapeutic efficacy of candidate therapeutic agents for complement-related nephropathy and liver fibrosis
AU2018235756A1 (en) 2017-03-13 2019-10-10 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
SG11201909048TA (en) 2017-04-21 2019-11-28 Genentech Inc Use of klk5 antagonists for treatment of a disease
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019051424A2 (en) 2017-09-08 2019-03-14 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
CA3078460A1 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
WO2019090242A1 (en) 2017-11-04 2019-05-09 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
JP2021523138A (en) 2018-05-11 2021-09-02 ヤンセン バイオテツク,インコーポレーテツド How to treat depression with IL-23 antibody
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
KR102090402B1 (en) 2018-10-31 2020-03-17 공주대학교 산학협력단 A method for producing the higher alkene from butene by using desilicated pentasil structure zeolite catalyst
CA3120237A1 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
JP2022514561A (en) 2018-12-18 2022-02-14 ヤンセン バイオテツク,インコーポレーテツド A safe and effective way to treat lupus with anti-IL12 / IL23 antibodies
CA3124103A1 (en) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
EP3938390A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EP3938391A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
CA3133388A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
MA55383A (en) 2019-03-18 2022-01-26 Janssen Biotech Inc METHOD OF TREATING PSORIASIS IN PEDIATRIC SUBJECTS WITH AN ANTI-IL12/IL23 ANTIBODY
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
WO2020227554A1 (en) 2019-05-09 2020-11-12 Genentech, Inc. Methods of making antibodies
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2021014885A (en) 2019-06-03 2022-04-06 Janssen Biotech Inc Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis.
CN114173873A (en) 2019-06-03 2022-03-11 詹森生物科技公司 anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
CA3149892A1 (en) 2019-09-05 2021-03-11 Eric M. Ostertag Allogeneic cell compositions and methods of use
WO2021127505A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
EP4118107A1 (en) 2020-03-11 2023-01-18 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
BR112022020650A2 (en) 2020-04-14 2023-01-31 Poseida Therapeutics Inc COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF CANCER
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2022087148A1 (en) 2020-10-21 2022-04-28 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
AU2022308201A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
US20230040065A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
WO2023060088A1 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023205334A1 (en) * 2022-04-20 2023-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Coupling assay for t cell specificity (cats) and method of its use
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643969A (en) * 1983-07-25 1987-02-17 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US5028530A (en) * 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359535A (en) * 1979-10-01 1982-11-16 George Pieczenik Autonomously replicating DNA containing inserted DNA sequences
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
DE3546806C2 (en) * 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
AU626252B2 (en) * 1985-08-28 1992-07-30 George Pieczenik Method and means for sorting and identifying biological information
WO1988005085A1 (en) * 1987-01-12 1988-07-14 Stratagene Dna cloning vectors with in vivo excisable plasmids
ATE114723T1 (en) * 1987-03-02 1994-12-15 Enzon Lab Inc ORGANISM AS CARRIER FOR ''SINGLE CHAIN ANTIBODY DOMAIN (SCAD)''.
WO1989006694A1 (en) * 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US4910140A (en) * 1988-04-18 1990-03-20 Bio-Rad Laboratories, Inc. Electroporation of prokaryotic cells
EP1997891A1 (en) * 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
WO1990005144A1 (en) * 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
AU652539B2 (en) * 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU7247191A (en) * 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
AU8081491A (en) * 1990-06-01 1991-12-31 Cetus Corporation Compositions and methods for identifying biologically active molecules
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0469897A3 (en) * 1990-07-31 1992-11-19 The Wistar Institute Engineered antibodies
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
CA2105300C (en) * 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
DE69229222D1 (en) * 1991-03-07 1999-06-24 Bradbury SELECTION OF SPECIFIC PROTEINS BY A BIOLOGICAL PROCESS
CA2108147C (en) * 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643969A (en) * 1983-07-25 1987-02-17 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US5028530A (en) * 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof

Non-Patent Citations (62)

* Cited by examiner, † Cited by third party
Title
Barrett and Goldstein, 1985, Neuropeptides 6:113 120 A Monoclonal Antibody Specific for a Dynorphin Precursor. *
Barrett and Goldstein, 1985, Neuropeptides 6:113-120 A Monoclonal Antibody Specific for a Dynorphin Precursor.
Besse et al., 1986, EMBO J. 5(6):1377 1381 Synthetic lac operator mediates repression through lac repressor when introduced upstream and downstream from lac promoter. *
Besse et al., 1986, EMBO J. 5(6):1377-1381 Synthetic lac operator mediates repression through lac repressor when introduced upstream and downstream from lac promoter.
Bowie and Sauer, May 5 1989, J. Biol. Chem. 264(13):7596 7602 Identification of C terminal Extension that Protects Proteins from Intracellular Proteolysis *
Bowie and Sauer, May 5 1989, J. Biol. Chem. 264(13):7596-7602 Identification of C-terminal Extension that Protects Proteins from Intracellular Proteolysis
Brake et al, Oct. 1978, Proc. Natl. Acad. Sci. USA 75(10):4824 4827 Beta Galactosidase chimeras:Primary structure of a lac repressor b galactosidase protein. *
Brake et al, Oct. 1978, Proc. Natl. Acad. Sci. USA 75(10):4824-4827 Beta-Galactosidase chimeras:Primary structure of a lac repressor-b-galactosidase protein.
Cwirla et al., Aug. 1990, Proc. Natl. Acad. Sci. USA 87:6378 6382 Peptides on phage:A vast library of peptides for identifying ligands. *
Cwirla et al., Aug. 1990, Proc. Natl. Acad. Sci. USA 87:6378-6382 Peptides on phage:A vast library of peptides for identifying ligands.
Daly and Matthews, 1986, Biochemistry 25:5474 5478 Characterization and Modification of a Monomeric Mutant of the Lactose Repressor Protein. *
Daly and Matthews, 1986, Biochemistry 25:5474-5478 Characterization and Modification of a Monomeric Mutant of the Lactose Repressor Protein.
Devlin et al., Jul. 27 1990, Science 249:404 406 Random Peptide Libraries:A Source of Specific Protein Binding Molecules. *
Devlin et al., Jul. 27 1990, Science 249:404-406 Random Peptide Libraries:A Source of Specific Protein Binding Molecules.
Ellington and Szostak, Aug. 30 1990, Nature 346:818 822 In vitro selection of RNA molecules that bind specific ligands. *
Ellington and Szostak, Aug. 30 1990, Nature 346:818-822 In vitro selection of RNA molecules that bind specific ligands.
Flashner and Gralla, Dec. 1988, Proc. Natl. Acad. Sci. USA 85:8968 8972 Dual mechanism of repression at a distance in the lac operon. *
Flashner and Gralla, Dec. 1988, Proc. Natl. Acad. Sci. USA 85:8968-8972 Dual mechanism of repression at a distance in the lac operon.
Gordon et al., 1988, J. Mol. Biol. 200:239 251 Missense Mutation in the lacI Gene of Escherichia coli; Inferences on the Structure of the Repressor Protein. *
Gordon et al., 1988, J. Mol. Biol. 200:239-251 Missense Mutation in the lacI Gene of Escherichia coli; Inferences on the Structure of the Repressor Protein.
Hsieh et al., Oct. 25 1987, J. Biol. Chem. 262(30);14583 14591 Influence of Sequence and Distance between Two Operators on Interaction with the lac Repressor. *
Hsieh et al., Oct. 25 1987, J. Biol. Chem. 262(30);14583-14591 Influence of Sequence and Distance between Two Operators on Interaction with the lac Repressor.
Kania and Brown, Oct. 1976, Proc. Natl. Acad. Sci. USA 73(10):3529 3533 The functional repressor parts of a tetrameric lac repressor galactosedase chimaera are organized as dimers. *
Kania and Brown, Oct. 1976, Proc. Natl. Acad. Sci. USA 73(10):3529-3533 The functional repressor parts of a tetrameric lac repressor-β-galactosedase chimaera are organized as dimers.
Kleina and Miller, 1990, J. Mol. Biol. 212:295 318 Genetic Studies of the lac Repressor XIII. Extensive Amino Acid Replacements Generated by the Use of Natural and Synthetic Nonsense Supporters. *
Kleina and Miller, 1990, J. Mol. Biol. 212:295-318 Genetic Studies of the lac Repressor XIII. Extensive Amino Acid Replacements Generated by the Use of Natural and Synthetic Nonsense Supporters.
Knight et al., Mar. 5 1989, J. Biol. Chem. 264(7):3639 3642 The Arc and Mnt Repressors; A new class of sequence specific DNA Binding Protein. *
Knight et al., Mar. 5 1989, J. Biol. Chem. 264(7):3639-3642 The Arc and Mnt Repressors; A new class of sequence-specific DNA Binding Protein.
Koob and Szybalski, Oct. 12 1990, Science 250:271 273 Cleaving Yeast and Escherichia coli Genomes at a Single Site. *
Koob and Szybalski, Oct. 12 1990, Science 250:271-273 Cleaving Yeast and Escherichia coli Genomes at a Single Site.
Kr mer et al., 1987, EMOB J. 6(5):1481 1491 lac repressor forms loops with linear DNA carrying two suitably spaced lac operators. *
Kramer et al., 1987, EMOB J. 6(5):1481-1491 lac repressor forms loops with linear DNA carrying two suitably spaced lac operators.
Labow et al., Jul. 1990, Mol. Cell. Biol. 10(7):3343 3356 Conversion of the lac Repressor into an Allosterically Regulated Transcriptional Activator for Mammalian Cells. *
Labow et al., Jul. 1990, Mol. Cell. Biol. 10(7):3343-3356 Conversion of the lac Repressor into an Allosterically Regulated Transcriptional Activator for Mammalian Cells.
Levens and Howley, Sep. 1985, Mol. Cell. Biol. 5(9):2307 2315 Novel Method for Identifying Sequence Specific DNA Binding Proteins. *
Levens and Howley, Sep. 1985, Mol. Cell. Biol. 5(9):2307-2315 Novel Method for Identifying Sequence-Specific DNA-Binding Proteins.
M ller Hill and Kania, Jun. 7, 1974, Nature 249:561 563 Lac repressor can be fused to galactosidase. *
Maurizot and Grebert, Oct. 1988, FEBS Lett. 239(1):105 108 Thermodynamic parameters of the binding of the tight binding I12X86 lac repressor to operator and non operator DNA. *
Maurizot and Grebert, Oct. 1988, FEBS Lett. 239(1):105-108 Thermodynamic parameters of the binding of the tight binding I12X86 lac repressor to operator and non-operator DNA.
Mossing and Record, Aug. 22 1986, Science 233:889 892 Upstream Operators Enhance Repression of the lac Promoter. *
Mossing and Record, Aug. 22 1986, Science 233:889-892 Upstream Operators Enhance Repression of the lac Promoter.
Muller-Hill and Kania, Jun. 7, 1974, Nature 249:561-563 Lac repressor can be fused to β-galactosidase.
Oliphant et al., 1986, Gene 44:177 183 Cloning of random sequence oligodeoxynucleotides. *
Oliphant et al., 1986, Gene 44:177-183 Cloning of random-sequence oligodeoxynucleotides.
Panayotatos et al., Sep. 5 1989, J. Biol. Chem. 264(25):15066 15069 Biosynthesis of a Repressor/Nuclease Hybrid Protein. *
Panayotatos et al., Sep. 5 1989, J. Biol. Chem. 264(25):15066-15069 Biosynthesis of a Repressor/Nuclease Hybrid Protein.
Parmley and Smith, 1988, Gene 73:305 318 Antibody selectable filamentous fd phage vectors:affinity purification of target genes. *
Parmley and Smith, 1988, Gene 73:305-318 Antibody-selectable filamentous fd phage vectors:affinity purification of target genes.
Sadler et al., Nov. 1983, Proc. Natl. Acad. Sci. USA 80:6785 6789 A perfectly symmetric lac operator binds the lac repressor very tightly. *
Sadler et al., Nov. 1983, Proc. Natl. Acad. Sci. USA 80:6785-6789 A perfectly symmetric lac operator binds the lac repressor very tightly.
Scott and Smith, Jul. 27 1990, Science 249:386 390 Searching for Peptide Ligands with an Epitope Library. *
Scott and Smith, Jul. 27 1990, Science 249:386-390 Searching for Peptide Ligands with an Epitope Library.
Simons et al., Mar. 1984, Proc. Natl. Acad. Sci. USA 81:1624 1628 Possible ideal lac operator:Escherichia coli lac operator like sequences from eukaryotic gemomes lack the central G C pair. *
Simons et al., Mar. 1984, Proc. Natl. Acad. Sci. USA 81:1624-1628 Possible ideal lac operator:Escherichia coli lac operator-like sequences from eukaryotic gemomes lack the central G-C pair.
Thiesen and Bach, 1990, Nucleic Acids Res. 18(11):3203 3209 Target Detection Assay (TDA):a versatile procedure to determine DNA binding sites as demonstrated on SPl protein. *
Thiesen and Bach, 1990, Nucleic Acids Res. 18(11):3203-3209 Target Detection Assay (TDA):a versatile procedure to determine DNA binding sites as demonstrated on SPl protein.
Tuerk and Gold, Aug. 3 1990, Science 249:505 510 Systematic Evolution of Ligands by Exponential Enrichment:RNA Ligands to Bacteriophage T4 DNA Polymerase. *
Tuerk and Gold, Aug. 3 1990, Science 249:505-510 Systematic Evolution of Ligands by Exponential Enrichment:RNA Ligands to Bacteriophage T4 DNA Polymerase.
Whitson et al., Oct. 25 1987, J. Biol. Chem. 262(30):14592 14599 Influence of Supercoiling and Sequence Context on Operator DNA Binding with lac Repressor. *
Whitson et al., Oct. 25 1987, J. Biol. Chem. 262(30):14592-14599 Influence of Supercoiling and Sequence Context on Operator DNA Binding with lac Repressor.
Winnacker, From Genes to Clones , 1987, VCH, Weinheim, Germany (FRG), pp 46 53. *
Winnacker, From Genes to Clones, 1987, VCH, Weinheim, Germany (FRG), pp 46-53.

Cited By (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008806A1 (en) * 1986-07-17 2006-01-12 University Of Washington Method for producing novel DNA sequence with biological activity
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US6156511A (en) * 1991-10-16 2000-12-05 Affymax Technologies N.V. Peptide library and screening method
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US20040029182A1 (en) * 1993-10-26 2004-02-12 Waldman Scott A. ST receptor binding compounds and methods of using the same
US20060269477A1 (en) * 1993-10-26 2006-11-30 Waldman Scott A ST receptor binding compounds and methods of using the same
US7744870B1 (en) 1993-10-26 2010-06-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US20120252701A1 (en) * 1994-02-17 2012-10-04 Codexis, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1996006188A1 (en) * 1994-08-18 1996-02-29 Cytogen Corporation Peptide librairies as a source of syngenes
US6331273B1 (en) 1995-04-25 2001-12-18 Discovery Partners International Remotely programmable matrices with memories
US5961923A (en) * 1995-04-25 1999-10-05 Irori Matrices with memories and uses thereof
US5751629A (en) 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
US6416714B1 (en) 1995-04-25 2002-07-09 Discovery Partners International, Inc. Remotely programmable matrices with memories
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US6284459B1 (en) 1995-04-25 2001-09-04 Discovery Partners International Solid support matrices with memories and combinatorial libraries therefrom
US6100026A (en) * 1995-04-25 2000-08-08 Irori Matrices with memories and uses thereof
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US5741462A (en) 1995-04-25 1998-04-21 Irori Remotely programmable matrices with memories
US6025129A (en) * 1995-04-25 2000-02-15 Irori Remotely programmable matrices with memories and uses thereof
US6465430B1 (en) 1995-06-07 2002-10-15 Smithkline Beecham Corporation Peptides and compounds that bind to a thrombopoietin receptor
EP2338897A1 (en) 1995-06-07 2011-06-29 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6121238A (en) * 1995-06-07 2000-09-19 Glaxo Wellcome Inc. Peptides and compounds that bind to a receptor
EP1961760A2 (en) 1995-06-07 2008-08-27 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
EP2055712A1 (en) 1995-06-07 2009-05-06 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US6506362B1 (en) 1995-06-07 2003-01-14 Glaxo Group Limited Labeled compounds that bind to a thrombopoietin receptor
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
US20100286924A1 (en) * 1995-11-29 2010-11-11 Affymetrix, Inc. Polymorphism detection
US8095323B2 (en) 1995-11-29 2012-01-10 Affymetrix, Inc. Polymorphism detection
US20080044920A1 (en) * 1995-11-29 2008-02-21 Affymetrix, Inc. Polymorphism Detection
US6586186B2 (en) 1995-11-29 2003-07-01 Affymetrix, Inc. Polymorphism detection
US6953663B1 (en) 1995-11-29 2005-10-11 Affymetrix, Inc. Polymorphism detection
US7674587B2 (en) 1995-11-29 2010-03-09 Affymetrix, Inc. Polymorphism detection
US20020061287A1 (en) * 1996-01-04 2002-05-23 Wolff Jon A. Process of making a compound by forming a polymer from a template drug
US7482160B2 (en) 1996-01-04 2009-01-27 Roche Madison Inc. Process of making a compound by forming a polymer from a template drug
US7049144B2 (en) * 1996-01-04 2006-05-23 Mirus Bio Corporation Process of making a compound by forming a polymer from a template drug
US20060159764A1 (en) * 1996-01-04 2006-07-20 Monahan Sean D Process of making a compound by forming a polymer from a template drug
AU717289B2 (en) * 1996-04-03 2000-03-23 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
EP0801307A2 (en) * 1996-04-03 1997-10-15 Chugai Biopharmaceuticals, Inc. Compositions and methods for screening drug libraries
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
EP0801307A3 (en) * 1996-04-03 1998-12-16 Chugai Biopharmaceuticals, Inc. Compositions and methods for screening drug libraries
WO1997037220A1 (en) * 1996-04-03 1997-10-09 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US8227422B2 (en) 1996-06-07 2012-07-24 Glaxosmithkline Llc Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US20030158116A1 (en) * 1996-06-07 2003-08-21 Dower William J. Peptides and compounds that bind to a receptor
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
WO1998015649A1 (en) * 1996-10-04 1998-04-16 Universität Heidelberg A method of purifying dna
US5942422A (en) * 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6187536B1 (en) 1997-02-18 2001-02-13 Thomas Jefferson University Methods of identifying and detecting pancreatic cancer
US9429576B2 (en) 1997-03-12 2016-08-30 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US8946168B2 (en) 1997-03-12 2015-02-03 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US6703362B1 (en) 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US7135457B1 (en) 1997-05-15 2006-11-14 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
AU755154B2 (en) * 1997-05-15 2002-12-05 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
US7053177B1 (en) 1997-05-15 2006-05-30 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
WO1998051325A2 (en) * 1997-05-15 1998-11-19 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
WO1998051325A3 (en) * 1997-05-15 1998-12-17 Cytogen Corp Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
US7316902B2 (en) 1997-08-07 2008-01-08 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US7135333B1 (en) 1997-08-07 2006-11-14 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6569435B1 (en) 1998-02-11 2003-05-27 Maxygen, Inc. Flavivirus and alphavirus recombinant antigen libraries
US20040001849A1 (en) * 1998-02-11 2004-01-01 Maxygen, Inc., A Delaware Corporation Antigen library immunization
US6576757B1 (en) 1998-02-11 2003-06-10 Maxygen, Inc. Polynucleotides encoding flavivirus and alphavirus multivalent antigenic polypeptides
US20050064464A1 (en) * 1998-02-11 2005-03-24 Maxygen, Inc., A Delaware Corporation Optimization of immunomodulatory properties of genetic vaccines
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US20050164222A1 (en) * 1998-02-11 2005-07-28 Maxygen, Inc., A Delaware Corporation Optimization of immunomodulatory properties of genetic vaccines
US20030148353A1 (en) * 1998-06-16 2003-08-07 Borrebaeck Carl Arne Krister Method for in vitro molecular evolution of protein function
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US20090186822A1 (en) * 1998-10-23 2009-07-23 Amgen Inc. Thrombopoietic Compounds
US7169905B2 (en) 1998-10-23 2007-01-30 Amgen Inc. Modified peptides as therapeutic agents
US8044174B2 (en) 1998-10-23 2011-10-25 Amgen Inc. Thrombopoietic compounds
US20060234307A1 (en) * 1998-10-23 2006-10-19 Amgen Inc. Modified peptides as therapeutic agents
US9145450B2 (en) 1998-10-23 2015-09-29 Amgen Inc. Thrombopoietic compounds
US20050080014A1 (en) * 1998-10-23 2005-04-14 Chuan-Fa Liu Thrombopoietic compounds
US20040053845A1 (en) * 1998-10-23 2004-03-18 Amgen Inc. Modified peptides as therapeutic agents
US9534032B2 (en) 1998-10-23 2017-01-03 Amgen Inc. Thrombopoietic compounds
US7994117B2 (en) 1998-10-23 2011-08-09 Amgen Inc. Thrombopoietic compounds
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20040087778A1 (en) * 1998-10-23 2004-05-06 Amgen Inc. Modified peptides as therapeutic agents
US20040077022A1 (en) * 1998-10-23 2004-04-22 Ulrich Feige Modified peptides as therapeutic agents
US7189827B2 (en) 1998-10-23 2007-03-13 Amgen Inc. Modified peptides as therapeutic agents
US7186810B2 (en) 1998-10-23 2007-03-06 Amgen Inc. Modified peptides as therapeutic agents
US20040071712A1 (en) * 1998-10-23 2004-04-15 Amgen Inc. Modified peptides as therapeutic agents
US20070049532A1 (en) * 1998-10-23 2007-03-01 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7166707B2 (en) 1998-10-23 2007-01-23 Amgen Inc. Modified peptides as therapeutic agents
US8748571B2 (en) 1998-10-23 2014-06-10 Amgen Inc. Thrombopoietic compounds
US8618044B2 (en) 1998-10-23 2013-12-31 Amgen Inc. Thrombopoietic compounds
EP2397549A2 (en) 1999-02-04 2011-12-21 BP Corporation North America Inc. Non-stochastic generation of genetic vaccines and enzymes
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US6887701B2 (en) 1999-07-30 2005-05-03 Large Scale Proteomics Corporation Microarrays and their manufacture
US6846635B1 (en) 1999-07-30 2005-01-25 Large Scale Proteomics Corp. Microarrays and their manufacture
US6653151B2 (en) 1999-07-30 2003-11-25 Large Scale Proteomics Corporation Dry deposition of materials for microarrays using matrix displacement
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
US20030219826A1 (en) * 1999-09-01 2003-11-27 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US20070253968A1 (en) * 1999-09-01 2007-11-01 Robbins Paul D Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US20050074884A1 (en) * 1999-09-01 2005-04-07 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and /or nuclear transport of proteins, DNA and viruses
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US8818735B2 (en) 1999-10-13 2014-08-26 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US8229677B2 (en) 1999-10-13 2012-07-24 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US7482433B2 (en) 1999-12-16 2009-01-27 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
EP3388534A1 (en) 2000-03-27 2018-10-17 Thomas Jefferson University Compositions for treating stomachal and oesophageal cancer cells
US20040224355A1 (en) * 2000-03-27 2004-11-11 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US8067007B2 (en) 2000-03-27 2011-11-29 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US7854933B2 (en) 2000-03-27 2010-12-21 Thmoas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US20110104050A1 (en) * 2000-03-27 2011-05-05 Thomas Jefferson University Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
EP2230320A1 (en) 2000-03-27 2010-09-22 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
EP2949762A1 (en) 2000-03-27 2015-12-02 Thomas Jefferson University Compositions for treating and imaging stomachal and oesophageal cancer cells
US6767704B2 (en) 2000-03-27 2004-07-27 Thomas Jefferson University Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expression
US6743778B2 (en) 2000-04-21 2004-06-01 Amgen Inc. Apo-AI/AII peptide derivatives
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US20020110843A1 (en) * 2000-05-12 2002-08-15 Dumas David P. Compositions and methods for epitope mapping
US7829276B2 (en) 2000-09-18 2010-11-09 Thomas Jefferson University Methods of using CRCA-1 as a stomach and esophageal cancer marker
US20050100895A1 (en) * 2000-09-18 2005-05-12 Waldman Scott A. Compositions and methods for identifying and targeting stomach and esophageal cancer cells
US7563578B2 (en) 2000-12-12 2009-07-21 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020146780A1 (en) * 2000-12-12 2002-10-10 Roland Carlsson Method for in vitro molecular evolution of protein function
US7816085B2 (en) 2000-12-12 2010-10-19 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7282334B2 (en) 2000-12-12 2007-10-16 Alligator Bioscience, Ab Method for in vitro molecular evolution of protein function
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US8071289B2 (en) 2000-12-22 2011-12-06 Alligator Bioscience Ab Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7662551B2 (en) 2000-12-22 2010-02-16 Alligator Bioscience Ab Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2002068453A3 (en) * 2001-02-22 2003-02-27 Xencor Inc Methods and compositions for the construction and use of fusion libraries using computational protein design methods
WO2002068453A2 (en) * 2001-02-22 2002-09-06 Xencor Methods and compositions for the construction and use of fusion libraries using computational protein design methods
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US8507426B2 (en) 2001-05-11 2013-08-13 Amgen, Inc. Peptides and related molecules that bind to TALL-1
US20060135431A1 (en) * 2001-05-11 2006-06-22 Amgen Inc. Peptides and related molecules that bind to TALL-1
EP2845864A2 (en) 2001-05-11 2015-03-11 Amgen, Inc Peptides and related molecules that bind to TALL - 1
US20100240590A1 (en) * 2001-05-11 2010-09-23 Amgen Inc. Peptides and related molecules that bind to tall-1
US7737111B2 (en) 2001-05-11 2010-06-15 Amgen, Inc. Peptides and related molecules that bind to TALL-1
US7259137B2 (en) 2001-05-11 2007-08-21 Amgen Inc. Peptides and related molecules that bind to TALL-1
US20030195156A1 (en) * 2001-05-11 2003-10-16 Amgen Inc. Peptides and related molecules that bind to TALL-1
EP2292655A1 (en) 2001-05-11 2011-03-09 Amgen SF, LLC Peptides and related molecules that bind to tall-1
US9139645B2 (en) 2001-05-11 2015-09-22 Amgen Inc. Peptides and related molecules that bind to TALL-1
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
EP2070944A1 (en) 2001-10-11 2009-06-17 Amgen Inc. Specific binding agents of human angiopoietin-2
EP2316845A1 (en) 2001-10-11 2011-05-04 Amgen Inc. Specific binding agents of human angiopoietin-2
EP2157097A1 (en) 2001-10-11 2010-02-24 Amgen, Inc. Specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20090011497A1 (en) * 2001-10-11 2009-01-08 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030176352A1 (en) * 2001-10-11 2003-09-18 Hosung Min Peptides and related compounds having thrombopoietic activity
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
GB2401433B (en) * 2001-12-17 2006-10-25 Tao Chen Codon-based sequence analysis
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
US20060166198A1 (en) * 2002-05-17 2006-07-27 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US8283313B2 (en) 2002-09-18 2012-10-09 Janssen Pharmaceutica, Nv Methods of increasing platelet and hematopoietic stem cell production
US8067367B2 (en) 2002-09-18 2011-11-29 Janssen Pharmaceutica, N.V. Methods of increasing platelet and hematopoietic stem cell production
EP2666473A1 (en) 2002-09-19 2013-11-27 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP2666474A1 (en) 2002-09-19 2013-11-27 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP2679235A2 (en) 2002-09-19 2014-01-01 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP2246363A1 (en) 2002-11-15 2010-11-03 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2287192A1 (en) 2002-11-15 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
US20040258687A1 (en) * 2003-02-10 2004-12-23 Thomas Jefferson University Use of GCC ligands
US20050048589A1 (en) * 2003-08-25 2005-03-03 Moncef Jendoubi Lung cancer specific gene products: their coding sequence, their antibodies and their use in diagnostic, therapeutic and disease management of lung cancer
US20060040866A1 (en) * 2003-08-28 2006-02-23 Macdonald Brian R Peptides and compounds that bind to a receptor
US20050137133A1 (en) * 2003-08-28 2005-06-23 Macdonald Brian R. Peptides and compounds that bind to a receptor
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US20080254020A1 (en) * 2004-07-08 2008-10-16 Amgen Inc. Therapeutic Peptides
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US20060057105A1 (en) * 2004-08-20 2006-03-16 Stern Michael E Methods of treating ocular inflammation and allergy
US8790653B2 (en) 2004-08-23 2014-07-29 Yeda Research And Development Co. Ltd. Peptide inhibitors for mediating stress responses
EP2578226A1 (en) 2004-08-23 2013-04-10 Yeda Research And Development Co., Ltd. Peptide inhibitors for mediating stress responses
US8067008B2 (en) 2004-08-23 2011-11-29 Yeda Research And Development Co. Peptide inhibitors for mediating stress responses
US20080267983A1 (en) * 2004-08-23 2008-10-30 Yeda Research And Development Co. Ltd. Peptide Inhibitors for Mediating Stress Responses
US20090012272A1 (en) * 2004-09-24 2009-01-08 Amgen Inc. Modified Fc molecules
US7645861B2 (en) 2004-09-24 2010-01-12 Amgen Inc. Modified Fc molecules
US7750128B2 (en) 2004-09-24 2010-07-06 Amgen Inc. Modified Fc molecules
US7750127B2 (en) 2004-09-24 2010-07-06 Amgen Inc. Modified Fc molecules
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US7662931B2 (en) 2004-09-24 2010-02-16 Amgen Inc. Modified Fc molecules
US7655765B2 (en) 2004-09-24 2010-02-02 Amgen Inc. Modified Fc molecules
US7655764B2 (en) 2004-09-24 2010-02-02 Amgen Inc. Modified Fc molecules
US20090022744A1 (en) * 2004-09-24 2009-01-22 Amgen Inc. Modified Fc molecules
US20060140934A1 (en) * 2004-09-24 2006-06-29 Colin Gegg Modified Fc molecules
US8022040B2 (en) 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
US20080279908A1 (en) * 2004-11-29 2008-11-13 The Regents Of The University Of California Hydroxyapatite-Binding Peptides for Bone Growth and Inhibition
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules
US10188740B2 (en) 2005-08-12 2019-01-29 Amgen Inc. Modified Fc molecules
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US11266744B2 (en) 2005-08-12 2022-03-08 Amgen Inc. Modified Fc molecules
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
US20090203572A1 (en) * 2005-11-19 2009-08-13 Karin Haraldsson Method for in Vitro Molecular Evolution of Protein Function
EP2322931A2 (en) 2006-03-22 2011-05-18 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
EP2275816A2 (en) 2006-03-22 2011-01-19 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
EP2594286A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2594288A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2594287A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2594284A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2594285A1 (en) 2006-04-21 2013-05-22 Amgen Inc. Lyophilized therapeutic peptibody formulations
US10166189B2 (en) 2006-04-21 2019-01-01 Amgen Inc. Lyophilized therapeutic peptibody formulations
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US20090258017A1 (en) * 2006-04-21 2009-10-15 Callahan William J Lyophilized therapeutic peptibody Formulations
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20080131431A1 (en) * 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
US20100239579A1 (en) * 2006-05-15 2010-09-23 Viral Logic Systems Technology Corp. CD47 Related Compositions and Methods for Treating Immunological Diseases and Disorders
US8541201B2 (en) 2006-06-19 2013-09-24 Amgen Inc. Thrombopoietic compounds
US20080070840A1 (en) * 2006-06-19 2008-03-20 Hosung Min Thrombopoietic compounds
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8629250B2 (en) 2007-02-02 2014-01-14 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
US20080213277A1 (en) * 2007-02-02 2008-09-04 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
EP2803675A2 (en) 2008-01-25 2014-11-19 Amgen, Inc Ferroportin antibodies and methods of use
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US9688759B2 (en) 2008-01-25 2017-06-27 Amgen, Inc. Ferroportin antibodies and methods of use
EP2574628A1 (en) 2008-01-25 2013-04-03 Amgen Inc. Ferroportin antibodies and methods of use
US20090233809A1 (en) * 2008-03-04 2009-09-17 Affymetrix, Inc. Resequencing methods for identification of sequence variants
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2816059A1 (en) 2008-05-01 2014-12-24 Amgen, Inc Anti-hepcidin antibodies and methods of use
EP2671891A2 (en) 2008-06-27 2013-12-11 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2010132609A2 (en) 2009-05-12 2010-11-18 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012094173A1 (en) 2011-01-06 2012-07-12 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring ampk activation
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US10288622B2 (en) 2011-05-23 2019-05-14 Yeda Research And Development Co. Ltd. Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US11852634B2 (en) 2011-05-23 2023-12-26 Yeda Research And Development Co. Ltd. Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013096926A1 (en) 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
EP3296310A1 (en) 2011-12-22 2018-03-21 GlycoMimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
WO2014089269A1 (en) 2012-12-07 2014-06-12 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
US10421824B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1
US11492417B2 (en) 2013-03-13 2022-11-08 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
US10421823B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2014201265A1 (en) 2013-06-14 2014-12-18 Pacific Biosciences Of California, Inc. Bis-biotinylation tags
EP3669881A1 (en) 2014-01-28 2020-06-24 Buck Institute for Research on Aging Compositions for use in the treatment of senescence-assiocated disease and disorders
US11535650B1 (en) 2014-06-12 2022-12-27 Ra Pharmaceuticals, Inc. Modulation of complement activity
US10208089B2 (en) 2014-06-12 2019-02-19 Ra Pharmaceuticals, Inc. Modulation of complement activity
US11014965B2 (en) 2014-06-12 2021-05-25 Ra Pharmaceuticals, Inc. Modulation of complement activity
US10106579B2 (en) 2014-06-12 2018-10-23 Ra Pharmaceuticals, Inc. Modulation of complement activity
US10435438B2 (en) 2014-06-12 2019-10-08 Ra Pharmaceuticals, Inc. Modulation of complement activity
US10562934B2 (en) 2014-06-12 2020-02-18 Ra Pharmaceuticals, Inc. Modulation of complement activity
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10918691B2 (en) 2015-01-28 2021-02-16 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10588936B2 (en) 2015-01-28 2020-03-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10328115B2 (en) 2015-01-28 2019-06-25 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11707503B2 (en) 2015-01-28 2023-07-25 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3903804A1 (en) 2015-04-06 2021-11-03 Subdomain, LLC De novo binding domain containing polypeptides and uses thereof
WO2016164308A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
WO2016164305A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
US10835574B2 (en) 2015-12-16 2020-11-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11752190B2 (en) 2015-12-16 2023-09-12 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11123399B2 (en) 2016-12-07 2021-09-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11723949B2 (en) 2016-12-07 2023-08-15 Ra Pharmaceuticals, Inc. Modulators of complement activity

Also Published As

Publication number Publication date
ATE213772T1 (en) 2002-03-15
EP0610448A4 (en) 1996-04-24
WO1993008278A1 (en) 1993-04-29
AU3759693A (en) 1993-05-21
EP0610448A1 (en) 1994-08-17
US5498530A (en) 1996-03-12
EP0610448B1 (en) 2002-02-27
DE69232439D1 (en) 2002-04-04
US5270170A (en) 1993-12-14

Similar Documents

Publication Publication Date Title
US5338665A (en) Peptide library and screening method
US5733731A (en) Peptide library and screening method
US6107059A (en) Peptide library and screening method
US11078479B2 (en) Polypeptide display libraries and methods of making and using thereof
EP1696038B1 (en) Isolating biological modulators from biodiverse gene fragment libraries
Mattheakis et al. An in vitro polysome display system for identifying ligands from very large peptide libraries.
Noren et al. Construction of high-complexity combinatorial phage display peptide libraries
Fisch et al. A strategy of exon shuffling for making large peptide repertoires displayed on filamentous bacteriophage.
CA2084411A1 (en) Peptide library and screening systems
US20080108789A1 (en) DNA &amp; protein binding miniature proteins
BRPI0612589A2 (en) phage presentation technologies
Schatz et al. [10] Screening of peptide libraries linked to lac repressor
US20020081570A1 (en) System to detect protein-protein interactions
EP1198586B1 (en) An in vivo library-versus-library selection of optimized protein-protein interactions
US20050130124A1 (en) Phagemid display system
Huang A combinatorial approach towards DNA recognition
US6818410B2 (en) Methods of isolating RNA-binding proteins and compositions related to the same
Rebar Selection studies of zinc finger-DNA recognition

Legal Events

Date Code Title Description
AS Assignment

Owner name: AFFYMAX TECHNOLOGIES N.V., NAMIBIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SCHATZ, PETER J.;CULL, MILLARD G.;STEMMER, WILLEM PETER CHRISTIANN;AND OTHERS;REEL/FRAME:006357/0501;SIGNING DATES FROM 19921113 TO 19921130

Owner name: AFFYMAX TECHNOLOGIES N.V., NAMIBIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SCHATZ, PETER J.;CULL, MILLARD G.;STEMMER, WILLEM PETER CHRISTIANN;AND OTHERS;REEL/FRAME:006364/0432;SIGNING DATES FROM 19921113 TO 19921130

Owner name: AFFYMAX TECHNOLOGIES N.V., NAMIBIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SCHATZ, PETER J.;CULL, MILLARD G.;MILLER, JEFF F.;AND OTHERS;REEL/FRAME:006359/0959;SIGNING DATES FROM 19921113 TO 19921130

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAT HLDR NO LONGER CLAIMS SMALL ENT STAT AS SMALL BUSINESS (ORIGINAL EVENT CODE: LSM2); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
AS Assignment

Owner name: AFFYMAX, INC., CALIFORNIA

Free format text: EXHIBIT A/ W AFFIDAVIT;ASSIGNOR:AFFYMAX TECHNOLOGIES, N.V.;REEL/FRAME:015629/0868

Effective date: 20010815

FPAY Fee payment

Year of fee payment: 12